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Abstract

Ovarian cancer (OC) accounts for 4% of all cancer cases and 4.2% of all cancer deaths
worldwide. OC is the most lethal gynecological cancer because it lacks early disease symptoms
and does not have a specific diagnostic marker. As a result, more than 70% of OC patients are
diagnosed in later stages when the disease has already metastasized and the 5-year survival rate
has decreased to less than 20% compared with approximately 90% survival for women diagnosed
with early stage disease. Therefore, I initiated my studies with a computational analysis of the 27
most commonly reported literature-derived ovarian cancer (LDOC) protein biomarkers. I found
that LDOC protein biomarkers share many biochemical features including a preponderance for a
stable protein structure, the ability to be secreted, and functionality related to extracellular matrix
(ECM) modification, immune response and/or energy production. Subsequently, I analyzed the
human proteome to identify proteins that also share these biochemical features. Of the 70,616
proteins in the human proteome, 683 proteins were found to have similar biochemical features to
the 27 LDOC proteins. I also identified a subset of 21 potential additional protein regulators of
ovarian cancer (APROC) that interact with LDOCs. Three of the APROCs identified were amylase
proteins AMY1A, AMY2A, and AMY2B which cleaves alpha 1, 4-glycosidic bonds in
polysaccharides. Amylase is reportedly overexpressed in and secreted by ovarian tumors but its
functional contribution to OC remains unknown[1]. In this thesis, I posit that amylase contributes

xiii

to OC invasion. I initiated my studies by computational characterizing the different amylase
isozymes to predict which amylase isozyme(s) is most likely overexpressed in and contributory to
OC invasion. I found that AMY1 and AMY2B have unique regions of disorder and unique
phosphorylation sites indicating that AMY1 and AMY2B would be more likely to interact with
other proteins, and to be easily secreted. Using OC patient serum samples, I was able to validate
AMY1 and AMY2B overexpression by western immunoblotting.
I then developed an in vitro model system to study the molecular contribution of amylase
to OC invasion using normal ovarian surface epithelial (IOSE) and OC cell lines. I showed that
OC cells generally overexpress and secrete metabolically active amylase isozymes AMY1 and
AMY2B. Abrogating amylase activity using siRNA silencing technology decreased the capacity
of OC cells to invade collagen coated Boyden chambers and increased sulfated
glycosaminoglycans (sGAG) production. Since a survey of OC cell lines indicated that cancer cells
have a bulkier glycocalyx compared to IOSE cells and immunogold labeling studies indicated the
presence of amylase within the immediate OC microenvironment, my data suggest that, by
cleaving alpha 1, 4-glycosidic bonds in glycoconjugates present within ECM, amylase may
remodel the ECM to promote an invasive cancer phenotype. Amylase is therefore a target for
therapeutic intervention in OC patients with hyperamylasemia. I established Spirulina, a dietary
supplement, as a novel transcriptional inhibitor of amylase. Spirulina inhibited amylase expression
in OC cell lines at both the message and protein levels. Spirulina reduced OC cell invasion and
migration in vitro, putatively by decreasing amylase expression.

xiv

Chapter 1
Overview of Ovarian Cancer Biomarkers

Ovarian Cancer
Ovarian cancer (OC) is the 5th leading cause of cancer death in women in the US after lung,
bronchial, breast, colorectal, and pancreatic cancers [2]. OC represents the most lethal
gynecological cancer [3].

Approximately 22,000 new cases are diagnosed each year and

approximately 14,000 women die from OC each year [2]. While the causes of OC remain
unknown, risk factors for OC include Caucasian race, age, increased number of ovulatory cycles
associated with early menarche, late menopause, nulliparity [4], family history of breast and/or
ovarian cancer, and BReast CAncer genes 1 and 2 (BRCA1/2) mutations [5–7].
A precursor of epithelial OC has not been identified [8,9] and the site of origin of OC remains
unknown [10]. OC is thought to arise from the ovarian surface epithelium [11,12], a specialized
mesothelial layer of cells derived from the coelomic epithelium [10] that covers and protects the
ovary [13]. The coelomic epithelium also gives rise to the epithelia of the peritoneum, the fallopian
tubes (FTs) and the uterus and expresses mesenchymal markers Vimentin and N-Cadherin [14].
Further, the common embryonic origin of the epithelia lining the majority of the female
reproductive tract is reflected in histologic subtypes of OC [15] such that serous, mucinous and
endometrioid OCs histologically mimic the epithelium lining the FT, cervix and uterus,
respectively [16]. Recent studies suggest the FT is an alternate source of OC [10], because serous
1

carcinoma, the most frequent OC subtype, resembles the FT [17]. High grade serous OCs account
for much of the mortality associated with OC due to their aggressive phenotype evidenced by
disease relapse following initial treatment and emergence of drug-resistant disease. [18–20].
Lastly, some OC may arise from extra-ovarian origins, i.e. clear cell OC mimics renal clear cell
carcinoma and mucinous OC bears a resemblance to the gastrointestinal tract [20,21].
Symptoms of OC are generally vague and unspecific; symptoms include bloating, pelvic
discomfort, gas pains and a change in urinary frequency. OC symptoms appear during early disease
stages, but the symptoms are usually mistaken for benign intestinal, musculoskeletal, or
gynecologic conditions. Eighty-nine percent of OC patients experience symptoms during the first
stages of disease and 97% of OC patients experience symptoms in the later stages of disease.
Unfortunately, the non-specific nature of symptoms and a lack of a specific screening test results
in OC generally being diagnosed when it has already metastasized [5].
Current modalities for the detection of OC include pelvic examination, transvaginal ultrasound,
transabdominal ultrasound, and serum CA125 levels (see below). Other imaging methods include
computed tomography, magnetic resonance imaging, and positron emission tomography.
However, none of these modalities is sufficiently sensitive or specific to identify OC, especially
in early stage disease when the 5-year survival rate can be as high as 90% [4,22]. As a result, the
5-year survival for OC patients diagnosed at late stages is generally no better than 30% [23].
Consequently, identifying new screening and detection methods as well as further elucidating the
etiology of OC remains imperative to improving OC patient survival [24].
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Literature-derived OC protein biomarkers
A number of OC biomarkers has been reported to date and include biomarkers found elevated
in the serum, urine and/or tissues of OC patients [25]. These biomarkers may have not only
diagnostic and prognostic clinical value as indicators of survival time, drug resistance and
recurrent disease, but also serve as possible therapeutic targets. OC biomarkers have been
associated with molecular and cellular processes that include inflammation, cellular movement,
proliferation and cell death. Many OC biomarkers also play a role in cancer development by
regulating metastasis, angiogenesis, immune responses, cell cycle regulation and inflammation
[26].
In order to identify the most prominent protein biomarkers associated with OC, a review of the
literature was carried out and monomer protein OC biomarkers with more than 100 publications
in Pubmed or proteins explored by the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening
trial and/or the National Academy of Clinical Biochemistry (NACB) due to their potential
diagnostic and prognostic utility were selected for further review by computational analyses. The
resulting set of 27 biomarkers identified are typically overexpressed in OC patient serum and tissue
and are associated with poor clinical outcome (Table 1). These biomarkers fell within the following
categories:
(1) Cytokines and growth factors: interleukin-6 (IL-6), interleukin-8 (IL-8/ CXCL8), interleukin10 (IL-10), prolactin (PRL), transforming growth factor beta 1 (TGF-β1), tumor necrosis factor
alpha (TNFα) and vascular endothelial growth factor (VEGF);
(2) Structural and Extracellular matrix (ECM) related proteins: claudin 3,4 (CLDN3,4),
collagen1A1, 11A1 (COL1A1 and COL11A1), human plasminogen activator inhibitor-1
(SERPINE1), kallikreins-10, -11 (KLK-10, -11), metalloproteinase-2, -9 (MMP-2, -9), mucin 1
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(MUC1), mucin 4 (MUC4), mucin 16 (MUC16), osteopontin (SPP1) and phosphoprotein 1
(STIP1);
(3) Metabolic regulators: apolipoprotein E (ApoE) and fatty acid synthase (FASN);
(4) Receptors: folate receptor-α (FOLR1);
(5) Proteins of unknown functions in cancer: human epididymis protein 4 (WFDC2/HE4),
mesothelin (MSLN), and tumor stress-induced prostasin (PRSS8).

Cytokines and growth factors
IL-6
IL-8
IL-10
PRL
TGF-β1
TNFα
VEGF
Adhesion proteins/proteases/ receptors

References

Marker of
disease
recurrence

Poor
prognosis

Angiogenesis

Reduced
overall
survival

Drug
resistance

Metastasis/
invasion

Cancer cell
proliferation

Urine

OC cells

Ascites

Tissue

Serum

Protein

Cystic fluid

Table 1.1: Functional and clinical characteristics of OC biomarkers
Protein expression
Clinical outcomes

[27–34]
[35–37]
[30,38,39]
[40–44]
[30,45–48]
[49–53]
[54–57]

CLDN3
CLDN4
COL1A1
COL11A1
FOLR1
SERPINE
KLK10
KLK11
1
MMP2
MMP9
MUC1
MUC4
MUC16
SPP1
STIP1
Metabolic Regulators

[58–66]
[58–66]
[67–69]
[69–71]
[72]
[73–76]
[77–91]
[77–91]
[92–95]
[92–95]
[96–98]
[99–101]
[102–104]
[87,105–109]
[110–117]

ApoE
FASN
Proteins of unknown function

[89,118]
[119–126]

WFDC2
MSLN
PRSS8

[87,127,128]
[129–132]
[133]

Grey shading indicates notable protein expression or reported clinical outcome.
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Herein follows a brief review of these 27 proteins describing their diagnostic, prognostic,
and clinical use as well as their potential contribution and function in the etiology of OC.
Cytokines and growth factors
While both cytokines and growth factors regulate the immune response, cytokines are small
polypeptides secreted from cells that stimulate proliferation, survival and differentiation of other
cells through cytokine receptors. Chemokines, a subtype of cytokines, attract cells to sites of
inflammation, thereby influencing cell migration. Cytokines overexpressed in OC enhance cancer
progression through increased cell survival, migration and chemoresistance [134].
Interleukin-6 (IL-6)
IL-6 is predominately a pro-inflammatory cytokine secreted by T-cells and macrophages to
stimulate the immune response [135]. However, in cancer cells, IL-6 may also promote metastasis
through down-regulation of E-cadherin, thereby inducing epithelial-mesenchymal transition
(EMT) [136]. IL-6 overexpression in OC cells results in an upregulation of anti-apoptotic
regulators and matrix metalloproteinase-9 leading to increased cancer cell proliferation and
invasion, respectively [31,34]. Elevated serum IL-6 is also associated with higher OC stage and
reduced chemotherapeutic responsiveness [32,33].
Interleukin-8 (IL-8)
IL-8 is a chemokine produced by macrophages, endothelial cells and a number of epithelial
cells [137]. IL-8 overexpression increases OC cell proliferation [35] by activating the PI3K/Akt
and Raf/MEK/ERK pathways and altering cell cycle regulating proteins. In addition, IL-8
overexpression appears to enhance OC invasion through an upregulation of matrix
metalloproteinase (MMP2/9 – see below) expression and activity [36].
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Interleukin-10 (IL-10)
IL-10 is an anti-inflammatory cytokine that mediates the immune response through signal
transducer and activator of transcription 3 (STAT3) signaling [138] and effectively inhibits
bacterial-mediated induction of pro-inflammatory cytokines [139,140]. IL-10 levels are elevated
in the serum and ascites fluid of OC patients where it is thought to serve as a useful prognostic
biomarker indicative of disease recurrence [30,39] and worse overall survival [38] by diminishing
the immune response in OC patients.
Prolactin (PRL)
Secreted by the pituitary, PRL is best known for its role to stimulate milk production [141].
However, specific PRL isoforms secreted by monocytes have been shown to enhance the
inflammatory response [142]. Further, by promoting endothelial cell migration and angiogenesis
via enhanced ERK1/2 and STAT5 signaling as well as enhancing breast cancer cell migration
through modulation of the actin cytoskeleton, PRL is believed to promote breast cancer
progression [40,41]. Prolactin is a circulating cytokine/hormone secreted by ovarian follicular cells
[42]. PRL is significantly elevated in OC patient serum [43] where it is believed that increased
PRL expression increases OC PRL receptor expression leading to enhanced OC proliferation via
activation of the MAPK/ERK1 pathway [42]. Further, PRL acts as a tumorigenic agent by
activating Ras in normal ovarian epithelial cells while also protecting these cells from apoptosis
following chemotherapeutic treatment [42]. Lastly, PRL overexpression can enhance OC
migration via reduction of E-cadherin expression [44].
Transforming growth factor beta 1 (TGF-β1)
TGF-β1, a member of the transforming growth factor beta family, is a highly pleiotropic
cytokine involved in cell growth, proliferation, differentiation and apoptosis through Mothers
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against decapentaplegic homolog 3 (SMAD3) signaling in OC [143–145]. TGF-β1 promotes
tumor cell-mediated ECM remodeling. TGF-β1 increases proteinase and plasmin expression by
tumor cells which creates a positive regulatory feedback loop that increases TGF-β1 activation and
release with subsequent ECM degradation. TGF-β1 expression also upregulates MMP expression
leading to increased ECM remodeling [146]. Elevated TGF-β1 serum levels parallel OC stage and
correlate with metastatic disease [30]. Likewise, OC patients with drug resistant disease also
demonstrate elevated serum TGF-β1 [45] so that OC patients with TGF-β1 overexpression have
poor prognosis [46]. Overexpressed TGF-β1 stimulates tumor growth and angiogenesis in
xenograft OC models [47] and OC metastasis through MMP-2 activation [48].
Tumor necrosis factor alpha (TNFα)
TNFα is typically produced by macrophages and lymphocytes to control immune cells during
the immune response [137]. However, TNFα is a multifunctional cytokine mediating diverse
cellular effects including apoptosis, angiogenesis and cell migration [50,51]. Consequently, TNFα
has been implicated in both anti- and pro-tumorigenic roles [147]. TNFα is overexpressed in OC
tissue [49]. Since TNFα overexpression modulates the expression of other cytokines, including IL6 and IL-8, TNFα may mediate inflammatory stimuli that contribute to OC tumorigenesis [52].
TNFα can also act as an endogenous tumor promoter contributing to cellular transformation,
invasion, dissemination and angiogenesis in OC [50,53].
Vascular endothelial growth factor (VEGF)
The VEGF family consists of endothelial cell mitogens that enhance endothelial cell growth
and migration following binding to cell surface receptors that trigger activation of receptor tyrosine
kinases [148]. Secreted VEGF recruits and promotes progenitor endothelial cell growth and
migration that create leaky and permeable cancer vasculature for nutrient transportation and waste
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removal necessary to the survival, proliferation, invasion and metastasis of cancer cells. VEGF
also acts as an anti-apoptotic factor for recruited endothelial cells [54]. VEGF released by and
sequestered in the ECM can be activated by extracellular cleavage by MMPs. Active VEGF then
binds to ECM collagens and proteoglycans in the ECM that then remodel the ECM to enhance
vascular branching and capillary density [149]. Overexpression of VEGF in OC tissue and patient
serum is associated with poor overall survival and can be indicative of tumor recurrence [55].
Serum VEGF levels have been used to predict patients’ response to anti-angiogenic treatment [56].
VEGF levels in the ovarian cyst fluids are elevated in malignant OC tumors compared with benign
or borderline cysts and tumors and inhibiting VEGF expression can lead to suppression of tumor
growth [57].
Structural and extracellular matrix (ECM) related proteins
Transmembrane proteins
Claudin-3 and -4
Claudins (20-27 kDa), a family of transmembrane proteins, play a central role in tight junction
formation, thereby maintaining epithelial integrity [58]. Both claudin-3 and claudin-4 have been
reported to be overexpressed in OC cells [58–65] and associated with increased cancer cell
survival, invasion and motility which may be mediated, in part, through increased MMP-2 activity
(see below). Claudins also play a role in drug resistance since claudin-4 is overexpressed in
cisplatin-resistant OC cells [66]. Claudin-3 and claudin-4 also act as specific receptors of
Clostridium perfringens enterotoxin (CPE) by mediating endotoxin-dependent cell lysis
[150,151]. Treatment of xenograft ovarian tumors with CPE-based therapies results in inhibited
tumor growth suggesting that claudin-3 and claudin-4 may serve as potential targets for therapeutic
intervention in OC [89,152].
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Mucin 1 (MUC1)
MUC1, also known as CA15-3, is a highly glycosylated transmembrane glycoprotein that
facilitates invasion, metastasis, immune system evasion, drug resistance, and survival via the ErbB
and β-catenin-Wnt pathways [96–98]. MUC1 is overexpressed on OC cell surfaces and in OC
patient serum. Compared with normal cells, MUC1 expressed by cancer cells is structurally
different – it is attached to shorter and less dense O-glycan moieties, thereby unmasking novel
protein core epitopes that can be exploited to create antibodies differentiating between normal and
diseased cells. MUC1 is overexpressed in over 90% of OC, but only 5% of normal ovarian tissue.
Mucin 4 (MUC4)
MUC4 is a highly glycosylated glycoprotein that lubricates epithelial cell surfaces. MUC4 is
also a signal modulator that can alter tumor phenotype by reorganizing actin indirectly by HER2mediated pathways [153]. MUC4 expression was reported to be upregulated in 100% and 88% of
early (stage I and II) and advanced (stage III and IV) OC samples, respectively – with an overall
incidence of 92% in OC samples. Though MUC4 plays a diagnostic role, there is no prognostic
correlation of MUC4 expression with prolonged patient survival [99]. OC cells in effusions have
higher MUC4 expression when compared with solid OC primary tumors and metastases [100].
MUC4-expressing OC cells demonstrate an enhanced motility due to the formation of
lamellipodia, filopodia and microspikes [101].
Mucin 16 (CA125)
Mucin16, a transmembrane mucin known as CA125, is a widely used serum marker of OC
[102]. However, CA125 can be elevated in benign conditions, including menstruation,
endometriosis and pregnancy as well as in malignancies of the liver, lung, bladder and pancreas
contributing to false positive results. In healthy adults, CA125 can be expressed in coelomic and
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Mullerian epithelium, as well as the pancreas, colon, gall bladder, lung, kidney, and stomach
epithelia. While CA125 values below 35U/L are considered normal, CA125 is only elevated in
50% of stage I OC patients leading to many false negative results. CA125 is elevated in 75-90%
of advanced stage ovarian disease and CA125 is elevated in approximately 80% of epithelial OCs.
[103,104]. CA125 plays a role in OC peritoneal metastasis by interacting with mesothelin. CA125
also plays an immunosuppressive role in OC by inhibiting natural killer cells’ cytotoxic responses
[98].
Structural and matrix-related proteins
Collagen (COL1A1 and COL11A1)
Collagens are abundant fibrous proteins found in the ECM. Collagen I (COL1A1) is the most
abundant structural constituent of the ECM of OC and has been shown to enhance OC adhesion
and proliferation by interacting with integrin receptors α3β1 and α6β1 that then activate the Ras,
Erk and Akt pathways in OC cell lines [154]. Collagen XI (COL11A1), which is absent in most
tissues, is overexpressed in OC ECM and OC patient serum potentially serving as one of the
earliest indications of cancer initiation and progression [67,69]. COL11A1 overexpression, as
triggered by TGF-β1 activation and SMAD2 signaling, promotes MMP3 activation in OC [68].
COL11A1 overexpression enhances OC migration and invasion [70]. The overexpression of
collagen by OC also serves to reduce chemotherapeutic drug efficacy by inhibiting drug
penetration/access to OC cells, therefore, contributing to drug resistance and OC tissue survival
[71].
Human plasminogen activator inhibitor-1 (PAI-1)
PAI-1, also known as SERPINE1, is a serine protease inhibitor that plays a role in tissue
remodeling [75]. Inactive plasminogen is converted to broad spectrum serine protease plasmin by

10

urinary (uPA) or tissue-type (tPA) plasminogen activators (PAs) which then cleave ECM
components such as fibronectin, laminin, vitronectin, proteoglycans, and fibrins. PAs are regulated
by plasminogen activator inhibitors (PAI) which curb plasmin generation [155]. PAIs prevent the
cleavage of plasminogen by binding to the active site of PA [156]. PAI is overexpressed in OC
patient serum [73] and tissue [74]. PAI-1 overexpression is associated with proliferation and PAI1 inhibitors can act as anticancer agents. PAI-1 expression is associated with poor prognosis [75]
and lower overall survival [73]. Overexpressed PAI-1 has been correlated with higher grade OC
tumors and a higher probability of disease recurrence [76].
Kallikrein (KLK-10, -11)
Kallikriens (KLKs) comprise a family of 15 secreted serine proteases that are dependent upon
a serine in their catalytic site. Secreted into the tumor microenvironment, KLKs, which are thought
to be stimulated by a steroid hormone–driven cascade [84], are involved in tissue remodeling and
neoplastic disease progression [77–79] by promoting ECM degradation, cellular invasion and
metastasis [80–83]. Kallikrein-4, -5, -6, -7, -8, -10, -11, -13, -14, and -15 are overexpressed in OC
tissues, serum, and cell lines at the mRNA and protein levels. Kallikrein-4, -6, and -10 are highly
expressed in serous epithelial ovarian tumors, and kallikrein-5, -11, and -13 are found in nonserous ovarian tumors. Kallikrein–8, -10, -11, -13 and -14 have also been found in ascites fluid of
OC patients [84]. Further, kallikrein-10 and -11, which are promising OC serum biomarkers are,
respectively, elevated in approximately 56% and 70% of OC patients serum and tissue [85–88].
Upregulation of KLKs in OC has been associated with worse overall survival, although conflicting
reports indicate that further research is required [89–91].
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Matrix metalloproteinases (MMP-2 and -9)
MMPs consist of a group of 23 proteins that play an important role in tumor progression by
degrading the basement membrane and ECM components; MMP2 cleaves fibronectin, vitronectin
and collagen I [157] into smaller fragments that enhance adhesion of OC cells via α5β1 (fibronectin
receptor) and αVβ3 (vitronectin receptor) integrin binding [158] and MMP9 degrades E-cadherin
which is involved in cell-cell adhesion and differentiation [93]. MMP-2 and -9 play a role in tumor
metastasis, migration, angiogenesis, cell proliferation and cell–cell interactions [92,93], therefore,
MMP-2 and -9 expression has been associated with poor survival [94]. Differential MMP
expression in OC tissue can be used to distinguish different OC subtypes and determine prognosis;
MMP-2 and -9 are more highly expressed in serous OC than mucinous OC tumors. MMP-2
expression is higher in benign tumors versus borderline and malignant tumors, but MMP-9
expression is higher in malignant tumors versus borderline tumors [95].
Osteopontin (SPP1)
Osteopontin, a glycophosphoprotein found in all body fluids and expressed in the ECM, is
involved in embryonic development, wound healing and tumor development. Osteopontin appears
to promote tumor growth, survival, angiogenesis and metastasis by upregulation of the PI3K/Akt
pathway [105] and MMP-9 activity [87,106,107]. Of clinical significance, osteopontin expression
is higher in OC cells, ovarian tumor tissue and serum of OC patients when compared with healthy
control patients. Osteopontin expression is higher in borderline and invasive tumors than in benign
tumors and normal ovaries, which suggests that osteopontin may be effective to detect early stage
OC [108,109].
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Stress induced phosphoprotein 1 (STIP1)
Stress induced phosphoprotein 1 (STIP1) forms nuclear scaffolds supporting formation of
protein complexes that participate in transcription, protein folding, signal transduction and cell
cycle regulation [159,160]. STIP1 is elevated in melanoma, glioma, hepatocellular carcinoma and
pancreatic cancer and is believed to induce survival and invasion in cancer by modulating the
SMAD pathway and MMP-2 expression [110–115]. STIP1 is significantly higher in OC patients
tissue and serum versus normal age-matched patients [116,117]. Analysis of STIP1 levels in OC
patients with low CA125 levels revealed that STIP1 levels can be used to detect invasive OC as
an alternative diagnostic marker of OC [161].
Metabolic regulators
Apolipoprotein E (ApoE)
ApoE is an essential component of the plasma lipoproteins responsible for cholesterol
transportation and metabolism. ApoE is mostly found in the liver, brain, adrenal glands, kidney,
and macrophages and is associated with cholesterol-rich proteins [162]. ApoE expression has been
associated with serous OC, but not with borderline serous tumors or normal ovarian surface
epithelial. Inhibiting ApoE expression leads to G2 cell-cycle arrest and apoptosis in ApoEexpressing OC cells, indicating ApoE is important for OC proliferation and survival [89,118].
Fatty acid synthase (FASN)
FASN, a cytoplasmic enzyme, is involved in de novo fatty acid synthesis via Nicotinamide
adenine dinucleotide phosphate (NADPH)-dependent condensation of malonyl-CoA and acetylCoA into palmitate [119]. Normal adult tissues minimally express FASN, however, FASN
overexpression has been reported in breast, colon, ovarian and prostate cancer [120,163–168] and
is associated with metabolic dysregulation in cancer cells. FASN levels are elevated in OC
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development, in serous carcinoma [119–121], and especially in recurrent serous carcinomas [122].
Elevated FASN levels parallel cancer aggressiveness, predict poorer overall survival as well as
disease recurrence [119,120,122–126]. FASN-based therapies have been developed for recurrent
OC patients; FASN can be successfully targeted by C93, a FASN inhibitor, to induce apoptosis in
drug resistant OC cells [89,169]. Since FASN is elevated in >75% of OC, the use of therapies
targeting FASN has great potential, but current inhibitors of FASN have limited efficacy due to
cell impermeability and solubility as well as lack of cell selectivity [170,171].
Receptors
Folate receptor-α (FLOR1)
FOLR1, a 38–40 kDa [172] glycosylphosphatidyl-inositol-membrane anchored protein, is
found in the kidneys where it reabsorbs folate (vitamin B9) from the urine filtrate back into the
blood. FOLR1 is normally expressed in the apical surface of epithelial cells [72], especially in the
lung and kidney [172]. FOLR1 is overexpressed in epithelial cancer, including ovarian, renal, lung,
and breast cancers, though its function in cancer is unknown. Overexpressed FOLR1 can be used
to target cancer with therapeutic drugs or imaging agents. FOLR1 is overexpressed in 72% in
primary OC and 81.5% in recurrent tumors and FOLR1 expression is equal in primary, metastatic
and recurrent tumors. Over 90% of non-mucinous OCs overexpress FOLR1, and the level of
FOLR1 correlates with aggressiveness of the malignancy [72]. Secreted functional FOLR1 in the
blood serves as an OC biomarker [172]. While FOLR1 is not a prognostic marker since levels of
FOLR1 do not correlate with survival or tumor response to treatment [173], FOLR1 could deliver
therapeutic drugs to OC tumors. For example, BGC 945, a thymidylate synthase inhibitor, is
transported into the cell via FOLR1 and, therefore, targets cells that overexpress FOLR1 [89,174].
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Proteins of unknown function in OC
Human epididymis protein 4 (HE4)
The WAP Four-Disulfide Core Domain 2 (WFDC2) gene encodes HE4, a secreted “fourdisulfide core” protein of unknown function. The four-disulfide core protein family is a varied
group of acid- and heat-stable proteins that have many proposed functions including aiding in
sperm maturation and storage [127,175]. HE4 is expressed at low levels in the female reproductive
tract, breast and respiratory system. HE4 is a 13KDa protein that is secreted as a 25kDa
glycosylated protein [176]. The WFDC2 gene is amplified in epithelial OC (EOC) tissue and this
is associated with increased HE4 in OC serum while HE4 expression remains low in normal tissue.
In comparison with CA125, serum HE4 levels have greater specificity in discriminating malignant
disease from benign ovarian disease and between early and late stage disease [127]. Likewise,
preoperative HE4 levels may be used to predict the extent and success of cytoreductive surgery
needed for optimal debulking [87,128]. Overexpression of HE4 in OC patients correlates with
lower overall survival and increased cisplatin resistance. Lastly, in vitro and in vivo HE4
overexpression increases tumor growth and cisplatin resistance in OC cells and tumors such that
targeting HE4 suppresses OC cells and tumor growth. HE4 may function by interacting with
EGFR, IGF1R, and TF HIF1α [176].
Mesothelin (MSLN)
The soluble mesothelin-related peptide (SMRP) gene encodes MSLN, a 40 kDa
glycosylphosphatidylinositol-anchored cell surface molecule, found on the cell surface of
mesothelial cells and overexpressed in the serum and urine of patients with mesotheliomas and
OC [129–131]. MSLN is highly expressed in non-mucinous OCs, including endometrioid, clear
cell, and transitional cell carcinoma as well as pancreatic adenocarcinomas, endometrium
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carcinoma and lung carcinoma [177]. While the function of MSLN has not been fully elucidated,
MSLN binds to CA125 on tumor cell surfaces which may alter cell-to-cell adhesion and increase
metastasis to the peritoneum [178]. The development of m912, a human monoclonal antibody to
MSLN, imparts tumor cell toxicity [179]. In contrast, other reports suggest that presence of MSLN
after treatment in advanced-stage OC disease patients is associated with prolonged survival
[130,132].
Prostasin (PRSS8)
PRSS8, first isolated from seminal fluid, is expressed at low concentrations in a variety of
tissues including salivary gland, lung, bronchus, kidney, liver, pancreas, and colon, but is absent
in normal testis and ovary [180]. PRSS8 is a secreted prostatic serine protease and potential OC
biomarker [181]. The function of PRSS8 is not completely understood, however, it is thought to
play a role in fertilization [133,182]. Elevated PRSS8 levels in the serum of OC patients have been
detected with the highest level of PRSS8 detected in stage II of the disease [133].
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Table 1.2. Computational characteristics of OC biomarkers
Biochemical
Characteristi
Posttranslational Modifications
cs
Proteins

Cytokines and growth factors
IL-6
IL-8
IL-10
PRL
TGF-β1
TNFα
VEGF
Adhesion proteins/proteases/ receptors
CLDN3
CLDN4
COL1A1
COL11A
FOLR1
1
SERPIN
KLK10
E1
KLK11
MMP2
MMP9
MUC1
MUC4
MUC16
SPP1
STIP1
Metabolic Regulators
ApoE
FASN
Proteins of unknown function
WFDC2
MSLN
PRSS8
*The protein sequences for the OC biomarkers isolated from the literature were retrieved from
Uniprot for bioinformatics analysis. The distribution of intrinsic protein disorder was analyzed
using disorder predictors PONDR® VLXT [183] and PONDR® VSL2 [184,185] which identify
regions of protein disorder and hydropathy. Amylpred 2 [186] was used to find protein sequences
prone to form protein aggregates. Uniprot [187] was used to determine regions of protein
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instability, signal localization, and binding sites. The predicted post-translational modifications of
each protein was elucidated using different programs. Phosphorylation was predicted using
PhosphoSitePlus (PSP) which provides phosphorylation, ubiquitination, acetylation and
methylation information pertaining to each protein as curated from literature and low- and highthroughput data sources [188]. N-linked glycosylation was predicted using NetNGlyc 1.0 Server
which predicts the acceptor sites of N-linked glycosylation at Asn-Xaa-Ser/Thr (where Xaa is not
Pro) residues. NetNGlyc 1.0 Server predicts glycosylation with 76% overall accuracy [189]. Olinked glycosylation was predicted using NetOGlyc 4.0 Server which predicts the addition of a
glycan moiety on Ser, Thr and Tyr residues. The NetOGlyc 4.0 determined glycosylated proteins
from mapping the proteome of different human cell lines [190]. Sumoylation was predicted by
SUMOplot Analysis Program. Sumoylation is the reversible attachment of a SUMO protein (11
kDa). SUMO protein is added to a peptide sequence of a hydrophobic residue bound to a lysine
bound to any amino acid followed by an acidic residue [191]. Palmitoylation, the reversible
attachment of a 16-carbon saturated fatty acid to a cysteine reside via a thioester linkage was
predicted vis NBA-Palm [192]. Acetylation was predicted to by NetAcet 1.0 Server which predicts
the addition of acetyl moiety by N-acetyltransferase A [193]. Tyrosine sulfation sites were
predicted by the Sulfinator which uses four different models to recognize sulfated tyrosine residues
located in the N- and C- terminals [194]. Myristoylation was predicted using Myristoylator which
looks for sequences that accept the addition of a myristate to a N-terminal glycine [195].
Prenylation was predicted using PrePS which determines protein farnesylation (15 carbon
polyisopren) as carried out by farnesyltransferases and geranylgeranylation (20 carbon
polyisopren) as carried out by geranylgeranyltransferase 1 and Geranylgeranyltransferase 2. PrePS
recognizes the motifs recognized by prenyltransfeases (the CaaX box and Rab escort protein in the
C-terminal of proteins. Therefore, PrePS recognizes CaaX Farnesylation, CaaX
Geranylgeranylation and Rab Geranylgeranylation [196]. Methylation was predicted using MeMo,
the methylation Modification Prediction Server 2.0 which predicts methylation on lysine and
arginine residues [197].
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Shared computational characteristics among OC protein biomarkers
All these OC biomarkers have limited diagnostic usefulness. While none are effective at
detecting all OCs, these OC biomarkers may contribute to malignant transformation and/or disease
progression in OC. Therefore, in order to better understand the molecular mechanisms involved in
OC it would be useful to identify other proteins that may also contribute to OC based on similar
biochemical protein characteristics. Therefore, to identify common biochemical features among
the 27 OC biomarkers derived from literature review, computational analyses for measurements
of protein order, hydropathy, posttranslational modifications, aggregation prone regions and
subcellular localization were performed (Table 1.2). As outlined below, computational analyses
indicated that these reported 27 OC protein biomarkers share characteristics of secreted (presence
of export signal sequence, hydrophilic) and stable (ordered, aggregation prone, glycosylated,
sumoylated) proteins.
Characteristics of secreted proteins - (presence of export signal sequence, hydrophilic)
The majority (22/27) of OC biomarkers examined (ApoE, COL1A1, COL11A1, FOLR1,
IL-6, IL-8, IL-10, KLK10, KLK11, MMP2, MMP9, MSLN, MUC1, MUC4, MUC16, PRL,
PRSS8, SERPINE1, SPP1, TGF-β1, VEGF, WFDC2) are secreted proteins based on the presence
of an export signal sequence while 5/27 (CLDN3, CLDN4, FASN, TNF-α) and only 1/27 (STIP1)
were predicted to be localized at cell membranes or within the cytoplasm, respectively.
Likewise, the vast majority (24/27) of these OC biomarkers (ApoE, COL1A1, CLDN3,
CLDN4, FASN, FOLR1, IL-6, IL-8, IL-10, KLK10, KLK11, MMP2, MMP9, MSLN, MUC1,
MUC4, MUC16, PRL, PRSS8, SERPINE1, TNF-α, TGF-β1, VEGF, WFDC2) were determined
to be hydrophilic in keeping with a secretory protein profile or function within hydrophilic
cytoplasmic environments. Similarly, almost half, 11/27, (COL11A1, IL-10, MUC1, MUC4,
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MUC16, MMP2, SPP1, STIP1, TGF-β1, TNF-α, VEGF) of the OC biomarkers were predicted to
be sulfated. Sulfation, the enzyme-catalyzed conjugation of a sulfo group, often to tyrosine
residues, is required by many secreted proteins that traverse the Golgi apparatus for export [198].
Consequently, it is not unexpected that many of the OC biomarkers should be sulfated.
In contrast, only 8/27 (ACTH, ALB, COL1A1, COL11A1, FASN, IL-10, MMP9, TGF-β1)
were predicted to be methylated. Since methylation increases protein hydrophobicity [199–201]
and the vast majority of OC biomarkers are hydrophilic, it is not surprising that few are predicted
to be methylated. In addition, only 4/27 biomarkers (ApoE, COL1A1, FASN, STIP1) were
predicted to be succinylated. While protein succinylation at lysine residues plays a significant role
in protein structure, folding and function due to the addition of a large structural moiety,
succinylation also typically changes protein charge from +1 to −1 [202]. Since secreted proteins
contain a positively charged amino terminal necessary for the export process, low levels of OC
biomarker succinylation (4/27) are consistent with characteristics of secreted proteins [203].
Lastly, only 3/27 (CLDN3, CLDN4, PRL) are predicted to be palmitoylated and none of the
OC biomarkers are predicted to be myristoylated or prenylated. Since palmitoylation,
myristoylation and prenylation anchor proteins to the membrane with potential for increased
interaction with the endoplasmic reticulum [204], the few OC biomarkers predicted to undergo
these posttranslational modifications suggests that they mostly operate without membrane
anchorage.
Characteristics of stable proteins - (ordered, aggregation prone, glycosylated, sumoylated)
In addition to a secretory protein profile, the majority (19/27) of reported OC biomarkers
(CLDN3, CLDN4, FASN, FOLR1, IL-6, IL-8, IL-10, KLK10, KLK11, MMP2, MMP9, MSLN,
PRL, PRSS8, SERPINE1, TNF-α, TGF-β1, VEGF, WFDC2) were determined to be ordered
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proteins with over 65% ordered content. Since highly ordered proteins have stable secondary
and/or tertiary structures with low physical binding potential to other proteins, these OC
biomarkers are unlikely to form larger multi-protein complexes [205]. Interestingly, 17/27
(CLDN3, CLDN4, FOLR1, IL-6, IL-8, IL-10, KLK10, KLK11, MMP2, MMP9, PRL, PRSS8,
SERPINE1, TGF-β1, TNF-α, VEGF, WFDC2) of the OC biomarkers contain amino acid
sequences of which, greater than 30% are considered aggregation prone regions (APR). APRs are
more likely to represent conserved regions and occur in ordered regions within close structural
proximity to catalytic residues and have, therefore, been theorized to stabilize proteins and
contribute to protein function [206].
With regards to possible post-translational modifications in support of stable protein structures,
most (23/27) of the OC biomarkers studied (ApoE, COL1A1, COL11A1, CLDN3, FOLR1, IL10, KLK10, KLK11, MMP2, MMP9, MSLN, MUC1, MUC4, MUC16, PRL, PRSS8, SERPINE1,
SPP1, STIP1, TNF-α, TGF-β1, VEGF, WFDC2) are predicted to be glycosylated. Glycosylation
can increase protein stability and modify protein function by increasing thermal stability that
destabilizes the unfolded state of proteins [207], thereby playing a role in many cellular functions
including intercellular communication, adhesion and migration, all of which are important in
cancer progression. Consequently, in addition to an ordered and aggregation prone protein
structure imparting a stable protein confirmation, additional protein stability would be conferred
by glycosylation.
Many of the OC biomarkers (20/27) (ApoE, COL1A1, COL11A1, CLDN3, CLDN4, IL-6,
KLK10, KLK11, MMP2, MMP9, MSLN, MUC1, MUC4, MUC16, SERPINE1, SPP1, STIP1,
TNF-α, TGF-β1, VEGF) are predicted to be phosphorylated. Phosphorylation can alter protein
activity, stability, function by changing serine, threonine or tyrosine residues from 0 to −2 [202]
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as well as protein interactions [208] by activating intracellular signaling cascades [209].
Phosphorylation is predicted to be a common posttranslational modification in OC biomarkers
because it affects many oncogenic processes, including transcriptional regulation, proliferation and
kinase signaling [210].
Further, the vast majority (22/27) of OC biomarkers (ApoE, COL1A1, COL11A1,CLDN3,
CLDN4, FASN, FOLR1, IL-10, KLK11, MMP2, MMP9, MSLN, MUC4, MUC16, PRL, PRSS8,
SERPINE1, STIP1, TNF-α, TGF-β1, VEGF, WFDC2) are also predicted to be sumoylated.
Sumoylation is a posttranslational modification resulting from the conjugation of Small Ubiquitinrelated MOdifiers (SUMO) to proteins; sumoylated proteins appear to take a part in transcription
[211,212], apoptosis [213], and signal transduction [214]. While the mechanisms that regulate
sumoylation are not well understood, conjugation of SUMO to proteins can alter protein
configuration potentially leading to new protein-protein interactions, inhibition of existing proteinprotein interactions and/or changes to existing protein functions and activity [215], thereby
enhancing functional diversity. In this way, sumoylation can increase protein stability by
promoting the formation of multimeric protein complexes as well as by inhibition of ubiquitination
[216].
In contrast, only 12/27 (ApoE, CLDN3, CLDN4, COL1A1, COL11A1, FASN, MMP9,
MUC1, MUC4, MUC16, STIP1, VEGF) of OC biomarkers were predicted to be acetylated. While
certain forms of protein acetylation can increase protein stability by reducing protein degradation
[217], the principal function of acetylation involves regulation of gene expression. Since the group
of OC biomarkers examined do not typically include transcriptional proteins, it is not surprising
that few might be acetylated. Likewise, only 10/27 (ApoE, CLDN3, CLDN4, COL11A1, FASN,
IL-6, KLK11, PRL, STIP1, TGF-β1) of OC biomarkers were predicted to be ubiquitinated.
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Ubiquitination marks proteins for degradation. Ordered proteins have fewer ubiquitination and
microRNA targeting sites, and lower mRNA decay rates. Therefore, ordered proteins can persist
within cells at higher levels for longer periods before facing decay [218]. This is consistent with
the prediction that most biomarkers (17/27) are not ubiquitinated.
As might be expected for disease biomarkers, computational biochemical analyses indicated
that the set of published OC protein biomarkers share characteristics of secreted (export signal
sequence, high hydrophilic, low hydrophobicity, low palmitoylation, myristoylation and
prenylation) and stable (ordered, aggregation prone, sumoylated, glycosylated, but not acetylated
or ubiquinated) proteins. However, given the functional diversity of these biomarkers as indicated
above, String [219] analysis was also performed to identify a network of functional interactions
among these established OC biomarkers (Figure 1.1). Interestingly, interactions among these
diverse biomarkers appear functionally related to: ECM/microenvironment modifications (CLDN3, CLDN-4, COL1A1, COL11A1, KLK10, KLK11, MMP2, MMP9, MUC1, MUC4, MUC16,
SERPINE1, SPP1); regulation/modulation of the immune response (IL-6, IL-8, IL-10, TNFα) and;
energy production (ApoE, FASN). Since the ECM/ tumor microenvironment encompasses many
components, including stromal cells, ECM components (cytokines, MMPs, integrins, etc.) and
exosomes, it plays an important role in OC dissemination and metastasis through a variety of
mechanisms that include the activation of signaling pathways (AKT and FAK) that induce invasion
and metastasis, the initiation of EMT changes, and the release of proteases and angiogenic factors
that remodel ECM and stimulate microvessel formation [220]. While the immune response
recognizes and eliminates tumor cells, in malignant states, immunosuppression and
immunoediting often prevail leading to unhindered tumor growth. Though increased tumorinfiltrating leukocyte expression is associated with improved survival, OC is associated with an

23

immunosuppressive environment.

Therefore,

future therapies

might

aim

to

reverse

immunosuppression and modulate the immune response to combat OC [221]. Lastly, besides
endogenous energy production, OC cells induce stromal fibroblasts to secrete energy metabolites
lactate and pyruvate that are then shuttled into the tricarboxylic acid (TCA) cycle in OC cell
mitochondria. This shuttling promotes increased energy production contributing to accelerated
tumor growth and angiogenesis [222].
Identifying additional key regulators of OC
The best OC biomarker in clinical use today is CA-125 which has a number of limitations
including expression in less than 50% of stage I disease and expression that is rarely elevated in
mucinous, endometrioid or clear-cell carcinomas. CA-125 is elevated in advanced-stage OC and
in some benign and malignant conditions and is dependent on additional factors including age,
history of hysterectomy and weight. Though many potential OC biomarkers have been identified
in the literature (see above), none have overcome CA-125’s clinical limitations [26]. However, the
potential biomarkers reported in literature highlight different biological pathways of ovarian
tumorigenesis that could increase our understanding of the etiology of OC. Many of the OC
biomarkers identified so far fall loosely within three functional groups - immune response,
ECM/microenvironment modifications, energy production and metabolism. Therefore, these
protein regulators of OC may be relevant for elucidating mechanisms and pathways of disease
initiation and progression.
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Figure 1.1. OC biomarkers have functional interactions. Analysis of the interactivity of published
OC biomarkers by String produced a network of predicted associations for these proteins. The
network nodes are proteins, whereas the edges represent the predicted or known functional
associations. An edge may be drawn with up to 7 differently colored lines that represent the
existence of the seven types of evidence used in predicting the associations. A red line indicates
the presence of fusion evidence; a green line - neighborhood evidence; a blue line – co-occurrence
evidence; a purple line - experimental evidence; a yellow line – text mining evidence; a light blue
line - database evidence; a black line – co-expression evidence.
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70,616 non-redundant proteins

8,059 proteins have signal peptide

Literature review of monomer OC
biomarkers with more than 100
publications in PubMed and proteins
explored by PLCO screening trial
and/or the NACB

1,848 proteins have signal peptides
and are secreted

1,578 proteins have signal pepties,
are secreted and ordered
Secreted proteins with export signal
peptide sequences that are ordered,
hydrophilic, and have aggregationprone sequences

758 secreted proteins with signal
peptides, are ordered and have
aggregation-prone regions

683
computational
derived
proteins

27 literature
derived
proteins
21 proteins that
interact with literature
biomarkers

Figure 1.2. Summarial schematic identifying additional protein regulators of OC. Proteins
(70,616) of the human proteome were subjected to sequential computational analysis to
identify proteins (21) that are secreted, ordered and aggregation-prone and which interact
with previously reported OC biomarkers (27).
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Consequently, expanding upon the characteristics of stable and secreted OC biomarkers
noted above (ordered, aggregation-prone, hydrophilic, export signal peptide sequence and secreted
proteins) potentially involved in immune response, ECM/microenvironment modifications, and
energy production and metabolism, I explored the human proteome to identify additional protein
regulators of OC (Figure 1.2). According to the Uniprot Database, the human proteome contains
70,616 non-redundant proteins, of which 8,059 proteins contain an export signal peptide and of
which 1,848 proteins are secreted. Of these 1,848 proteins 1,578 proteins are ordered and 758 of
the non-redundant proteins have aggregation-prone regions that cover 30% of their total amino
acid composition. Of these proteins, 75 proteins are putative or uncharacterized proteins of
unknown function and, therefore, were removed from the proposed list of proteins to identify 683
proteins as potential protein regulators of OC (Appendix I). Interestingly, of those 683 proteins,
243 proteins are functionally related to the regulation/modulation of the immune response, 235
proteins functionally related to ECM/microenvironment modifications, 120 proteins functionally
related to energy production and metabolism and 86 proteins of unknown function. Subsequent
String analysis demonstrated possible interactions between 27 of the functionally known literaturebased OC biomarkers and 21/683 putative biomarkers (Figure 1.3, Table 1.3) including three
isozymes of amylase, a secreted and stable protein involved in carbohydrate metabolism.
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Table 1.3: Proteins that interact with literature reported ovarian cancer biomarkers
Protein
Protein name
Function in cancer
CXCL12
Stromal cell-derived factor 1 (SDF-1) (hSDF-1) (C-X- Tumor growth,
C motif chemokine 12) (Intercrine reduced in
angiogenesis,
hepatomas) (IRH) (hIRH) (Pre-B cell growthimmune functions,
stimulating factor) (PBSF) [Cleaved into: SDF-1inflammation,
beta(3-72); SDF-1-alpha(3-67)]
invasion [26]
IL2
Interleukin-2 (IL-2) (T-cell growth factor) (TCGF)
Immune response
(Aldesleukin)
[223]
GHR
Growth hormone receptor (GH receptor)
(Somatotropin receptor) [Cleaved into: Growth
Tumor growth and
hormone-binding protein (GH-binding protein)
metastasis [224]
(GHBP) (Serum-binding protein)]
IFNG

Interferon gamma (IFN-gamma) (Immune interferon)

VWF
KDR

Von Willebrand Factor
Kinase Insert Domain Receptor/ Vascular endothelial
growth factor receptor 2
Tissue-type plasminogen activator (t-PA) (tplasminogen activator) (tPA) (EC 3.4.21.68)
(Alteplase) (Reteplase) [Cleaved into: Tissue-type
plasminogen activator chain A; Tissue-type
plasminogen activator chain B]
Urokinase-type plasminogen activator (Uplasminogen activator) (uPA) (EC 3.4.21.73) [Cleaved
into: Urokinase-type plasminogen activator long chain
A; Urokinase-type plasminogen activator short chain
A; Urokinase-type plasminogen activator chain B]
Heparanase (EC 3.2.1.166) (Endo-glucoronidase)
(Heparanase-1) (Hpa1) [Cleaved into: Heparanase 8
kDa subunit; Heparanase 50 kDa subunit]
Thymic stromal lymphopoietin
Cytokine receptor-like factor 2 (Cytokine receptor-like
2) (IL-XR) (Thymic stromal lymphopoietin protein
receptor) (TSLP receptor)
Alpha-amylase 1 (EC 3.2.1.1) (1,4-alpha-D-glucan
glucanohydrolase 1) (Salivary alpha-amylase)

PLAT

PLAU

HPR

TSLP
CRLF2

AMY1A

AMY2A

Pancreatic alpha-amylase (PA) (EC 3.2.1.1) (1,4alpha-D-glucan glucanohydrolase)

Immune functions,
Inflammation [225]
Angiogenesis [54]
Angiogenesis [54]
Tumor invasion [155]

Tumor invasion [155]

Tumor proliferation
and metastasis [226]
Inflammation [227]
Inflammation [227]

Cleaves alpha 1, 4glycosidic bonds in
polysaccharides; role
in cancer unknown
[228]
Cleaves alpha 1, 4glycosidic bonds in
polysaccharides; role
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AMY2B

Alpha-amylase 2B (EC 3.2.1.1) (1,4-alpha-D-glucan
glucanohydrolase 2B) (Carcinoid alpha-amylase)

TIMP1

Metalloproteinase inhibitor 1 (Erythroid-potentiating
activity) (EPA) (Fibroblast collagenase inhibitor)
(Collagenase inhibitor) (Tissue inhibitor of
metalloproteinases 1) (TIMP-1)
Metalloproteinase inhibitor 2 (CSC-21K) (Tissue
inhibitor of metalloproteinases 2) (TIMP-2)
Lipoprotein lipase (LPL) (EC 3.1.1.34)

TIMP3
LPL
APOB
APOA2

INS
LY6G5C

Apolipoprotein B (Including Ag(X) Antigen)
Apolipoprotein A-II (Apo-AII) (ApoA-II)
(Apolipoprotein A2) [Cleaved into: Proapolipoprotein
A-II (ProapoA-II); Truncated apolipoprotein A-II
(Apolipoprotein A-II(1-76))]
Insulin [Cleaved into: Insulin B chain; Insulin A
chain]
Lymphocyte antigen 6 complex locus protein G5c

in cancer unknown
[228]
Cleaves alpha 1, 4glycosidic bonds in
polysaccharides; role
in cancer unknown
[228]
Invasion/metastases
[26]

Invasion/metastases
[26]
Lipid metabolism,
inflammation [229]
Tumor growth [26]
Tumor growth [26]

Tumor growth,
transformation [26]
Unknown
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Figure 1.3. Identification of proteins that interact with literature-derived OC biomarkers. The 27
literature OC biomarkers interact with 21 proteins from the human proteome with similar structural
and functional characteristics, including the amylase isozymes AMY-1A, -2A, and -2B. Analysis
of the interactivity of published OC biomarkers by String produced a network of predicted
associations for these proteins. The network nodes are proteins, whereas the edges represent the
predicted or known functional associations. An edge may be drawn with up to 7 differently colored
lines that represent the existence of the seven types of evidence used in predicting the associations.
A red line indicates the presence of fusion evidence; a green line - neighborhood evidence; a blue
line – co-occurrence evidence; a purple line - experimental evidence; a yellow line – text mining
evidence; a light blue line - database evidence; a black line – co-expression evidence.
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Rationale
Given the overall poor survival associated with OC, it is imperative to identify and
delineate the role of novel protein regulators of OC in order to understand their role OC progression
and which could also one day serve as potential targets for therapeutic intervention. While
comprising a diverse group of functional proteins, OC biomarkers share several features including
a preponderance for a stable protein structure (ordered, hydrophilic, aggregation-prone,
glycosylated and sumoylated), the ability to be secreted (export signal peptide sequence,
hydrophilic) and functionality related to ECM modification, immune response and/or energy
production. Interestingly, several amylase isozymes are noted among the potential OC protein
biomarkers of interest identified for further investigation (Figure 3, Table 3). Elevated serum levels
of amylase or hyperamylasemia, has been long associated with OC and has been studied as both a
diagnostic and prognostic indicator even though its functional contribution to OC progression
remains unknown. Amylase is also interesting because it can potentially play multiple roles in OC,
including cleaving alpha 1, 4-glycosidic bonds in polysaccharides to initiate carbohydrate
metabolism, thereby contributing to energy production. Amylase may also play a role in ECM
remodeling by cleaving polysaccharide moieties in the tumor microenvironment; amylase has
already been shown to degrade bacterial biofilm in wounds [228]. It has also been proposed that
amylase is released as part of an immune response due to inflammatory microenvironment induced
by OC [230].

Central Hypothesis
The objective of this study is to determine the function of amylase in OC. My central
hypothesis is that increased amylase expression and secretion alters ECM structure and
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composition to enhance OC cell invasion. This study also proposes that Spirulina is a novel
transcriptional inhibitor of amylase which can decrease OC invasion. Three aims are proposed.

Aim 1: Characterize and predict which amylase isozyme(s) is overexpressed in OC.
Currently, it is unclear which amylase isozyme is overexpressed in OC. Computational
analyses will be performed on the amylase isozyme (AMY1A, -1B, -1C, -2A, and -2B) sequences
to determine the characteristics of each isozyme and predict which isozyme is most likely
overexpressed in OC. Predicted overexpression of specific amylase isozymes will be validated in
serum samples from healthy controls and patients with OC.

Aim 2: Determine the extracellular function of amylase in OC.
In order to begin to understand the role of amylase for OC progression, an in vitro model
system of OC cell lines that overexpress and secrete amylase will be established, then utilized to
show that by remodeling ECM, amylase may contribute to OC cell invasion.

Aim 3: Transcriptionally inhibit amylase expression using a novel agent.
Since hyperamylasemia is associated with poor clinical outcome in cancer [231], amylase may
represent a novel target for therapeutic intervention. Commercially available amylase inhibitors
typically inhibit amylase at the protein level. I propose to employ Spirulina, a dietary supplement,
as a novel transcriptional inhibitor of amylase. Subsequently, the ability of Spirulina to inhibit OC
cell migration and invasion will be determined.
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Defining the function of amylase in OC will fill a much needed gap about the etiology of OC.
Further, these studies will establish a novel transcriptional inhibitor of amylase that may lead to
more effective treatment options for OC patients with hyperamylasemia.
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Chapter 2
Computational Analysis of Amylase Isozymes Contributing to Ovarian Cancer

Introduction
Glucose metabolism is the fundamental biochemical reaction providing energy to cells.
Whether by oxidative phosphorylation or glycolysis [232], glucose consumption is typically
greater in cancer cells than their normal counterparts [233,234]. Alpha-amylase (commonly
referred to as amylase) was first characterized as a starch digesting enzyme in 1913 [235]. There
are three main classes of amylase (α, β and γ) that differ in their structure, mechanism of action
and phylogenetic location; α-amylase is found in animals, plants, fungi, and bacteria, β-amylase is
found in plant seeds and γ-amylase is found in yeast and fungi [236]. Amylase cleaves alpha 1, 4glycosidic bonds in polysaccharides to initiate carbohydrate metabolism. Consequently, since αamylase is restricted to mammalian cells and since starch is the major source of dietary glucose,
changes in the levels of α-amylase could influence cancer cell survival.

History of the amylase genes
In 1988, cloned amylase genes examined by Southern blot indicated there are three distinct
copies of the amylase genes in the human genome (AMY1, amy2 and amy3 ) whereas previously,
it was thought there is only salivary AMY1 and pancreatic AMY2 [237,238]. In 1989, amy2 and
amy3 were dubbed AMY2A and AMY2B, respectively. Previously, amy3 was mostly associated
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with carcinoid tissue because it was isolated from lung cancer tissue [239]. The AMY2B amylase
gene was cloned and characterized; it was found to consist of ten exons that are highly homologous
to the ten exons that make up AMY1 and AMY2A (amy2). The introns of AMY1, AMY2A, and
AMY2B were also reported to be highly homologous. However, it was found that AMY2B has
two unique untranslated regions in the 5’ region, placing the promoter of the AMY2B gene farther
upstream than the promoters of AMY1 and AMY2A [240]. A later report found AMY1 consists
of 11 exons [241].

Evolution and expression of amylase genes
Amylase consists of a family of isozymes derived from a single ancestral gene. The
evolution of amylase genes started 43 million years ago with the insertion of a γ-actin pseudogene
before the primordial amylase gene constituting the ancestral amylase gene (Figure. 2.1A). The
ancestral gene underwent duplication. One copy of the ancestral amylase genes has maintained its
structural integrity to date and is referred to as AMY-2B (Figure. 2.1A). However, approximately
39 million years ago, a retroviral insertion interrupted the actin pseudogene of the other copy of
the ancestral gene and is dubbed the ‘retroviral’ amylase gene. The ‘retroviral’ amylase gene then
underwent further duplication. One copy of the ‘retroviral’ amylase gene underwent long terminal
repeat (LTR) recombination to become AMY-2A. Approximately a million years ago, the other
‘retroviral’ amylase gene triplicated to become AMY-1A, -1B, and -1C. Consequently,
evolutionary diversification has resulted in five amylase genes (AMY-1A, -1B, -1C, AMY-2A, 2B) clustered on the short arm of chromosome one at p21 (Figure 2.1B). These genes are
characterized by three distinct gene flanking regions including a retroviral insertion (AMY1A,
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AMY1B, and AMY1C), a 3/5’LTR recombination (AMY2A) and an actin pseudogene (AMY2B)
(Figure 2.1C) [242].
A

B

C

Figure 2.1. Schematic of mammalian amylase gene distinction. (A) The five amylase genes
evolved from a single primordial gene. Adapted from [244]. (B) Current amylase genes are
clustered on chromosome 1.p21. Figure adapted from [242]. (C) Evolution of amylase resulted
in three distinct regions flanking the amylase genes characterized by a retroviral insertion
(AMY1A, AMY1B, and AMY1C), a 3/5’LTR recombination (AMY2A) and an actin
pseudogene (AMY2B). Figure adapted from [244].
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The retroviral insertion is thought to have resulted in amylase tissue specificity.
Historically, AMY-1A, AMY-1B, and AMY-1C were thought to encode salivary amylase,
whereas AMY2A and AMY2B encoded pancreatic amylase [243]. However, recently, AMY-2B
protein has been found endogenously in many normal tissues because it does not have tissue
specificity established by the retroviral insertion [243,244]. There are also reports of AMY2B
protein expression in normal tissue such as the liver, gonads, fallopian tubes, ovary, leukocytes
and intestinal tract. There has been evidence that AMY2B’s expression in different tissues is
regulated by unique promoters. The AMY2B’s pancreatic start site differs from its hepatic start
site [243]. AMY1 expression was thought to be exclusively found in salivary glands, however,
AMY1 expression has been reported in two cases of normal thyroid gland tissue, two cases of
cervix tissue, and one case of fallopian tube tissue. A case of normal ovary tissue presented with
AMY1 expression, but a second case of ovarian tissue did not present with AMY1 expression
[245,246]. Both AMY2B and AMY1 expression have been isolated in normal lung tissue [246].
Total amylase levels in the serum of normal healthy human adults are elevated with age; amylase
levels are elevated in women in their 30s and 40s [247].

Amylase gene regulation
The promoter of AMY-2B, the ancestral amylase gene, has not yet been identified. It is
hypothesized that the retroviral insertion either activates a hidden promoter within the actin
pseudogene or acts as an enhancer that drives the endogenous promoter of AMY-2B. Regardless,
the retroviral insertion plays an important regulatory role in the transcription of amylase [248,249].
No work has been done on the regulation of AMY2A and the promoter of AMY2A has not been
validated experimentally.
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In contrast, it has been assumed that the promoters for AMY-1A, -1B, and -1C reside in the
region flanking these genes. Studies targeting the flanking regions of AMY-1C indicate that AMY1C can be activated by integrin and/or growth factor stimulation [248]. Integrin activation leads to
stimulation of downstream signaling cascades and an increase in intracellular calcium levels that
leads to increased amylase expression. Transforming growth factor (TGF)-α activation triggers
phosphatidylinositol phospholipase C (PLC), inositol triphosphate (IP3) and increases intracellular
calcium levels. Downstream protein kinase C (PKC) and ERK1/2 phosphorylation activate the
amylase 1C promoter [249,250]. Both pathways result in increased amylase 1C expression
indicating that the region flanking the amylase gene may play a role in the regulation of amylase
1C expression.
It has been reported that the amylase genes contain general transcriptional enhancer (GRE)
regions in their promoters that respond to glucocorticoid binding. There are two GRE regions in
the promoters of the pancreatic amylase genes and five GRE regions in the promoter of the salivary
amylase genes [238]. The LTRs inserted in the promoters of the salivary AMY1 and AMY2A
genes contain transcriptional control elements including a TATA box, a CCAAT box, a
polyadenylation signal, and GREs [244].

Differentiating amylase isozymes
The amylase enzymes are predominately secreted by the pancreas and salivary glands [251].
Amylase isozymes have been differentiated by digestion of the fluorogenic substrate, FG5P, by
salivary (AMY-1A, -1B, or -1C), pancreatic (AMY-2A) and AMY-2B amylases into FG3 and pnitrophenyl α-maltoside or FG4 and p-nitrophenyl α-glucoside. The FG4/FG3 ratios are 1.88 for
AMY2B, 1.08 for AMY-2A and 0.52 AMY-1A, -1B, or -1C [252].
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Amylase isozymes can also be distinguished by differences in isoelectric points (pI) and
molecular weight. Experimentally, salivary amylase (AMY1A, AMY1B, and AMY1C) has a pI at
6.36 and 6.65 and pancreatic amylase has a pI at 7.4 [253]. On western blots, ovarian tumor
amylase and salivary amylase have a similar migratory pattern and appear as a doublet of
approximately 57 and 60 kDa. The doublet formation is believed to be due to posttranslational
modifications including glycosylation and deamination. In contrast, the pancreatic amylase
isoenzyme migrates as a single band at 55 kDa [253].

Known amylase characteristics
It has been reported that the amylase genes are located on the short arm of chromosome 1 and
amylase proteins have an average molecular weight of 56 kDa [254]. There is also high homology
among the amylase genes. The three AMY1 are more than 99.9% homologous. AMY1 is 93.2%
homologous to AMY2A and 93.6% homologous to AMY2B. AMY2A and AMY2B are 94%
homologous [255]. The 3D structures of the pancreatic [256] and salivary [257] α-amylase were
obtained by X-ray crystallography. The resulting tertiary structures of the salivary and pancreatic
amylase were revealed to be very similar. However, in these studies it was not indicated which
pancreatic amylase (AMY2A or AMY2B) was used to elucidate the tertiary structure. Further,
while calcium (Asn100, Arg158, Asp167, and His201) and chloride ion (Arg195, Asn298,
Arg337) binding sites of the pancreatic amylase protein have been elucidated, all amylase
isozymes have three similar domains: Domain A (residues 1-99, 469-404), Domain B (residues
100-168), and Domain C (residues 405-496) with active sites at residues Asp197, Glu233, and
Asp300.
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A trans-species comparison of human pancreatic amylase, porcine amylase, Aspergillus oryzae
“Taka” (fungus) amylase and Aspergillus niger (fungus) amylase revealed very little primary
sequence homology among these amylases. Yet, strong homology across species in residues 96101, 201, 233-236, and 294-301 confers structural homology of amylases derived from different
animal species [256]. Likewise, amylase isozymes exhibit similar enzyme activity and degrees of
inhibition [253]. Amylase from Aspergillus oryzae has been reported to have a single Nglycosylation site at Asn 197 [258,259].
In rats, amylase activity is affected significantly by the sex cycle; the change in amylase
expression is not correlated to calcium levels in the ovary, but to sex hormones acting on the ovary.
Both salivary and pancreatic amylases were isolated in rat ovary, but only salivary amylase was
isolated in rat serum [260].

Amylase in cancer
Amylase is overexpressed in and secreted by a number of tumors [261] including ovarian
tumors [262]. However, it remains controversial as to which amylase gene encodes amylase
isoenzymes secreted by tumors. Some suggest that amylase secreted by tumors is encoded by
AMY-2B [237,245,263–265], while others consider salivary AMY-1A, -1B, or -1C [240,246,266–
271] as the source of tumor amylases. A unique amylase isoenzyme secreted by tumors has also
been suggested [253,272–274]. Further, it is unknown whether several amylase isozymes or a
single isoform is secreted by tumors. As a result, disagreement and mischaracterization of tumor
amylase isozyme expression is common [253,271].
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Objectives
Hyperamylasemia is associated with disease progression although its contribution to OC is
unclear [1]. Although functionally similar, differential expression of amylase isozymes in OC may
be clinically significant for diagnostic and/or prognostic outcome. Since there is a controversy as
to which amylase isozyme(s) is overexpressed in OC, in this chapter I sought to characterize and
predict which amylase isozyme is overexpressed in OC using computational analyses (evolution,
disorder, hydrophobicity, aggregation, structure, structural features, possible binding partners,
mutation profile, and promoter transcription factors) of human amylase isozymes AMY-1A, -1B,
-1C, -2A, and -2B. Lastly, I sought to validate my prediction in clinical serum samples.

Materials and methods
Sequences used in computational characterization
Computational amylase analyses were performed using the human AMY-1A (NCBI Reference
Sequence: NP_001008222.1); AMY-1B (NCBI Reference Sequence: NP_001008219.1); AMY1C (NCBI Reference sequence: NP_001008220.1); AMY-2A (NCBI Reference Sequence:
NP_000690.10) and AMY-2B (NCBI Reference Sequence: NP_066188.1) protein sequences.
Amylase isozyme homology
ClustalW2 is a program used to align multiple DNA and protein sequences using pairwise
sequence alignment tools; ClustalW2 [275–277] was used to determine the percentage of
homology between amylase protein sequences.
Protein biochemical properties databases
ProtParam [278] was used to define the molecular weight, theoretical pI, instability index
(distinctive dipeptides that confer instability to a protein), and GRAVY (grand average of
hydropathy—the sum of hydropathy values of the entire protein, divided by the number of residues
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in the sequence). Uniprot [187] was used to determine regions of protein instability, signal
localization, and binding sites. The information gathered from Uniprot jointly with SignalP 4.1
and SBASE was also used to construct a general structure depicting the common features shared
by the amylase isozymes.
SignalP 4.1 [279] was used to predict the presence and the cleavage site of a possible signal
transport sequence. The protein sequences were run in SBASE [280] to determine which domains
are in each amylase isozyme. Domains were confirmed with pfam [281,282], a large collection of
the protein families.
Protein disorder
The distribution of intrinsic amylase protein disorder was analyzed using disorder
predictors PONDR® VLXT [183] and PONDR® VSL2 [184,185] which identify regions of protein
disorder and hydropathy. PONDR® VLXT is capable of identifying potential molecular
interactions motifs in disordered proteins and disordered protein regions [184] while PONDR®
VSL2 more accurately predicts general protein disorder.
Secondary structure prediction
CSSP (Consensus Secondary Structure Prediction)[283] was used to predict the consensus
secondary structure of the amylase isozymes. I-TASSER was used to predict the tertiary structure
of the amylase isozymes [284–287]. Amylpred 2 [186] was used to identify protein sequences
prone to form protein aggregates.
Potential protein binding sites within amylase isozyme proteins were identified by the
ANCHOR algorithm [288,289] which determines protein binding motifs within regions of
disordered proteins. String [219] analysis was performed to identify potential amylase isozyme
binding partners by depicting a network of proteins that physically and/or functionally interact
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with amylase. RaptorX-binding [290] analysis was performed to determine ligands that potentially
bind to the amylase isozymes.
Posttranslational modification
HMMpTM [291] was used to predict phosphorylation and glycosylation sites in the
amylase isozymes. Disorder Enhanced Phosphorylation Predictor (DEPP) is a PONDR
phosphorylation predictor that determines possible phosphorylated amino acid residues through
patterns of disorder, hydrophobicity and charge. Sumoylation was predicted by SUMOplot
Analysis Program.
Transcription regulation by promoter analysis
The promoters of the amylase isozymes have not been previously validated by
experimentation. The suspected amylase promoters used were the -600 base pairs flanking the 5'
transcription start site as retrieved from Ensembl genome browser [292]. The promoter regions of
all five amylase isozymes were examined by the Promo database [293,294] to find possible
transcription factor binding sites that could regulate amylase expression. To find other regulatory
regions in the promoter, the Eukaryotic Promoter Database (EPD) [295] was utilized to find the
promoter of the amylase isozymes and then find the TATA box, the GC box and the CCAAT box
sequences within the promoter sequence to better distinguish the core promoter elements.
Mutational analysis of the amylase isozymes
The mutation profiles of AMY-1A, AMY-2A, and AMY-2B were found on cBioPortal
[296,297] for Cancer Genomics, a large scale cancer genomics database that determines the
individual mutations in genes as well as the prevalence of mutations in cancer.
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Clinical Specimens
With prior University of South Florida Institutional Review Board committee approval
serum samples were collected at the H. Lee Moffitt Cancer Center and at the University of South
Florida. A total of 30 de-identified serum samples were collected from women with benign
gynecologic disease (N = 8) as well as from patients with serous OC (N = 8), endometrial cancer
(N = 5), mucinous OC (N = 5), thecoma (N = 1), teratoma (N=1), ovarian anaplastic metastatic
carcinoma (N =1) and clear cell OC (N = 1). Pooled serum (N = 4) from healthy individuals was
obtained from Valley Biomedical Cat. HS1021, Lot. 7A0032 and Lot. 6K2146 (Winchester, VA)
and Atlanta Biomedical Cat. S40590, Lot. M14161 and Lot. C16037 (Flowery Branch, GA) to be
used as control. All serum samples were kept on ice following collection, centrifuged at 3000 g
for 15 minutes at 4°C and supernatants were then aliquoted and stored at –20°C.
Western blot
Serum samples were diluted in CHAPS buffer and 120ug of serum protein were separated
by a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were
transferred to Polyvinylidene fluoride (PVDF) membranes, washed in Tween 20-Tris buffered
Saline (TBST), and blocked in 5% milk in TBST. Blots were incubated in their respective primary
antibodies overnight, followed by incubation with a horseradish peroxidase (HRP)-conjugated
secondary antibody (Fisher, Pittsburgh, PA), and developed via FEMTO Cat. 34095 Life
Technologies (Grand Island, NY). Antibodies used were: AMY1A (1:1000) Cat.H00000276-M04
Abnova (Taipei City, Taiwan); AMY2A (1:500) LS-C114393 LSBio (Seattle, WA); AMY2B
(1:2000) Cat. LS-C173958 LSBio (Seattle, WA); Transferrin ab82411 abcam (San Francisco, CA).
Densitometry was performed using ImageJ software to normalize amylase band strength to the
transferrin bands in serum samples.
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Results:
Amylase isozymes are highly homologous.
Alignment analyses were performed on amylase isozyme protein sequences using
ClustalW2 software. AMY-1A, -1B, and -1C have 100% alignment, whereas they were only 96%
homologous to AMY-2A and 97% homologous to AMY-2B. Amy-2B and AMY-2A are 98%
homologous (Figure 2.2). In short, all the amylase proteins are highly homologous. Henceforth,
AMY-1A, -1B, and -1C are collectively referred to as AMY1.
Amylase isozymes have similar molecular weights and isoelectric points.
While the amylase isozymes contain up to 12 exons (11 exons in AMY1 and 12 exons in
AMY2B), all the amylase isozymes contain 10 coding exons resulting in proteins of 511 amino
acids (Table 2.1). Computational analysis revealed the molecular weight of salivary amylase
(AMY1) and pancreatic amylases (AMY2A and AMY2B) are 57,767.8 Da, 57,706.8 Da and
57,709.8 Da respectively (Table 2.1). Computational pI for AMY1A, AMY2A and AMY2B is
6.47, 6.60 and 6.64, respectively (Table 2.1).
Amylases are highly ordered proteins with one predicted protein binding site.
Protparam predicted that all amylases are stable (ordered) proteins, because they were
beneath the threshold of 40, above of which indicates instability. In mammalian cells, all the
amylase isozymes have an identical half-life of 30 hours in vitro (Table 2.1). PONDR protein
disorder predictor indicated that all amylase isozymes are mostly ordered proteins with small
regions of disorder. While the amylase isozymes have similar regions of disorder, AMY1 and
AMY2B have unique regions of disorder that are not found in AMY2A. AMY1 has two unique
regions of disorder encompassing amino acids 51 through 63 and amino acids 375 through 384;
AMY2B also has two unique regions of disorder encompassing amino acids 51 through 63 and
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Figure 2.2. Amylase proteins are highly homologous. The protein sequences of the amylase
isozymes were subjected to ClustalW2 for alignment. AMY-1A, -1B, and -1C have 100%
alignment, whereas they were only 96% homologous to AMY-2A. AMY-1A, -1B, and -1C are
97% homologous to AMY-2B. Amy-2B and AMY-2A are 98% homologous. Homologous
amino acids share the same color. Clear amino acids are non-homologous.
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Table 2.1. Biochemical properties of amylase determined by computational analyses
AMY1—AMY1A, AMY-1B,
AMY-1C
11 but only 10
coding

AMY-2A

AMY-2B

Significance

10

12 but only
10 coding

Length of αamylase (amino
acids)
Theoretical
molecular
weight (Da)

511

511

511

57767.8

57706.8

57709.8

Theoretical pI

6.47

6.60

6.64

Instability index

23.58

23.56

25.26

Half-life

The estimated half-life is:
>30 hours (mammalian reticulocytes, in
vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
aa107-112
aa109-110
aa108-111

All amylase
isozymes have 10
coding exons
All amylase
isozymes are the
same length
All amylase
isozymes have an
average
computational
molecular weight of
57KDa
All amylase
isozymes have an
average
computational
isoelectric point of
6.57.
All amylase
isozymes are
ordered
All amylase
isozymes are stable
for long periods of
time

Exons

Possible protein
binding
(ANCHOR)
GRAVY
-0.436
(hydrophobicity)
PONDR
hydropathy

0.4516

-0.396

-0.417

0.4559

0.4537

All amylase
isozymes have one
possible binding site
All amylase
isozymes are
hydrophilic
All amylase
isozymes are
hydrophilic
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A

*

*

B

C

*

*

Figure 2.3. Amylase isozymes are ordered proteins. Amylase isozymes AMY-1A, -1B, 1C (A), AMY-2A (B) and AMY-2B (C) were subjected to PONDR analyses for protein
disorder. AMY1 has two unique regions of disorder encompassing amino acids 51 through
63 and 375 through 384; AMY2B has two unique regions of disorder encompassing amino
acids 51 through 63 and 117 through 134 (denoted by*).
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Figure 2.4. Amylase isozymes are hydrophilic. Amylase isozymes AMY-1A, -1B, -1C (A),
AMY-2A (B) and AMY-2B (C) were subjected to PONDR analyses for protein
hydropathy. The amylase isozymes are hydrophilic according to the mean scale
hydropathy. The amylase isozymes also have low absolute mean net charge values
indicating that amylase isozymes are ordered.
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amino acids 117 through 134 (Figure 2.3; denoted by *).
The ANCHOR program predicted a single potential protein binding site within the ordered
protein regions, unique to each amylase isozyme. AMY1 could potentially bind another protein at
amino acids 108-111; AMY2A at 109-110 and AMY2B at 107-112 (Table 2.1).
Amylase isozymes are hydrophilic.
All amylase isozymes have low negative GRAVY (grand average of hydrophobicity index)
scores: AMY1 is -0.436, AMY2A is -0.396 and AMY2B is -0.417 (Table 2.1) indicating they are
hydrophilic (increasing positive GRAVY values indicate higher hydrophobicity). Likewise,
PONDR predicted hydrophobicity scores of 0.4516 for AMY1, 0.4559 for AMY2A and 0.4537
for AMY2B (Figure 2.4, Table 2.1) suggesting that the amylase isozymes are hydrophilic proteins.
Amylase is predicted to be glycosylated and phosphorylated.
HMMpTM and PONDR Disorder Enhanced Phosphorylation Predictor (DEPP) database
were used to identify potential posttranslational modifications, especially glycosylation and
phosphorylation sites (Table 2.2). According to HMMpTM, the amylase isozymes do not differ
significantly from each other with each isozyme containing 13-15 possible glycosylation and seven
possible phosphorylation sites. DEPP predicted that all amylase isozymes also have two
phosphorylated residues at amino acids 166 and 197. AMY2B appears to have a unique
phosphorylation residue at amino acid 133 (Table 2.2, Figure 2.5). The SUMOplot Analysis
Program predicted that all amylase isozymes were sumoylated at amino acids 2, 50, 275 and 279
(Table 2.2).
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Table 2.2 – Secondary structural and posttranslational modifications among amylase
isozymes
AMY1—AMY-1A,
AMY-2A
AMY-2B
AMY-1B, AMY-1C
166, 197
133, 166, 197
Phosphorylation 166, 197
(DEPP)
Phosphorylation 7; residues 246, 259,
269, 279, 290, 291,
(HMMpTM)
304
14; O-linked: 58,
Glycosylation
127, 452, 457, 493
(HMMpTM)
N-linked: 61, 96,
102, 103, 165, 365,
411, 427, 476
2,50, 275, 279
Sumoylation
(SUMO plot)

7; residues 246, 259,
269, 279, 290, 291,
304
13; O-linked: 58,
127, 452, 457, 493
N-linked: 61, 96,
102, 103, 165, 365,
427, 476
2,50, 275, 279

7; residues 246, 259,
269, 279, 290, 291,
304
15; O-linked: 58, 123,
127, 452, 457, 493
N-linked: 61, 96, 102,
103, 165, 365, 411,
427, 476
2,50, 275, 279

Signal peptide
(SignalP)

Yes; 1-15

Yes; 1-15

Yes; 1-15

Consensus
Secondary
Structure
(CSSP)
Aggregation
prone regions
(Amylpred)

Alpha helix: 15.65%
beta strand: 22.30%

Alpha helix: 16.24%
beta strand: 24.07%

Alpha helix: 16.04%
beta strand: 22.11%

16 aggregation prone
regions

21 aggregation prone
regions

22 aggregation prone
regions

The amylase isozymes have common domains, and structural features.
According to SBASE and pfam, all the amylase isozymes have two main structural domains:
an alpha amylase catalytic domain from amino acids 36 to 351 and a C-terminal all-beta domain
from amino acids 421 to 510 (Figure 2.5). The C-terminal all-beta domain is unique to the glycosyl
hydrolase family members and is important for folding and secretion of amylase [298]. SignalP
analysis predicted a transport signal cleavage site at amino acid 15 in all amylase isozymes (Table
2.2) which is in keeping with secretion of amylase out of the cell [299].
Uniprot determined possible cofactor binding sites in amylase isozymes. All amylase
proteins require calcium and chloride cofactors for enzymatic function [300,301] and have calcium
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binding sites at amino acids 115, 173, 182, and 216 and chloride binding sites at amino acids 210,
313, and 352. Amino acids 212 and 248 play an essential role in the active site of all amylase
isozymes (Figure 2.5). All amylase isozymes have four disulfide bonds connecting amino acids 43
to 101, amino acids 85 to 130, amino acids 156 to 175, and amino acids 393 to 399. ProtParam
also predicted that amylase requires calcium and chloride as cofactors with calcium and chloride
binding sites at the same residues predicted by Uniprot (Figure 2.5).
Amylase isozymes have unique binding regions for chloride, calcium and glucose.
RaptorX binding analysis suggested that while all the amylase isozymes bind chloride,
calcium, and glucose, individually, they may have additional binding residues for chloride,
calcium and glucose. All amylase isozymes can bind chloride at residues R210, E248, N313, and
R352 (Figure 2.5). However, AMY2A and AMY2B could bind chloride at residue T269 and
AMY2B might additionally bind chloride at residue H216 (Figure 2.5). Likewise, all amylase
isozymes could bind calcium at residues R173 and D182 (Figure 2.5). However, AMY1 can also
bind calcium at residues N115 while AMY2A might bind calcium at residues N115 and H216
(Figure 2.5). All amylase isozymes appear capable of binding glucose at residues W73, W74, Y77,
Q78, H116, L177, L180, R210, D212, A213, H216, E248, I250, H314, D315, and H320 (Figure
2.5). However, AMY2A and AMY2B can also bind glucose at residues T178 and G321 (Figure
2.5). Therefore, AMY2A and AMY2B appear to share the greatest number of unique binding
residues for chloride, calcium, and glucose which further supports the high homology between
these isozymes.
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Transport signal cleavage site
Calcium binding sites
Chloride binding sites
Glucose binging sites
Active sites
Phosphorylation sites
O-linked glycosylation
N-linked glycosylation
Disulfide bonds
AMY1 calcium binding site
AMY2A calcium binding site
AMY2B calcium binding site
AMY1 anchor possible binding site
AMY2A anchor possible binding site
AMY2B anchor possible binding sites
AMY2A/AMY2B glucose binding site
AMY1/AMY2B N-linked glycosylation site
AMY2A/AMY2B chloride binding site
AMY2B phosphorylation site
AMY2B O-linked glycosylation site

Figure 2.5. Amylase isozymes share structural
features. The SBASE, Uniprot, and DEPP database,
Raptor binding, HMMpTM databases were used to
define general structural features of the amylase
isozymes including domains, co-factor binding sites,
post-translational modifications and residues that
may play an important role in amylase catalytic
activity. The amylase isozymes have an amylase
catalytic domain from amino acid 36 to 351, a Cterminal all-beta domain from amino acid 421 to 510,
calcium binding sites at amino acids 173 and 182,
chloride binding sites at amino acids 210, 248, 313,
and 352, and glucose binding sites at amino acids 73,
74, 77, 78, 116, 117, 180, 210, 212, 213, 2116, 248,
250, 314, 315, and 320. The amylase isozymes also
have four disulfide bonds at amino acids 43 to 101,
amino acids 85 to 130, amino acids 156 to 175, and
amino acids 393 to 399. Uniprot also determined that
amino acids 212 and 248 play an essential role in the
active site. All amylase isozymes have
phosphorylation sites at amino acids 166, 197, 246,
259, 269, 279, 290, 291, and 304. All amylase
isozymes have O-linked glycosylation sites at amino
acids 58, 127, 452, 457, and 493 and N-linked
glycosylation sites at amino acids 61, 96, 102, 103,
165, 365, 427, and 476. B) Unique calcium, chloride,
and glucose binding sites, phosphorylation and
glycosylation sites and anchor potential binding sites
are also depicted on the bottom of the figure.
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The amylase isozymes have similar secondary and tertiary structure profiles.
The secondary structure of amylase isozymes was examined by Consensus Secondary
Structure (CSSP) (Table 2.2). The predicted secondary structure of all amylase isozymes is
composed of over 50% of coil. The other 50% is composed of alpha helices and beta sheets. AMY1
is predicted to have 15.65% alpha helical structure and 22.30% beta sheet structure. AMY2A is
predicted to have 16.24% alpha helical structure and 24.07% beta sheet structure. AMY2B is
predicted to have 16.04% alpha helical structure and 22.11% beta sheets. Therefore, the predicted
secondary structure makeup of the amylase isozymes is very similar.
The tertiary structure as isolated by I-TASSER analysis shows that the tertiary structure of
amylase isozymes AMY1 and AMY2B is identical (Figure 2.6). Though the structure of AMY2A
was similar to the structure of AMY1 and AMY2B, it has looser, less organized and less defined
coil structures (Figure 2.6, denoted by orange arrows).

A

B

C

Figure 2.6. AMY2A has a unique 3D structure. The amylase isozymes
were subjected to RAPTORX to render a 3D structure. The 3D structure of
AMY1 (A), AMY2A (B), and AMY2B (C) determined that the structures
of AMY1 and AMY2B are identical and AMY2A has different coil
structures as denoted by orange arrows.
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Multiple regions of amylase are prone to aggregation.
The aggregation prone regions of the amylase isozymes were predicted by AmylPred2.
AMY1 has 16 aggregation prone regions. AMY2A has 21 regions of aggregation and AMY2B has
22 regions of aggregation (Table 2.2, Figure 2.7). AMY2A and AMY2B displayed unique
aggregation prone regions (Figure 2.7). Unique aggregation regions within AMY2A were mapped
to amino acids 2, 64-68, 97-98, 116, 118, 197, 279-281, 325-332,340-345, 355-356, 383-386, 407415, 439, 456, and 478-480. Likewise, unique aggregation regions within AMY2B mapped to
amino acids 2, 26, 40, 97-98, 116, 176-182, 325-332, 340-345, 355-356, 383-386, 408-409, 413414, 439, and 464-466. While aggregation prone regions were found throughout the proteins, the
isozyme unique aggregation prone regions were mostly found at the terminal ends of the protein
isozymes (Figure. 2.7).

Figure
2.7.
Amylase
isozymes have multiple
aggregation prone regions.
The amylase isozymes were
subjected to analysis by
AmylPred2 in order to
determine aggregation prone
regions. AMY1 has 16
aggregation prone regions.
AMY2A has 21 regions of
aggregation and AMY2B has
22 regions of aggregation.
AMY2A and AMY2B have
unique regions of aggregation
not found in AMY1 (*).
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The amylase isozymes functionally interact with metabolic proteins
According to String analysis, amylase interacts functionally with metabolic proteins
(Figure 2.8). Using a medium confidence interval of interaction, I could isolate proteins that most
likely interact with amylase. Proteins that interact with all amylase isozymes are glycogen
phosphorylase, brain form (PYGB), glucan (1,4-alpha-) branching enzyme 1 (GBE1), glycogen
phosphorylase, liver form (PYGL), glycogen debranching enzyme (AGL), and sucrase-isomaltase
(SI). The proteins that interact with all the amylase isozymes have functions associated with
carbohydrate metabolism (Table 2.3, Figure 2.8). Both AMY2A and AMY2B interact with
Thyroid Stimulating Hormone, Beta (TSHB)
However, amylase isozymes also have unique probable interactions. AMY1 interacts with
lactase (LCT), kinase A anchor protein 1 (AKAP1), kinase A anchor protein 8 (AKAP8), collagen,
type X, alpha 1 (COL10A1), and bacterial/permeability-increasing protein (BPI). The unique
proteins associated with AMY1 are connected to carbohydrate metabolism, antibacterial functions,
and extracellular matrix glycoprotein remodeling. AMY2A interacts with maltase-glucoamylase
(MGAM), glycoprotein 2 (GP2), enolase 1 (ENO1), and pancreatic lipase (PNLIP). The unique
proteins associated with AMY2A are connected to carbohydrate and lipid metabolism, and
immune and antibacterial functions. AMY2B interacts with phosphoglucomutase 1 (PGM1), CD
molecule (CD2), ATPase, Na+/K+ transporting, Alpha 4 Polypeptide (ATP1A4), ATPase,
Na+/K+ transporting, and Alpha 1 Polypeptide (ATP1A1). The unique proteins associated with
AMY2B are connected to carbohydrate metabolism, energy production and immune functions.
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Figure 2.8. Amylase isozymes form functional interactions with other metabolic enzymes.
String database indicate that AMY1 (A), AMY2A (B), and AMY2B (C) have functional
interactions with other starch digesting enzymes. Shown is the interaction network of the
amylase isozymes at medium confidence. Green lines connect proteins which are associated
by recurring conserved genomic neighborhood, red lines indicate gene-fusion events in other
species, blue connections are inferred by phylogenetic co-occurrence derived from similar
patterns of absence and presence of genes, black lines indicate co-expression analysis derived
from similar patterns of mRNA expression, purple lines indicate high-throughput
experimental data, light blue lines indicate associations in curated database, and light green
lines indicate textmining or co-occurrence of gene/protein names in abstracts.
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Table 2.3. Proteins that functionally interact with amylase isozymes
Proteins that interact with all amylase isozymes
AGL
Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase. Glycogen debrancher
enzyme which is involved in glycogen degradation.
PYGB
Phosphorylase, glycogen; brain; Glycogen phosphorylase found predominantly in
the brain as an allosteric enzyme in carbohydrate metabolism.
GBE1
Glucan (1,4-alpha-), branching enzyme 1; Glycogen branching enzyme required
for sufficient glycogen accumulation.
PYGL
Phosphorylase, glycogen, liver. This gene encodes a protein that cleaves alpha-1,
4-glucosidic bonds to release glucose-1-phosphate from liver glycogen stores.
SI
Sucrose-isomaltase (alpha-glucosidase). This gene encodes a sucrose-isomaltase
complex essential for the final stage of digestion of dietary carbohydrates.
Proteins that interact with both AMY2A and AMY2B
TSHB
Thyroid Stimulating Hormone, Beta is indispensable for the control of thyroid
function and metabolism.
Proteins that interact only with AMY1
LCT
Lactase-glycosylceramidase is an integral protein in the plasma membrane that has
both lactase activity and phlorizin hydrolase activity.
AKAP1
A kinase (PRKA) anchor protein 1; binds to type I and II regulatory subunits of
protein kinase A and anchors them to the mitochondrion.
AKAP8
A kinase (PRKA) anchor protein 8; anchoring protein that mediates the
compartmentation of PKA and other signaling molecules. AKAP8 may target
PKA and the condensin complex to chromatin during mitosis for chromosome
condensation.
COL10A1 Collagen, type X, alpha 1; type X collagen is a homotrimer product of
hypertrophic chondrocytes during endochondral ossification
BPI
Bactericidal/permeability-increasing protein. This gene encodes a
lipopolysaccharide binding protein associated with human neutrophil granules and
has antimicrobial activity against gram-negative organisms.
Proteins that interact with only AMY2A
MGAM
Maltase-glucoamylase (alpha-glucosidase) is a brush border membrane enzyme
that plays a role in the final steps of digestion of starch.
GP2
Glycoprotein 2 (zymogen granule membrane) encodes an integral membrane
protein that is secreted from intracellular zymogen granules and associates with
the plasma membrane via glycosylphosphatidylinositol (GPI) linkage. The
encoded protein binds pathogens such as enterobacteria, thereby playing an
important role in the innate immune response.
ENO1
Enolase 1, (alpha). Each isoenzyme is a homodimer composed of 2 alpha, 2
gamma, or 2 beta subunits, and functions as a glycolytic enzyme. Alternative
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splicing of this gene results in a shorter isoform that has been shown to bind to the
c-myc promoter and function as a tumor suppressor.
PNLIP
Pancreatic lipase. It encodes a carboxyl esterase that hydrolyzes insoluble,
emulsified triglycerides, and is essential for the efficient digestion of dietary fats.
Proteins that interact with only AMY2B
PGM1
Phosphoglucomutase 1 belongs to the phosphohexose mutase family. There are
several PGM isozymes, which are encoded by different genes and catalyze the
transfer of phosphate between the 1 and 6 positions of glucose. In most cell types,
this PGM isozyme is predominant, representing about 90% of total PGM activity.
ATP1A4
ATPase, Na+/K+ Transporting, Alpha 4 Polypeptide. The protein encoded is the
catalytic subunit of the subfamily of Na+/K+ -ATPases, an integral membrane
protein responsible for establishing and maintaining the electrochemical gradients
of Na and K ions across the plasma membrane essential for osmoregulation, for
sodium-coupled transport of molecules, and for electrical excitability of nerve and
muscle.
ATP1A1
The catalytic component catalyzes the hydrolysis of ATP coupled with the
exchange of sodium and potassium ions across the plasma membrane. This action
creates the electrochemical gradient of sodium and potassium ions, providing the
energy for active transport of various nutrients.
CD2
CD2 molecule, a surface antigen of the human T-lymphocyte lineage that is
expressed on all peripheral blood T cells. It is one of the earliest T-cell markers,
being present on more than 95% of thymocytes and on some natural killer cells.
* Protein description was retrieved from GeneCards

Amylase isozyme expression may be driven by differential promotor activation
To begin to understand the mechanisms responsible for hyperamylasemia in OC, additional
computational analyses were performed to identify potential transcription factors that might
regulate amylase expression. Promo was used to analyze the probable promoter regions of the
amylase isozymes. Promo predicted probable attractive transcription factor binding sites within
each probable promoter region. It also predicted which transcription factors would be most likely
to bind to these potential transcription factor binding sites (Figure 2.9). The binding sites of these
transcription factors are located at different regions of the isozyme promoter sequences, suggesting
differing patterns of regulation.
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Transcription factors C/EBP alpha (regulates cell cycle regulation), C/EBP delta (regulates
immune and inflammatory responses), and Zic1/2 (regulates mammalian development) were
predicted to regulate AMY1 and AMY2A promoter activity. STAT5A (signal transduction and
transcription factor) is a unique transcription factor of AMY1. C/EBP delta was also identified as
a candidate transcription factor for AMY2B, however, POU1F1 (regulates mammalian
development) and Cdx-1 (regulates intestine-specific gene expression) were uniquely predicted to
regulate AMY2B (Figure 2.9).
The EPD was utilized to find potential core promoter elements such as the TATA, CG and
CCAAT boxes (Figure 2.9). AMY1 has a TATA box at residues -51 to -33 and a CG box at
residues 40 to 55. AMY2A has TATA boxes at residues -52 to -21 and -17 to -5. AMY2A also has
two CCAAT boxes at residues -598 to -585 and -547 to -534. AMY2B has two TATA boxes at
residues -138 to -101 and -50 to -33 and a CG box at residues 15 to 28.
AMY2B overexpression is the most likely to be associated with amplification mutations in
cancer
cBioPortal for Cancer Genomics database determined the frequency and pattern of mutations in
the amylase isozymes. The number of reported amylase genes’ mutation reflects their evolutionary
history. AMY2B, the most evolutionarily conserved amylase gene, has developed the most
mutations (n = 86), whereas AMY1, the most recently evolved, has developed the least amount of
mutations (n = 4). All the AMY1 mutations are missense mutations; AMY2B mutations are 90.7%
missense mutations, 3.5% nonsense mutations, 4.6% frameshift mutations and 1.1% splice site
mutations. AMY2A has an intermediate number of mutations (n = 51). Mutations in AMY2A are
82.4% missense mutations and 17.6% nonsense mutations (Figure 2.10).
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Figure 2.9. AMY2B has unique potential transcription factors. The potential promoters of the
amylase isozymes were retrieved from Ensembl genome browser and analyzed by Promo database
to identify candidate transcription factors driving amylase promoter activity.
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Figure 2.10. Mutational events are highest in AMY2B. cBioPortal for Cancer Genomics
database determined the pattern of mutations in the amylase isozymes AMY1 (A), AMY2A
(B), and AMY2B (C). Mutations are denoted by lollipops – green lollipops denote missense
mutations, red lollipops denote truncating mutations, black lollipops denote inframe deletions
and insertions. Purple lollipops denote residues affected by multiple mutation types. AMY2B,
the most conserved amylase gene, has developed 86 mutations, whereas AMY1, the most
recently evolved, has developed 4 mutations. AMY2A developed 41 mutations.
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Figure 2.11: AMY2B is altered in most cancer types (Continued on Next Page)
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Figure 2.11. AMY2B is altered in most cancer types. Amplifications comprise the majority
of amylase mutations in OC. cBioPortal for Cancer Genomics database determined the
mutational profiles for amylase; AMY1 (A), AMY2A (B), and AMY2B (C).

cBioPortal for Cancer Genomics database determinations also revealed a variety of mutations
among the amylase isozymes, including non-specific mutations, deletion mutations and
amplification mutations present in many cancer types including cancers of the lung, colon, uterus
and skin (Figure 2.11). Mutations in AMY1, AMY2A, and AMY2B were found in 21, 24, and 26
cancer types, respectively. AMY1 mutations in cancers other than OC mostly arise from genetic
amplifications and deletions whereas AMY2A mutations in other cancers are comprised of a
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mixture of deletions, amplifications and missense mutations. Likewise, AMY2B mutations in
other cancers typically occur as missense mutations and amplification mutations (Figure 2.11).
The pattern of amylase isozyme mutations in OC is somewhat different from that in other
cancer types. In OC, the mutational profile of amylase isozyme AMY1 consists mostly of
amplifications and deletions while the mutational profile of the amylase isozyme AMY2A in OC
is mostly amplifications as well as some deletions and nonsense mutations. The pattern genetic
mutation of the amylase isozyme AMY2B in OC is also mostly due to amplifications although
some deletions, truncations and in-frame mutations are also noted. Further, in OC, the mutation
frequency of the amylase isozyme AMY1 was determined to be 2.2% amplifications and 0.3%
deletions. The mutation frequency of AMY2A was 2.1% amplification, 0.3% deletion, 0.1%
missense mutation and 0.1% mixed missense mutation and amplification while the mutation
frequency of AMY2B was 2.2% amplifications and 0.3% deletions (Figure 2.11).
Lastly, cBioPortal for Cancer Genomics database was utilized to determine amylase isozyme
mRNA expression in different cancers (Figure 2.12). AMY1 mRNA expression was low in most
cancers. Only OC, lung squamous carcinoma, thyroid cancer and lung adenocarcinoma expressed
relatively high AMY1 mRNA levels. AMY2A mRNA expression was almost negligible in most
cancers except for its high mRNA expression in pancreatic cancer. AMY2B mRNA expression
was relatively high in all cancers explored by the database. In OC, AMY2B mRNA expression
levels were highest followed by AMY1 and AMY2A mRNA expression levels.
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Figure 2.12: AMY2B is the most expressed amylase isozyme in OC (Continued on Next Page)
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Figure 2.12. AMY2B is the most expressed amylase isozyme in OC. cBioPortal for Cancer
Genomics database determined amylase isozyme mRNA expression in cancers at the
transcriptional level; AMY1 (A), AMY2A (B), and AMY2B (C). AMY2B demonstrated the
highest RNA expression in OC when compared with other amylase isozymes (denoted by
boxes). AMY2B RNA is most expressed in OC followed by AMY1 and AMY2A mRNA.

Clinical validation confirms elevated levels of AMY2B protein in OC
While my computational analyses predicted elevated AMY2B RNA levels in OC, validation
of elevated AMY2B protein had yet to be determined in OC. Therefore, to validate differential
amylase isozyme protein expression with OC, serum samples from healthy controls, women with
benign gynecologic disease and women with OC and endometrial cancer were subjected to WB
analyses. Using the 95th percentile of amylase values for healthy controls as the threshold for serum
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amylase positivity, the amount of serum AMY1, AMY2A and AMY2B was generally negligible
in healthy pooled controls and individual serum samples from women with benign gynecologic
disease (Figure 2.13). Likewise, negligible amounts of AMY1A and AMY2A protein were present
in serum samples from endometrial cancer, clear cell carcinoma and mucinous OC. While elevated
levels of AMY2B protein were noted in most endometrial cancers (4/5) and clear cell OC (1/1),
AMY2B protein levels were only elevated in 2/5 mucinous OC. AMY2B levels. In contrast, serum
samples from patients with serous ovarian carcinoma revealed AMY1 (in 3/8 samples) and
AMY2B (in 7/8 samples) protein levels up to 2x greater than healthy controls.

Figure 2.13: Serum levels of AMY2B protein are altered in OC (Continued on Next Page)
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Figure 2.13. Serum levels of AMY2B protein are altered in OC. Serum samples from normal
controls (*), women with benign gynecologic disease and cancer were subjected to western
immunoblotting for amylase AMY1, AMY2A, AMY2B (upper panel). Amylase band intensity
was quantified and densitometry values are expressed relative to the transferrin control group
(lower panel).

Discussion:
The chromosomal localization of the amylase isozymes on chromosome 1p21 [302,303],
evolutionary development of the amylase isozymes from a single ancestral gene [242–244], and
similar biochemical properties such as the molecular weight, isoelectric point [242,304] and
calcium and chloride cofactor binding features common to the amylase isozymes have been
identified in the literature previously [305,306]. Further, the catalytic domain and the C-terminal
domain of the amylase isozymes [307], and crystalized tertiary structure of the amylase isozymes
[257,308] have also been elucidated.
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Given the common evolutionary background and shared sequence homology, it is not
surprising that the amylase isozymes share biochemical and structural features despite differential
tissue expression. Computational analyses indicated that the amylase isozymes are composed of
511 amino acids, have an average computational molecular weight of 57 kDa and an average
computational isoelectric point of 6.57. The amylase isozymes also bind chloride and calcium as
enzymatic cofactors. This, coupled with predictions that the amylase isozymes are hydrophilic,
suggests that amylase is secreted from cells, in keeping with its known digestive function.
Structurally, the amylase isozymes share a common structure dominated by an amino terminal
transport signal site and a catalytic domain. The amylase isozymes also share common
phosphorylation, glycosylation, and calcium, chloride and glucose binding sites.
Computational analysis was not always in agreement with known properties of amylase
reported in literature. Both computational and known literature reported the homology of the
amylase isozymes as being above 90%; however, the amylase isozymes are much more
homologous according to the computational analysis. Literature reported molecular weight and
isoelectric point did not differentiate between the AMY2A and AMY2B making the computational
analysis of the amylase isozymes size more specific. There was no agreement between the results
of the computational analysis and literature reported domains of the amylase isozyme, the position
of the active sites or the calcium and chloride binding sites. This discrepancy may be due to the
different algorisms used by the computational programs and may not accurately depict biological
conditions. It may also be that experimental validation of the new biological knowledge found by
computational programs has not been done.
In order to begin to understand the role of and mechanisms contributing to hyperamylasemia
seen in OC, I performed computational analyses to identify unique features of the amylase
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isozymes in order to predict which isozyme would most likely be overexpressed in OC-associated
hyperamylasemia. Computational analyses highlighted new features of the amylase isozymes not
previously reported (Table 2.4). They include the following:
First, potential unique post-translational modifications, including novel glycosylation and
phosphorylation sites, were identified among the amylase isozymes. Glycosylation is a regulated
and reversible modification including the covalent bonding of a sugar moiety of variable length
and arrangement to a protein residue [309]. Glycosylation plays a role in folding and structural
stability of protein, protein localization and interactions as well as immune responses and
modifying cell signaling. Glycosylation of proteins confers a more stable configuration that is less
prone to degradation [310–312]. Glycan dysfunction can lead to cancer, diabetes and liver cirrhosis
[209,313,314], therefore, additional glycan sites at residues 411 for AMY1 and residues 423 and
411 for AMY2B may lead to enhanced protein stability.
Phosphorylation is a flexible, simple, reversible regulatory mechanism utilized by 30% of
human proteins via protein kinases. Phosphorylation can alter protein activity, stability, function,
and interactions. Abnormal phosphorylation is often a cause or consequence of human disease
[208,315]. Phosphorylation affects intracellular signaling cascades that regulate metabolism,
enzyme reactions and protein degradation [209] so a unique phosphorylation site at amino acid
residue 133 in AMY2B (according to DEPP) can be responsible for increased protein stability and
possibly more protein-protein interactions. These potential posttranslational modifications may be
key for amylase function. Together, these unique and/or aberrant posttranslational modifications
could alter amylase transcription, secretion or enzymatic activity contributing to overexpression
of amylase in cancer.
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Table 2.4. Distinguishing computational characteristics among amylase isozymes
AMY1
AMY2A
AMY2B
Tissue specificity
Salivary gland
Pancreas
None
Unique regions of
Amino acid 51-63,
Amino acid 51-63 and
disorder
117-134 and 375-384
117-134
Unique calcium
N115
N115, H216
H216
binding residues
Unique chloride
269
T269
binding residues
Unique glucose
T178, G321
V178, G321
binding residues
Unique 3D structure +
Unique regions of
2, 64-68, 97-98, 116, 2, 26, 40, 97-98, 116,
aggregation
118, 197, 279-281,
176-182, 325-332,
325-332,340-345,
340-345, 355-356,
355-356, 383-386,
383-386, 408-409,
407-415, 439, 456,
413-414, 439, 464-466
478-480
Unique
Amino acid 133
phosphorylation
sites
Unique
N-linked: residue 411 N-linked: residue 411
glycosylation sites
O-linked: residue 123
Unique interacting
LCT, BPI, COL10A1, MGAM, TSHB,
TSHB, ATP1A4,
proteins
AKAP1, AKAP8
GP2, PNLIP, ENO1
ATP1A1, CD2, PGM1
Unique transcription C/EBP alpha, Zic1/2, C/EBP alpha and
POU1F1 and Cdx-1
factors
STAT5A
Zic1/2
No. of mutations
4
41
86
* Common features of the amylase isozymes are discussed in the results section. Table indicates
the unique characteristics of the different amylase isozymes.
Sumoylation is the reversible attachment of a Small Ubiquitin-related MOdifiers (SUMO) to
proteins. SUMO protein is added to a specific peptide sequence of a hydrophobic residue bound
to a lysine bound to any amino acid followed by an acidic residue [316]. Sumoylated proteins
appear to take a part in transcription [211,212], apoptosis [213], and signal transduction [214].
While the mechanisms that regulate sumoylation are not well understood, conjugation of SUMO
to proteins can alter protein configuration potentially leading to new protein-protein interactions,
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inhibition of existing protein-protein interactions and/or changes to existing protein functions and
activity [215], thereby enhancing functional diversity. In this way, sumoylation can increase
protein stability by promoting the formation of multimeric protein complexes as well as by
inhibition of ubiquitination [216]. Since all amylase isozymes are predicted to be sumoylated, it is
expected that sumoylation imparts stability and may result in a longer half-life due to lack of
ubiquitination and, subsequently, degradation.
Second, protein function is determined by protein structure which, in turn, is based on protein
sequence. Consequently, evolutionarily related proteins have similar structural motifs and the
structural similarities between the amylase isozymes are indicative of their evolutionary history
[317]. In agreement, I found that all the amylase isozymes are generally highly ordered proteins
with long half-lives. Therefore, the amylase isozymes have a stable secondary and/or tertiary
structure. Since ordered proteins have low binding potential to other proteins and usually do not
form complexes, it is unlikely that amylase forms larger protein complexes [205]. However, I also
found that AMY1 and AMY2B have unique internal regions of protein disorder. AMY1 has unique
disorder regions at amino acids 51 to 63 and 375 to 384 while AMY2B has a unique disorder
profile at amino acids 51 to 63 and 117 to 134. These internal regions of protein disorder in AMY1
and AMY2B represent zones of flexible protein configurations that: (1) are more prone to
posttranslational modifications (such as the unique phosphorylation site at amino acid 133 in
AMY2B) that increase protein functionality; (2) may function as linkers between the two
structured domains of the amylase isozymes or; (3) may confer increased binding potential to the
structured domains of other proteins [317].
Third, amylase function may be related to protein aggregation inherent in amylase protein
structure. Alpha-amylase was found to be more prone to aggregation as compared to β-amylase
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due to the presence of cysteine residues on the surface of amylase which help form intermolecular
sulfide bonds that covalently-link amylase dimers [318]. Computational analyses revealed that the
amylase isozymes share multiple, common aggregation prone regions, but AMY2A and AMY2B
have additional unique regions of aggregation. Unique aggregation prone regions were mostly
found in AMY2B, indicating it is most likely to aggregate. Aggregation prone regions are more
likely to be in ordered regions and stabilize proteins. Aggregation prone regions are also very likely
to be found in close structural proximity to catalytic residues further indicating that aggregation
prone regions contribute to protein function. Aggregation prone regions can be conserved in
proteins to maintain protein stability and function [206]. AMY2A and AMY2B have unique
regions of aggregation which is in keeping with their evolutionary history. Unlike AMY1, since
AMY2B is the oldest of the amylase isozymes, it has the most conserved ordered protein regions
which is in keeping with the view that intrinsically ordered proteins are associated with high selfaggregability. This was further supported by analyses of tertiary amylase structure. Specifically,
alpha helixes are the most common secondary structure to transverse the membrane due to their
ability to maintain more polar structures inside the helix [319] while beta sheets play a large part
in amyloid formation [320]. The pancreatic amylase isozyme AMY2A has more alpha helix
structure indicating it may more readily transverse the membrane than AMY1 and AMY2B
amylase isozymes.
The salivary glands and pancreas account for most of the amylase activity in the body.
Increased amylase expression and activity (hyperamylasemia) has been associated with insult to
the pancreas or salivary glands, chronic alcoholism, amylase secreting cancers and anorexia
nervosa or bulimia. Hyperamylasemia is due to an overproduction of amylase that is secreted into
the serum as well as decreased amylase clearance. Decreased amylase clearance may be due to
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macroamylasemia, an asymptomatic condition wherein amylase aggregates into high-molecular
weight complexes containing immunoglobulins [321]. Reportedly, hyperamylasemia and
macroamylasemia can occur as secondary conditions to cancer [322]. The amylase proteins
displayed different potential aggregation-prone regions. Since AMY2A and AMY2B may be more
prone to self-aggregate because they have more aggregation prone regions, they may contribute to
macroamylasemia [323].
Fourth, while the ordered nature of the amylase isozymes typically precludes their physical
interaction with other proteins, computational analyses predicted several potential functional
amylase-protein interactions, mostly associated with carbohydrate metabolism. However, unique
functional interactions among amylase isozyme family members were also noted and might
represent novel functions limited to specific amylase isozymes. That is, AMY1 has unique
interactions with lactase (LCT), kinase A anchor protein 1 (AKAP1), kinase A anchor protein 8
(AKAP8), collagen, type X, alpha 1 (COL10A1), and bacterial/permeability-increasing protein
(BPI). These unique interactions indicate that AMY1 might participate in a variety of established
and novel functions including carbohydrate metabolism, extracellular matrix remodeling, and cell
immunity. AMY2A has interactions with maltase-glucoamylase (MGAM), glycoprotein 2 (GP2),
enolase 1 (ENO1), pancreatic lipase (PNLIP), and TSHB. These unique interactions indicate that
AMY2A could participate in a variety of functions including carbohydrate and lipid metabolism
and cell immunity. With possible involvement in lipid metabolism, AMY2A may play a role in
alternate energy production. AMY2B has interactions with phosphoglucomutase 1 (PGM1), CD
molecule (CD2), ATPase, Na+/K+ transporting, Alpha 4 Polypeptide (ATP1A4), Alpha 1
Polypeptide (ATP1A1), and TSHB. These unique interactions suggest that AMY2B could also
participate in carbohydrate metabolism as well as ATP production and cell immunity.
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Interestingly, all amylase isozymes functionally interact with different immunity related proteins,
indicating that amylase may modulate the immune response. These novel interactions point to
potential alternative functions of the amylase isozymes. It is important to note that all the proteins
that interact with amylase do not form physical interactions, but have functional interactions. There
is no indication that amylase forms complexes with other metabolic enzymes. However, it has
been proposed that amylase is sequestered in normal tissue and during inflammatory events,
amylase is released into the blood [324]. Consequently, the high levels of tissue amylase may be
related to an anti-bacterial role [325].
Fifth, unique amylase isozyme expression profiles may arise through differential gene
expression regulated, in part, by different transcription factors. The current study revealed that
AMY1 transcription may be regulated by the C/EBP alpha, C/EBP delta, zic1/2, and STAT5a
while AMY2A is regulated by C/EBP alpha, C/EBP delta and zic1/2 and AMY2B is regulated by
C/EBP delta, POU1F1 and Cdx-1. The function of the differentiation-inducing C/EBP
transcription factor family has been found to be abrogated in hematopoietic, lung and skin cancers
[326]. C/EBP beta is overexpressed in OC epithelial cells in vivo and C/EBP alpha and delta have
constant expression levels regardless of tumor stage/progression [327]. Zic1 plays a role in cancer
progression in medulloblastomas, endometrial cancers, colorectal and mesenchymal neoplasms
such that Zic1 is downregulated during transformation [328]. In breast cancer, loss of STAT5A is
associated with poor clinical outcome and advanced tumor progression [329]. Not much is known
about the role many of these transcription factors play in OC in particular though it is clear that
they play a large role in cancer progression in other cancer types.
In addition to all the above, all three amylase isozymes had TATA boxes in their promoter
regions while only AMY1 and AMY2B have CG boxes in their promoter regions and only
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AMY2A has CCAAT boxes in its promoter region. Core promoter elements determine
transcriptional regulations by governing which transcription factors are recruited. The TATA box
is a DNA sequence that specifies where transcription initiates by binding transcription factors.
TATA boxes are typically found in highly regulated genes [330]. The GC box is usually found
upstream of the TATA box and acts like a transcriptional enhancer that binds transcription factors
[331]. The CCAAT box also occurs upstream of the transcription start site and is known to be part
of the core promoter. Interestingly, the C/EBP proteins are highly conserved CCAAT enhancerbinding proteins with multiple functions in proliferation, metabolism, immunity and inflammation
[332–335]. This indicates that the amylase isozymes have different core promoter and enhancer
regions that recruit transcriptional factors by unique methods.
Lastly, computational analyses indicated that the number of potential mutations among
amylase isozymes was greatest in AMY2B (with 86 possible mutations) compared with AMY2A
(with 41 possible mutations) and AMY1 (with 4 possible mutations). It is also interesting that the
AMY1 mutations are located at the end of the alpha-amylase catalytic domain while mutations in
AMY2A are localized mutations mostly in the N-terminal and alpha-amylase catalytic domain.
This suggests that the alpha-amylase catalytic domain may be prone to mutations. In contrast,
AMY2B has mutations uniformly distributed throughout its protein. Nonetheless, mutations of
amylase isozymes often lead to amplification and could explain overexpression leading to
hyperamylasemia in OC.
Despite many similarities among the amylase isozymes, computational analyses revealed
significant differences among these isozymes based on regions of protein disorder, calcium
binding sites, glycosylation sites, phosphorylation sites, regulatory transcription factors, tertiary
structure, aggregation prone regions and susceptibility for mutational events. Consequently,
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structural, functional and regulatory differences among the amylase isozymes may contribute to
differential tissue expression in disease. The computational differences among amylase isozymes
leads me to believe that AMY2A and AMY2B may be more prone to self-aggregation. AMY1 and
AMY2B have unique regions of disorder indicating these isozymes may mediate more
interactions, and be more susceptible to mis-folding and aggregation. AMY1 and AMY2B have
identical tertiary structures indicating AMY1 and AMY2A may have similar interactions and
patterns of secretion. AMY2B is endogenously expressed in many tissues due to its lack of a
retroviral insertion that induces tissue specificity. During malignant transformation, AMY2B
expression may be exacerbated by genetic deregulation.
Taken together, my computational analyses predict that AMY2B and, to a lesser extent,
AMY1 may be the amylase isozymes overexpressed in OC-associated hyperamylasemia. While
my computational analyses suggest that AMY2B RNA is overexpressed in OC and elevated levels
of AMY2B amylase have been anecdotally reported in OC serum and tissues, information about
the specific amylase isozyme overexpressed at the protein level in OC disease is lacking.
Therefore, to validate my computational predictions, serum samples from normal controls and
from women with benign gynecologic disease and reproductive cancers were assessed by amylase
isozyme protein expression by western immunoblotting. I was able to confirm that, compared to
normal controls and benign disease, AMY2B was preferentially overexpressed at the protein in
serous ovarian cancers, the most frequently occurring ovarian histologic subtype. Consequently,
computational strategies can serve as a first step to help identify novel protein regulators for OC,
such as AMY2B, which can then be expanded in further studies on the molecular mechanism(s)
contributing to OC progression.
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Chapter 3
Amylase promotes OC cell invasion in vitro

Introduction:
Hyperamylasemia has been reported in OC [262,336,337], specifically in women with serous
ovarian tumors [338] and ovarian cystadenocarcinoma [230]. Zakrezewska et al. found that
amylase is overexpressed in 39% of OC patients [339]. Hyperamylasemia is associated with poor
prognostic outcome including rapid disease progression and increased mortality; it has been
suggested that amylase is a marker of disease progression as amylase activity only decreases in
response to treatment and rapidly increases when diseases relapse [340–343]. However, its
contribution to OC disease etiology remains unknown [1]. Nonetheless, since hyperamylasemia in
OC patients is reduced after ovarian tumor removal or treatment, elevated serum levels of amylase
in patients with hyperamylasemia are thought to result by secretion of amylase by OC cells
[269,336].
My computational analyses predicted AMY1A and AMY2B as the most likely amylase
isozymes overexpressed in OC, and western blot analysis of OC patient serum samples confirmed
high levels of AMY1 and AMY2B in OC (Chapter 2). To begin to determine the contribution of
amylase for OC progression, in this chapter, an in vitro model of amylase secretion by OC cells
will be developed. The functional contribution amylase for OC will be evaluated by measurement
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of cellular proliferation and invasion as well as the ability for amylase to degrade ECM
components. Lastly, by demonstrating amylase within the cellular glycocalyx and the ECM
environment, I propose a role/mechanism by which amylase may not only drive energy production,
but invasion by OC cells.

Materials and Methods:
Tissue culture
The following human cell lines were used: normal human dermal fibroblasts HDF; SV 40Large T-Antigen transfected human ovarian surface epithelial (IOSE) cell lines MCC3, IOSE-80,
IOSE-121, and IOSE-144 derived from normal patients with no family history (NFH) of breast
and/or OC [344,345]; OC cell lines CaOV3, OVCAR5, OV-90, SKOV3, TOV21G and IGROV;
colorectal adenocarcinoma cancer cell lines WiDr and SW626; breast cancer cell lines MDA-MB231 and MCF7; head and neck cancer cell line HN5α [346]; cervical cancer cell lines Hela, C13,
OV2008; pancreatic cancer cell line Panc1; lung cancer cell lines NCI-H2009 and H69; and
glioblastoma U373MG cells. Cells were cultured in Medium 199/MCDB 105 (Sigma, St. Louis,
MO) with 5% fetal bovine serum (FBS) and gentamicin and incubated at 37°C with 5% CO 2.
Media was concentrated using Centriprep Centrifugal Filter Devices (Ultracel YM-3 Cat.4302
Merck Millipore Ltd, Tullagreen, Ireland).
Transmission Electron Microscopy (TEM)
Cells were grown on routine tissue culture plasticware in a monolayer on a 13mm coverslip in
6 well plates overnight. Adherent cells were fixed with 75 mM lysine in 0.075% (w/v) alcian blue,
2% paraformaldehyde (PFA), 2.5% glutaraldehyde (GA) in 0.1 M cacodylate (CAC) buffer
solution, buffered at pH 7.2, for 0.5 hour at 37°C. The coverslips were then washed for 1.5 hours
at room temperature followed by storage at 4°C overnight. Coverslips were then rinsed three times
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for five minutes with 0.1 M CAC, pH 7.2 and postfixed with 1% osmium tetroxide-potassium
ferrocyanide (OsO4/0.8% K4Fe(CN)6) in 0.1M CAC, pH 7.2 for 1 hr. Coverslips were then rinsed
for five minutes with 0.1M CAC, pH 7.2, and washed with dH2O twice for five minutes. Coverslips
were dehydrated with a graded ethanol (ETOH) series: 35%, 50%, 70%, and 95% ETOH followed
by three exchanges of anhydrous 100% ETOH prior to critical point drying via three ten minute
washes in 100% acetone. For resin infiltration, cells were incubated in graded acetone/Epon 812
resin solutions: 2:1 acetone to resin solution for ten min, 1:1 acetone to resin solution for 48 hours,
1:2 acetone to resin solution for two hours and pure resin twice for two hours each. The coverslips
were then cut into 2mm x 6.5mm segments and baked on pure resin at 40°C for 2-4 hours and at
70°C overnight to polymerize the resin. The coverslips were then sectioned, examined and
photographed on a Zeiss EM 30 electron microscope. Cell cultures were screened for yeast
contamination and contaminated cultures were replaced.
Quantitative PCR
Cells were treated with TRIzol reagent from Invitrogen (Carlsbad, CA) and ribonucleic acid
(RNA) was isolated according to the manufacturer’s instructions. To generate single-stranded
complementary DNA (cDNA), the Applied Biosystems GeneAmp RNA polymerase chain
reaction (PCR) Core Kit (Foster City, CA) was used with 3 ug/mL total RNA using a Biometra
UNO-thermo-block and Perkin-Elmer-GeneAmp PCR system 9600. qPCR was carried out with
SYBR Green Universal Master Mix (Applied Biosystems), cDNA, and primers. Primers used were
AMY1A (GeneCopoeia: Hs-QRP-21480; Rockville, MD), AMY2A (GeneCopoeia: Hs-QRP21450), AMY2B (GeneCopoeia: Hs-QRP-21451; Rockville, MD), and GAPDH (GeneCopoeia:
Hs-QRP-20169; Rockville, MD) as control. Sequences for the amylase primers remain the
proprietary property of GeneCopoeia. Amplification was performed with 40 cycles of denaturation
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(95°C, 10 sec), annealing (60°C, 20 sec), and extension (72°C, 15 sec) using a Bio-RAD Chromo4
Real Time PCR Detector using Opticon Monitor 3 program. Levels of amylase were normalized
to their respective GAPDH message values and the fold difference was determined by dividing the
threshold cycle (Ct) value by the reference sample.
Western blot
Cells were washed in PBS, trypsinized, pelleted, rewashed with PBS and counted. Cells
were lysed in CHAPS buffer for 30 minutes on ice before being centrifuged at 115,000 x g, at 4°C
for 1h. Twenty ug of protein were separated by a 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Proteins were transferred to Polyvinylidene fluoride (PVDF)
membranes, washed in Tween 20-Tris buffered Saline (TBST), and blocked in 5% milk in TBST.
Blots were incubated in their respective primary antibodies overnight, followed by incubation with
a horseradish peroxidase (HRP)-conjugated secondary antibody (Fisher, Pittsburgh, PA), and
developed via FEMTO Cat. 34095 Life Technologies (Grand Island, NY). Antibodies used were:
AMY1A (1:1000) Cat.H00000276-M04 Abnova (Taipei City, Taiwan); AMY2A (1:500) 158451-AP Proteintech (Chicago, IL); AMY2B (1:2000) Cat. LS-C173958 LSBio (Seattle, WA); Beta
Actin Loading Control Antibody (BA3R) (1:10,000) Cat. # MA5-15739 Thermo Scientific
(Rockford, IL). Densitometry was performed using ImageJ software to normalize amylase band
strength to the actin band.
Amylase ELISA
To measure amylase protein levels in OC samples and/or their conditioned medium, 100ul
of samples corresponding to 104 cells were assayed in triplicate using the quantitative double
sandwich enzyme-linked immunosorbent assay (Amy-p ELISA Kit; Cat. MBS264855;
MyBioSource, San Diego, CA). Absorbance was read on a Microplate Reader BioTek ELx800
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(Winooski, Vermont) using Gen5 Data Analysis Software (Biotek, Winooski, Vermont). Resultant
values were derived from a standard curve and expressed as the mean amylase concentration of
triplicate samples.
Amylase activity assay
The Amylase Assay Kit (Cat: ab102523 Abcam, Cambridge, MA) was used to measure
amylase activity according to the manufacturer’s instructions from concentrated conditioned
media (CCM). The CCM corresponding to 104 cells was incubated with ethylidene-pNP-G7, a
substrate that is cleaved by amylase into smaller fragments targeted by α-glucosidase to release a
chromophore whose concentration was measured at 405 nm using μQuant plate reader from Biotek instruments, Inc. (Winooski, VT).
Amylase transfection
For silencing experiments, IOSE and OC cells were split into four groups, including a
control group supplemented with only the transfection reagent, a negative control group
transfected with a non-targeting control scramble siRNA and the transfection reagent, a third group
supplemented separately with the three different amylase siRNAs and the transfection reagents
and, lastly, a fourth group transfected with GFP to monitor transfection efficiency. Cells were
transfected with ON-TARGETplus Human AMY1A siRNA-SMARTpool (Cat. L-012691-010010), ON-TARGETplus Human AMY2B siRNA-SMARTpool (Cat. L-015880-01-0010), and
ON-TARGETplus Human AMY2A siRNA-SMARTpool (Cat. L-016978-01-0010) or ONTARGETplus Non-targeting scramble siRNAs (Cat. D-001810-01-0010) GE Healthcare
Dharmacon (Lafayette, CO). The SMARTpool is a mix of four siRNAs provided as a single
reagent. Cells were plated in 6 well plates, serum starved overnight then treated with 145 pmol
siRNA per well incubated with Lipofectamine 3000 Transfection Reagent (Invitrogen, Madison,
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WI, United States) according to the manufacturer’s instructions. Transfection efficiency was
determined by transfecting cells with pmaxGFP™ Control Vector (Cat. VCA-1003) Lonza (Basel,
Switzerland). Transfected cells were maintained for 48 h before further experiments, unless
otherwise described.
Invasion assay
Cells were incubated on type I collagen coated transwells (CytoSelect 96-Well Cell Invasion
Assay, catalog number: CBA-112-COL (San Diego, CA)) for 24 hours. Following incubation,
cells that had invaded through the collagen gel and onto the transwell membrane insert were
stained with 0.1% crystal violet solution and photographed using an Olympus DP20 digital camera
(Burnaby, BC, Canada) under a Leica DMIRE2 microscope. The number of cells that invaded the
transwell was then counted and subjected to statistical analysis.
Glycosaminoglycan (GAG)/proteoglycan quantification assay
GAG content was determined using a Blyscan colorimetric assay (Biocolor Assays, County
Antrim, BT38 8YF, United Kingdom). After transfection with amylase siRNA, and scramble
RNA, 7x106 IOSE-121 and OVCAR5 cells were digested in a papain extraction reagent. The GAG
content in each sample was detected with spectrometry at 656 nm after precipitation and dye
binding of GAG according to the manufacturer’s instructions. A standard curve was created using
controls according to the manufacturer’s instructions.
Immunogold staining
For immunogold staining, cells were grown on coverslips and prepared for TEM analysis
as described earlier. Sectioned grids of cells were incubated in 4% w/v aqueous sodium
metaperiodate for two minutes, washed multiple times in water, blocked in PBSG (PBS containing
0.001% (v/v) Tween 20 and Triton X-100 and 1% (w/v) gelatin from cold water fish) for 10

84

minutes before incubation overnight in 6ug/ml anti-salivary alpha amylase antibody (Cat. ab54765
Abcam (Cambridge, MA)). The grids were then washed twice in PBS then eight times in water
before a two-hour incubation in goat-anti-mouse IgG (H&L) conjugated to 15nm colloidal gold
particles 1:40 (Cat. 25133 Electron Microscopy Sciences (Hatfield, PA)). The grids were rinsed in
H2O for 30-40 sec then counterstained in uranyl acetate (saturated) in 50% methanol for 2 minutes.
To confirm the specificity of the primary antibody, non-immune goat IgG were used as negative
control in place of primary antibody. The cells were then viewed by TEM.
Statistical analyses
For real time PCR, error bars illustrate RQmin and RQmax, which were calculated as: RQave
divided by (standard deviation^ student’s t value at the 95% confidence interval, for 5 degrees
freedom) and RQave times (standard deviation^ student’s t value at the 95% confidence interval,
for 5 degrees of freedom), respectively. This range represents the 95% confidence level. For
amylase activity assay, amylase ELISA, GAG assay and invasion assay, student’s t test was
performed to assess statistical difference between means of triplicates ± standard error. P-values ≤
0.05 were considered statistically significant.

Results:
Confirmation of yeast-free cell cultures.
Since cell culture contaminants, including commensal yeast, can produce amylase, it was
necessary to ensure that cell lines used for this study were free of microbial contaminants.
Examination of cell cultures by light microscopy did not detect presence of yeast in any cultures.
However, for more stringent examination, IOSE and OC cell lines were examined by TEM for
possible yeast contamination. IOSE-121, HIO118, SKOV3, OV-90 and OVCAR5 were found to
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be free of yeast, while yeast was found in CaOV3 and IGROV (Figure 3.1). I replaced the yeastinfected cell lines with yeast-free cell lines as validated by TEM visualization.
A. CaOV3:

B. IGROV:

Figure 3.1. Establishing cell cultures are free of yeast. Cells cultures were examined by TEM
to detect microbial contamination, including yeast. Representative photographs illustrate
endogenous yeast (arrows) in CaOV3 (A) and IGROV (B) ovarian cancer cell lines.
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OC cells overexpress amylase in vitro.
Computational analyses predicted that AMY1 and AMY2B would be overexpressed in OC
(Chapter 2). A panel of cell lines was used to confirm which amylase isozymes are overexpressed
in established OC cell lines as well as from other cancer types at the message level using qPCR
(Figures 3.2 and 3.3) and at the protein level using western immunoblotting (Figure 3.4). At the
message level, there were variable levels of amylase expression in OC and normal cell lines (Figure
3.2). Moderate levels of AMY1 and AMY2B RNA were expressed in MCC3, while IOSE-121
essentially only expressed AMY1 RNA. As defined by the average signal ratio of
amylase/GAPDH in IOSE cells, only 2/5 (40%) of OC cell lines, OVCAR5 and IGROV,
overexpressed amylase AMY1 and AMY2B to a greater extent than IOSE cells. Though
expressing small levels of amylase message, SKOV3, OV-90, and TOV21G were shown to
express AMY1 and AMY2B RNA. Likewise, there was no clear pattern of which amylase isozyme
is overexpressed in other cancer types at the RNA level (Figure 3.3). Whereas human dermal
fibroblast (HDF) most notably expresses AMY1 RNA, lung cancer cells H2009 displayed an
overexpression of amylase AMY1 and AMY2A while amylase RNA was not detected in H69
cells. Likewise, colorectal cancer WiDr cells displayed an overexpression of amylase AMY1 and
AMY2B while SW626 cells expressed negligible amounts of AMY1. Similarly, cervical cancer
cells (Hela, C13) expressed small amounts of AMY1 and AMY2B. Cells lines representing breast
cancer, head and neck cancer, glioblastoma and pancreatic cancer expressed negligible amounts
of amylase although when detected, these cell lines preferentially expressed AMY1 RNA and,
occasionally, AMY2B (Figure 3.3).
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Figure 3.2. Amylase AMY1 and AMY2B RNA are typically expressed in OC cell lines.
Cellular RNA was collected from IOSE and OC cells and analyzed by qPCR to determine
AMY1, AMY2A, and AMY2B message expression. Data are expressed as the average ratio of
amylase isozyme expression to control GAPDH mRNA from triplicate samples.
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Figure 3.3. Most non-OC cell types express AMY1 and AMY2B RNA. Cellular RNA was
collected from HDF and representative cancer cells and analyzed by qPCR to determine AMY1,
AMY2A, and AMY2B message expression. Data are expressed as the average ratio of amylase
isozyme expression to control GAPDH mRNA from triplicate samples.
At the protein level, all OC cell lines examined, TOV21G (8x for AMY1 and 4x for AMY2B),
OV-90 (13x for AMY1 and 8x for AMY2B), OVCAR5 (10x for AMY1 and 20x for AMY2B),
SKOV3 (5x for AMY1 and 16x for AMY2B) and IGROV (3x for AMY1 and 9x for AMY2B),
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expressed 3x-20x more amylase AMY1 and AMY2B protein relative to IOSE-121 and IOSE-144
cells (Figure 3.4, Table 3.1). With the exception of U373MG, MDA231 and H2009 cells, cells
representing other cancer types, also expressed more AMY1 and/or AMY2B protein relative to
HDF. That is, breast cancer MCF7 (7x), colorectal cancer WIDR (2x) and SW626 (12x), pancreatic
cancer PANC1 (9x) and cervical cancer Hela (3x) overexpress AMY1; colon cancer cell line
SW626 (114x), and pancreatic cancer cell line PANC1 (137x) cells overexpress AMY2A. Breast
cancer cell line MCF7 (214x), colorectal cancer cell lines WIDR (74x) and SW626 (475x),
glioblastoma cell line U373MG (20x), pancreatic cancer cell line PANC1 (412x), and cervical
cancer cell line HELA (200x) overexpressed AMY2B (Figure 3.4, Table 3.1). Overall, protein
levels of the amylase isozymes were greater in cancer cell lines than normal cells and the amylase
isozymes most typically expressed are AMY2B and AMY1. Analysis of amylase at the protein
level showed that AMY1 and AMY2B are consistently elevated in OC cells, whereas, other cancer
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types don’t show consistent amylase overexpression.
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Figure 3.4: AMY1 and AMY2B protein are overexpressed in OC cell lines (Continued on Next
Page)
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Figure 3.4. AMY1 and AMY2B protein are overexpressed in OC cell lines. HDF, IOSE and a
panel of cancer cells were subjected to western blot to determine the expression of amylase
isozymes at the protein level (upper panel). Densitometry analysis of was used to determine
the intensity ratio of amylase isozyme band signal to respective loading control actin bands
and are shown in corresponding lower panels.
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Table 3.1: AMY1 and AMY2B are typically overexpressed in cancer cells
Cancer type

Cell line

Amylase isozyme overexpressed

Ovarian

TOV21G

AMY2B

Ovarian

OV-90

AMY1, AMY2A and AMY2B

Ovarian

OVCAR5

AMY2B

Ovarian

IGROV

AMY2B

Breast

MCF7

AMY1 and AMY2B

Colorectal

SW626

AMY1 and AMY2B

Glioblastoma

U373MG

AMY2A

Lung

H2009

AMY1 and AMY2A

Pancreas

Panc1

AMY1 and AMY2B

Cervical

Hela

AMY1, AMY2A and AMY2B

Amylase secreted by OC cells is metabolically active.
To determine the proportion of amylase that remains in cell lysates and the proportion that
is secreted into the media, cytoplasmic lysates from IOSE-121, IOSE-144, OVCAR5 and SKOV3
cells and their respective CCM of equivalent 104 cells were subjected to an amylase ELISA.
Normal cells IOSE-121 (total 3 ng/ml) and IOSE-144 (total 2.26 ng/ml) produced negligible
amounts of amylase protein in cell lysate and CCM, whereas OVCAR5 (total 47.9 ng/ml) and
SKOV3 (total 8.9 ng/ml) produced 3x to 16x more amylase than normal cells with the majority of
amylase produced by OC cells secreted into their conditioned medium (Figure 3.5)
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Figure 3.5. OC cells produce more amylase than normal cells. Cell lysates and their CCM were
subjected to amylase elisa to determine the amounts of amylase in cell lysates and secreted into
the cell media. Data are expressed as the average of triplicates ± standard deviation (*P < 0.05).
To determine if secreted amylase was metabolically active, CCM from a panel of cancer
cell lines was subjected to the amylase activity assay. All cancer cell lines secreted active amylase
ranging from 0.7 mU/ml to 10 mU/ml. Cervical cancer cell lines secreted active amylase ranging
from 0.7 mU/ml to 10.5 mU/ml, averaging 4.9 mU/ml. Lung cancer cell lines secreted active
amylase ranging from 2.6 mU/ml to 3.7 mU/ml, averaging 3.2 mU/ml (Figure 3.6). Levels of
amylase activity by IOSE cells ranged from 1.5 to 3.7, averaging 2.4 mU/ml. OC cells secreted
metabolically active amylase to a greater extent than IOSE cells, ranging from 5.1 mU/ml to 34.2
mU/ml, averaging 11.2 mU/ml so that OC cells secreted up to 4x more active amylase compared
to normal OSE cells (Figure 3.6). Interestingly, only the glioblastoma (U373MG) and a single
cervical cancer cell line (C13) secreted greater amounts of metabolically active amylase (6.5 &
10.5 mU/ML) than IOSE cells. All other remaining cancer cell lines examined secreted amounts
of metabolically active amylase within a similar range seen in IOSE cells.
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Figure 3.6. OC cells secrete more metabolically active amylase than IOSE cells. CCM,
equivalent to 104 cells, was subjected to the amylase activity assay. Results are expressed as
the average amylase activity in mU/ml, normalized for cell number from triplicate samples
± SE.

Inhibiting amylase decreases OC invasion.
To begin to understand how amylase promotes OC progression, I investigated whether
abrogation of amylase affected the invasive capacity of OC cells using collagen coated Boyden
chambers. Amylase knockdown was performed using pooled amylase siRNAs targeting all
amylase isozymes. Amylase knockdown was validated by qPCR for amylase mRNA levels
(Figure 3.7A). Compared to untreated cells, siAMY abrogated AMY1 and AMY2B RNA levels
in OVCAR5 cells up to 3.7x and 7.8x, respectively. While scramble RNA inhibited AMY2B to
a lesser extent than siAMY, it did not alter AMY1 expression. As determined by parallel GFP
signals, transfection efficiency in OVCAR5 and IOSE 121 was determined to be 80% and 76%,
respectively. Amylase knockdown reduced OC cell invasion especially in SiAMY-treated OC
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cell line OVCAR5 by 32% (Figure 3.7B). Scramble RNA did not alter invasive capacities of
OC cells. Since IOSE121 cells have little amylase expression, reduction of their amylase
expression did not significantly affect IOSE121 invasion (Figure 3.7). After transfection, cell
numbers did not change, therefore, amylase does not affect cell proliferation. Cells were
counted after transfection with scramble RNA and amylase SiRNA for 48 hours and an
insignificant percent change ranging from 0.5% to 5.3% was noted.
The glycocalyx of OC cells is thicker than the glycocalyx of IOSE cells:
Given that amylase appears to mediate OC cell invasion and that amylase is an extracellular
metabolically active enzyme, I proceeded to examine whether amylase could modulate the
ECM/tumor microenvironment. To begin, IOSE121 cells and OC cells were examined by TEM
to determine the thickness of their respective glycocalyces. As shown in Figure 3.8, the average
glycocalyx thickness measured from 10 fields of IOSE-121, IGROV, and CAOV3, OVCAR5 and
SKOV3 was 83.7 nm, 207.4 nm, 264.8 nm, 257.2 nm, and 263 nm, respectively. The glycocalyces
of OC cells, then, were 2.4x to 3.2x thicker than the glycocalyx of IOSE121 cells (Figure 3.8).
In order to localize amylase to the OC cell surface and/or its immediate ECM, immunogold
labeling for amylase was performed. Immunogold labeling illustrated the presence of anti-amylase
gold particles in OVCAR5 cells (Figure 3.9). Immunogold particles appeared localized at the
external cell membrane and within the immediate tumor microenvironment. Control sections failed
to demonstrated presence of immunogold particles.
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Figure 3.7. Abrogation of amylase reduces invasion in OC cells. A) IOSE121 and OVCAR5
cells were treated with siRNA targeting amylase and scramble RNA as control. Verification
of siRNA efficiency was validated by qPCR. B) Treated cells were then seeded into invasion
assay chambers and number of invasive cells were evaluated after 24-hour incubation. Results
are expressed as the average relative fluorescence (a measure of the number of invasive cells)
from triplicate samples ± SE (*P < 0.05).
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Figure 3.8. The glycocalyx of OC cells is thicker than IOSE cells. IOSE and OC cells were
examined by TEM for visualization of their respective glycocalyces. Representative
photographs IOSE and OC morphology at the ultrastructural level (upper panel) and respective
glycocalyces as depicted with lines (lower panel).
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Figure 3.9 Amylase can be localized to the OC cells glycocalyx/cell surface. OVCAR5 cells
were examined by TEM following immunogold labeling with anti-AMY antibodies (upper
panel) or serum controls (lower panel).

97

Inhibiting amylase increases GAG production.
In order to better understand how extracellular amylase could promote OC cell invasion,
IOSE-121 and OVCAR5 cells were treated with scramble RNA and siRNA targeting amylase and
subjected to the

Blyscan Sulfated Glycosaminoglycan Assay to measure sulfated glycan

(proteoglycans and glycosaminoglycans) content at the same time as my Boyden chamber
experiments. Successful validation of transfection is shown in Figure 3.7A. Abrogating amylase
in IOSE-121 cells slightly increased cellular GAG content over untreated IOSE-121 cells from
0.11 ug GAG to 0.33 ug GAG. In contrast, abrogating amylase increased cellular GAG levels in
OVCAR5 over untreated or scramble RNA treated cells from 1.382 ug to 3.787 ug (Figure 3.10).
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Figure 3.10 Amylase promotes GAG digestion. IOSE 121 and OVCAR5 cells were treated
with scramble RNA and amylase siRNA and subjected to the sulfated glycosaminoglycan
assay. Results are expressed as the total ug of GAGs from triplicate samples ± SE (*P < 0.05).
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Discussion:
Amylase (originally known as ptyalin) was discovered in 1831 [347] and has been
extensively studied since its isolation in 1862 from pancreatic trypsin [348]. Since Weiss et al.
(1950s) reported a case of an amylase-producing tumor, multiple cases of cancer-associated
hyperamylasemia have been reported although hyperamylasemia appears limited to few types of
cancers [273] Nonetheless, hyperamylasemia has been strongly associated with lung cancer,
ovarian cancer, multiple myeloma and pheochromocytoma cancers [349]. Hyperamylasemia is
typically asymptomatic and its cause, isozyme profile and contribution to cancer progression are
still unknown. Salivary amylase (AMY1) and pancreatic amylase (AMY2B) have both been
proposed to be overexpressed in cancer. AMY2A has also been proposed to be a tumor suppressor
gene; mutation, deletion, or silencing of AMY2A may lead to malignant transformation in gastric
cancer [350]. Since OC remains the most lethal gynecologic cancer, studies on the contribution of
hyperamylasemia to OC are warranted, but require the establishment of an appropriate model
system.
Potentially owing to differences in reproductive physiology, humans are the only animals in
which OC occurs with regular frequency. Laying hens are the only animals that spontaneously
develop OC, therefore, a laying hen model of OC was characterized to determine its validity as an
in vivo model of OC [351]. Laying hens spontaneously developed serous, endometrioid, mucinous
and clear cell ovarian carcinomas with staging, histology and metastatic characteristics similar to
human OC conditions. However, laying hens only have one ovary, making staging ovarian cancer
more challenging in hens. Also, lymph nodes in chickens are not well organized so OC metastasis
in laying hens is not reflective of OC in humans [351]. Rabbit models for papillogenesis may be
informative for the very early stages of ovarian tumor growth, but these benign conditions
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indicative of hyper-proliferative events do not progress to full malignant transformation [352].
Current mouse models of OC are also of limited use because they either employ intraperitoneal
(IP) or subcutaneous xenografts or are of genetic backgrounds that do not produce ovarian tumors
that histologically reflect serous adenocarcinoma of the human ovary. Of note, the most common
mouse models of OC employ xenograft model types which are effective in mimicking different
aspects of OC growth and metastasis. However, xenograft models do not reflect the initial
transformation events that lead to OC tumorigenesis. Genetically engineered mouse models
(GEMM) are important for investigating early changes that lead to OC; however, GEMMs are
complicated to generate due to lack of knowledge on OC etiology [353]. Therefore, I chose to use
an in vitro model system using established human cells lines to study the contribution of amylase
to OC progression. While a number of OC cell lines have been established and many are
commercially available, an important advantage for using an in vitro model for studies on the role
of amylase for OC progression is that normal control cell lines derived from pure human ovarian
surface epithelium and transfected with SV-40 large T antigen for enhanced lifespan are also
available. As a result, studies using IOSE cell lines have shown the capacity of OSE cells to
produce, lyse and reconstruct extracellular matrix components [344,345,354] and a demonstration
that OSE has the capacity to undergo epithelial-mesenchymal conversions [355].
As predicted in chapter 2, using cell lines devoid of yeast contamination, I found increased
protein levels of amylase AMY1 and AMY2B in OC cell lines. In addition, since the majority of
amylase produced by OC cells was both secreted and metabolically active, so these cell lines
represent a valid model system to pursue studies on the biological and molecular contribution of
amylase to OC disease.
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The glycocalyx is the outermost layer of the cell composed of a negatively charged web of
enzymes, proteins, and glycoconjugates—one or more glycan units covalently bound to noncarbohydrate units. Glycoconjugates include glycosaminoglycans (GAGs), glycoproteins,
glycolipids, and proteoglycans [356]. The glycocalyx is associated with many functions including
mediating cell-to-cell and cell-to-matrix interactions [357]. It also mediates ligand-receptor
interactions and other biological processes including specific recognition events. During malignant
transformation, atypical glycocalyx component expression and structure influences tumor
progression [356] by enhancing tumor growth, adhesion, motility, and invasion [358]. The
glycocalyx is also proposed to facilitate cancer progression [356] and cancer metastasis [359].
There is a correlation between glycoconjugates present at the cell membrane and the metastatic
potential of a cell [360]. A denser glycocalyx may promote more receptor interaction and lead to
more adhesion and migration of tumor cells [358]. It is also believed that the bulky glycocalyx of
malignant cells may serve a drug-resistant function by acting as a barrier against therapeutic agents
[358]. My survey of OC cell lines indicated that cancer cell lines have a bulkier glycocalyx
compared to normal IOSE cells.
Quintarelli et al. found that amylase degraded the glycan moieties that crosslink collagen
fibrils, therefore disassociating collagen fibrils and allowing for collagen degradation [361,362].
Inhibition of amylase decreased the ability of OC cells to invade collagen coated Boyden
chambers, thereby identifying a functional behavior of amylase to promote OC progression.
Amylase secreted by OC cells may, therefore, degrade the glycosylation links that play a role in
linking collagen fibrils to facilitate OC cell invasion. The role of amylase in the glycocalyx is
further supported by the presence of amylase in the glycocalyx and ECM as indicated with
immunogold studies. Amylase in the glycocalyx and ECM suggests that amylase may modify the
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ECM to promote invasion. Amylase, which cleaves alpha 1, 4-glycosidic bonds in polysaccharides
to initiate carbohydrate metabolism and contribute to energy production, can also play a role in
ECM remodeling by cleaving polysaccharide moieties in the tumor microenvironment. Amylase
has already been shown to degrade connective tissue in bacterial biofilm in wounds [228].
In summary, to test the hypothesis that secreted amylase may modify the cancer cell glycocalyx
by digesting α1, 4-glycosidic bonds [235] found in glycosaminoglycans, which in turn leads to
altered downstream signaling that promotes proliferation, survival or migration/invasion, an in
vitro model to explore the contribution of hyperamylasemia to OC was established by analyzing
amylase message and protein levels from a panel of established cell lines. The activity of amylase
in cell lysates and conditioned concentrated media was also investigated. Lastly, to begin to
explore the contribution of hyperamylasemia to OC, the in-vitro model established was used to
determine how amylase contributes to OC cell invasion.
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Chapter 4
Regulation of Amylase by Spirulina

Introduction
Using an in vitro model system, I have been able to demonstrate that elevated levels of
amylase in OC cells lines, representing hyperamylasemia, may drive disease progression, at least
in part, by promoting cellular invasion related to alterations in the tumor microenvironment
(Chapter 3). Amylase, then, may serve as a novel target for therapeutic intervention in OC patients
with hyperamylasemia. However, commercially available amylase inhibitors typically inhibit
amylase activity at the protein level and produce a variety of adverse gastrointestinal side effects
such as flatulence, abdominal distension, and diarrhea [363]. Therefore, there is a need for the
development of new amylase inhibitors. Spirulina, a dietary supplement, has recently gained
popularity with many health claims including that it enhances immunity, controls high blood
pressure and serum cholesterol levels and has anti-tumorigenic, anti-inflammatory and antioxidant properties [364,365]. Spirulina is also associated with neuro-protective properties, as has
been shown by reduced ischemic brain damage in rats, improved post-stroke locomotor activity
and reduced levels of pro-inflammatory cytokines in the brain [366–368].
There are several species of the microalgae spirulina: Spirulina platensis, Spirulina
fusiforme, and Spirulina maxima. Spirulina has been used as a food source for centuries; with the
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earliest recorded human consumption of spirulina by the Chadiansa of Africa and Aztecs of
Mexico [369]. Spirulina is a good nutritional source because of its high protein content; 60-70%
and 5-10% of spirulina’s dry weight is protein and lipid, respectively. Further, the protein in
spirulina is complete, meaning it contains all the essential amino acids. Spirulina also contains
many essential fatty acids (gamma-linolenic, linoleic and oleic acids) and, lastly, spirulina contains
high levels of vitamin B12, beta-carotene, phycocyanin, superoxide dismutase, iron, calcium and
phosphorous [369,370].
In this chapter, I propose employing spirulina or phycocyanin, one of the active ingredients
in spirulina with high anti-inflammatory potential [371], as novel transcriptional inhibitors of
amylase. By determining whether spirulina can inhibit OC cell invasion without cytotoxicity to
normal cells, a novel clinical use for spirulina will be established.

Materials and Methods
Tissue Culture
The following human cell lines were used: normal human dermal fibroblasts HDF; SV 40Large T-Antigen transfected human ovarian surface epithelial (IOSE) cell lines MCC3, IOSE-80,
IOSE-121, and IOSE-144 [344,345]; OC cell lines CaOV3, OVCAR5, OV-90, SKOV3, TOV21G
and IGROV; colorectal cancer cell lines WiDr and SW626; breast cancer cell lines MDA-MB231, MDA-MB-231, MCF7; head and neck cancer cell line HN5α [346]; cervical cancer cell line
Hela; pancreatic cancer cell line Panc1; lung cancer cell lines NCI-H2009 and H69; and
glioblastoma U373MG cells. Cells were cultured in Medium 199/MCDB 105 (Sigma, St. Louis,
MO) with 5% fetal bovine serum (FBS) and gentamicin and incubated at 37°C with 5% CO 2.
Conditioned media was concentrated (CCM) using Centriprep Centrifugal Filter Devices (Ultracel
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YM-3 Cat.4302 Merck Millipore Ltd, Tullagreen, Ireland). Cell lines were treated with ± 0-150
ug/ml spirulina (kindly provided by Dr. P Bickford, USF) or 1-100 ug/ml phycocyanin (Catalog
number: P2172-25MG; Sigma Aldrich; St. Louis, MO) for 0-72 h.
Microarray
HN5α cells were treated for 24h ± 100ug/ml spirulina, RNA collected, reverse transcribed,
amplified and labeled with biotin at the H. Lee Moffitt Cancer Center Microarray core facility.
Biotin-labeled DNA was applied to Human Genome U133A Affymetrix chips and analyzed using
Affymetrix Microarray MAS 5.0 software to identify increased and decreased gene expression at
p < 0.005.
Quantitative PCR
Cells were treated with TRIzol reagent from Invitrogen (Carlsbad, CA) and ribonucleic acid
(RNA) was isolated according to the manufacturer’s instructions. To generate single-stranded
complementary DNA (cDNA), the Applied Biosystems GeneAmp RNA polymerase chain
reaction (PCR) Core Kit (Foster City, CA) was used with 3 ug/mL total RNA using a Biometra
UNO-thermo-block and Perkin-Elmer-GeneAmp PCR system 9600. qPCR was carried out with
SYBR Green Universal Master Mix (Applied Biosystems), cDNA, and primers. Primers used were
AMY1A (GeneCopoeia: Hs-QRP-21480), AMY2A (GeneCopoeia: Hs-QRP-21450), AMY2B
(GeneCopoeia: Hs-QRP-21451), and GAPDH (GeneCopoeia: Hs-QRP-20169) as control.
Sequences for the amylase primers remain the proprietary property of GeneCopoeia. Amplification
was performed with 40 cycles of denaturation (95°C, 10 sec), annealing (60°C, 20 sec), and
extension (72°C, 15 sec) using a Bio-RAD Chromo4 Real Time PCR Detector using Opticon
Monitor 3 program. Levels of amylase was normalized to the GAPDH message values and the
fold difference was determined by dividing the threshold cycle (Ct) value by the reference sample.
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Western blot
Cells were washed in PBS, trypsinized, pelleted, rewashed with PBS and counted. Cells were
lysed in CHAPS buffer for 30 minutes on ice before being centrifuged at 115,000 x g, at 4°C for
1h. Twenty ug of protein were separated by a 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Proteins were transferred to Polyvinylidene fluoride (PVDF)
membranes, washed in Tween 20-Tris buffered Saline (TBST), and blocked in 5% milk in TBST
or PBST. Blots were incubated in their respective primary antibodies overnight, followed by
incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody (Fisher,
Pittsburgh, PA), and developed via FEMTO Cat. 34095 Life Technologies (Grand Island, NY).
Antibodies used were: AMY1A (1:1000) Cat.H00000276-M04 Abnova (Taipei City, Taiwan);
AMY2A (1:500) 15845-1-AP Proteintech (Chicago, IL); AMY2B (1:2000) Cat. LS-C173958
LSBio (Seattle, WA); Beta Actin Loading Control Antibody (BA3R) (1:10,000) Cat. # MA515739 Thermo Scientific (Rockford, IL). Densitometry was performed using ImageJ software to
normalize amylase band strength to their respective actin band.
Amylase ELISA
To measure amylase protein levels, 100ul of cytoplasmic lysate and CCM of equivalent cell
number (104/well) were assayed in triplicate using the quantitative double sandwich enzymelinked immunosorbant assay (Amy-p ELISA Kit; catalog number: MBS264855; MyBioSource,
San Diego, CA) according to the manufacturer's instructions. Absorbance was read on a Microplate
Reader BioTek ELx800 (Winooski, Vermont) using Gen5 Data Analysis Software (Biotek,
Winooski, Vermont). Resultant values were derived from a standard curve and expressed as the
mean amylase concentration of triplicate samples.
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Invasion assay
Spirulina treated cells were incubated on type I collagen coated transwells (CytoSelect 96Well Cell Invasion Assay, catalog number: CBA-112-COL (San Diego, CA)) for 24 hours.
Following incubation, transwell filters were stained with a 0.1% crystal violet solution and
photographed using an Olympus DP20 digital camera (Burnaby, BC, Canada) under a Leica
DMIRE2 microscope. The number of cells that had migrated through the collagen cell and across
the transwell membrane was then counted.
MTS assay
Cell growth and cytotoxicity were determined by the MTS assay (Promega, Madison, WI)
according to the manufacturer's directions. Cells (1 × 103) were seeded in 96-well plates and grown
in Medium 199/MCDB 105 (Sigma, St. Louis, MO) containing 0.1% FBS. Cells were treated with
varying concentrations of spirulina (0ug/ml, 50ug/ml, 100ug/ml, 150ug/ml). Absorbance was read
nm using a multi-well plate reader (BioTek, Winooski, VT, USA) every 24 hours for 72 hours.
The samples were assayed in two separate experiments, each in triplicate and the results were
expressed as the mean ± standard error.
Statistical Analyses
For real time PCR, error bars illustrate RQmin and RQmax, which were calculated as: RQave
divided by (standard deviation^ student’s t value at the 95% confidence interval, for 5 degrees
freedom) and RQave times (standard deviation^ student’s t value at the 95% confidence interval,
for 5 degrees of freedom), respectively. This range represents the 95% confidence level. For
amylase activity assays, ELISA, MTS, and invasion student’s t test was performed to assess
statistical difference between means of triplicates ± standard error.
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Results
Amylase is a downstream target of spirulina.
In order to screen for downstream targets of spirulina, an Affymetrix microarray was
performed on spirulina treated HN5α cells. The results indicated that spirulina downregulated all
amylase isozyme expression at least 2.5 fold. Spirulina also suppressed expression of multiple
transcription factors predicted to regulate amylase gene expression (Chapter 2) including C/EBP
alpha, C/EBP delta, Zic1 and POU1F1 (Table 4.1).
Table 4.1: Spirulina transcriptionally targets amylase
Gene

Fold change

AMY1A, AMY1B, AMY1C, AMY2A, AMY2B, ACTG1P4, AMYP1

-2.62

AMY1A, AMY1B, AMY1C, AMY2A, AMY2B

-2.5

AMY1A, AMY1B, AMY1C, AMY2A, AMY2B, ACTG1P4, AMYP1

-2.5

CCAAT/enhancer binding protein (C/EBP), alpha

-1.18

CCAAT/enhancer binding protein (C/EBP), delta

-1.15

Zic1

-1.05

POU1F1

-1.19

Spirulina downregulates amylase mRNA expression in OC cell lines.
To confirm that spirulina inhibits amylase expression, a panel of cancer cell lines was
treated ± 100ug/ml spirulina and amylase expression was measured using qPCR. While spirulina
downregulated amylase expression in normal human dermal fibroblasts between 43% (AMY2B)
to 95% (AMY2A) among the amylase isozymes, the pattern of spirulina-mediated inhibition of
amylase expression varied among cancer cell types (Figure 4.1).
Spirulina significantly downregulated the expression of all amylase isozymes by 46% to
99% in colon cancer cells (WIDR and SW626) and by 57% to 77% in breast cancer cells MDA231,
but it actually increased amylase isozyme expression by 1302% for AMY1, 79418% for AMY2A,
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and 588% for AMY2B in MCF7 breast cancer cells. Similarly, spirulina increased amylase
isozyme expression by 511% to 1875% in glioblastoma cells U373MG.

Spirulina also

downregulated amylase isozyme expression by approximately 80% in cervical cancer cells Hela.
Spirulina downregulated AMY1 (43%) and AMY2A (82%) expression in pancreatic cancer cells
PANC1, but increased AMY2B (200%) expression. In addition, spirulina downregulated at least
two amylase isozymes in lung cancer cells (H2009) by 54%.
In contrast, spirulina consistently downregulated amylase expression in amylase positive OC
cells with spirulina-mediated inhibition of AMY1 and AMY2B, ranging from 6% to 99% (Figure
4.2). However, spirulina did not significantly decrease small endogenous levels of amylase
expression in IOSE-121 (Figure 4.2).
Spirulina downregulates amylase protein expression in OC cell lines.
Since RNA levels do not always accurately reflect target protein levels, to determine if
spirulina-mediated inhibition of amylase could be detected at the protein level, cells were treated
with 100ug/ml spirulina for 24 hours and protein amylase isozyme expression was determined
using western blot. While there was no significant change in amylase protein levels in IOSE-121
cells after spirulina treatment (Figure 4.3), spirulina reduced AMY1 protein levels in OVCAR5
and OV-90 cells by 23% and 26%, respectively; spirulina reduced AMY2A protein levels in
OVCAR5 and OV-90 cells by 51% and77%, respectively and spirulina reduced AMY2B protein
levels in OVCAR5 and OV-90 cells by 25% and 43%, respectively.
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Figure 4.1. Spirulina downregulates most amylase isozymes in cancer cells. Cells treated ± 100 ug/ml spirulina were subjected to
qPCR to determine amylase isozyme expression. Data are expressed as the ratio of amylase isozyme signal to GAPDH.

Ratio of AMY/GAPDH mRNA

0.001
0.0009
0.0008
0.0007
0.0006
0.0005
0.0004
0.0003
0.0002
0.0001

IOSE-121 IOSE-121 +
100ug/ml
spirulina

OV-90

OV-90 +
100ug/ml
spirulina

TOV21G TOV21G +
100ug/ml
spirulina

IGROV

AMY2B

AMY1

AMY2A

AMY2B

AMY2A

AMY1

AMY2B

AMY1

AMY2A

AMY2B

AMY1

AMY2A

AMY2B

AMY2A

AMY1

AMY2B

AMY1

AMY2A

AMY2B

AMY2A

AMY1

AMY2B

AMY1

AMY2A

AMY2B

AMY2A

AMY1

AMY2B

AMY2A

AMY1

0

IGROV + OVCAR5 OVCAR5 +
100ug/ml
SPIR
spirulina

AMY1A
AMY2A
AMY2B
ACTIN

Ratio of amylase/actin protein

IOSE -121
IOSE-121 + spirulina
OVCAR5
OVCAR5 + spirulina
OV-90
OV-90 + spirulina

Figure 4.2. Spirulina transcriptionally downregulates amylase in OC cell lines. Cells treated
± 100 ug/ml spirulina treatment were subjected to qPCR to determine amylase isozyme
expression. Data are expressed as the ratio of amylase isozyme signal to GAPDH.
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Figure 4.3. Spirulina reduces amylase protein levels in OC cell lines. Cells treated ± 100
ug/ml spirulina were subjected to western blot analysis to determine amylase isozyme protein
expression (left panel). Densitometric analyses representing ratio of amylase isozyme band
signal to respective actin loading control band signals are shown in the right panel.
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Spirulina reduces amylase secretion by OC cell lines.
To determine if spirulina inhibited amylase secretion, cell lysates and CCM collected from
IOSE-121, IOSE-144, OVCAR5 and SKOV3 cells treated with 100ug/ml spirulina for 24 h and
then subjected to an amylase ELISA (Figure 4.4). In agreement with figure 4.3, I found 12%
reduction in cellular amylase in IOSE-121 and -144, respectively. In addition, levels of secreted
amylase in IOSE-121 and -144 were reduced by 28% and 18% following spirulina treatment,
respectively. Also in agreement with figure 4.3, I found 72% and 16% reduction in cellular amylase
in OVCAR5 and SKOV3 cells, respectively. More notably, levels of secreted amylase in OVCAR5
and SKOV3 cells were reduced by 90% and 6% following spirulina treatment, respectively.
60

ng/ml amylase

50
40

Cell lysate

CCM

30
20
10

*

0

IOSE-122 IOSE-122 + IOSE-144 IOSE-144 + OVCAR5 OVCAR5 +
100ug/ml
100 ug/ml
100 ug/ml
spirulina
spirulina
spirulina

SKOV3

SKOV3 +
100 ug/ml
spirulina

Figure 4.4. Spirulina reduces amylase secretion in OC cell lines. Cell lysates and CCM from
cells treated ± spirulina were subjected to amylase ELISA to determine relative amounts of
cellular and secreted amylase. Data are presented as the mean of triplicates ± SE (*P<0.05).
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Spirulina decreases the invasive capacity of OC cells.
Using Boyden chamber assays, I found that spirulina did not significantly reduce invasive
capacity in IOSE-121 cells (Figure 4.5). However, spirulina significantly reduced invasive
capacity of OVCAR5 by 51% compared to untreated cells.
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Figure 4.5. Spirulina decreased invasive capacity in OC cells. IOSE-121 and OVCAR5 cells
were treated ± 100 ug/ml spirulina and assayed in Boyden chambers. Data are presented as
the mean of triplicates ± S.E. (*P<0.05).

Spirulina decreased migration of OVCAR5 cells.
To confirm the inhibitory effect of spirulina for OC cell motility, OVCAR5 cells were
visualized in a scratch assay for 0-24 hours ± 100 ug/ml spirulina. Untreated cells migrated to fill
the scratch gap within 24 h (Figure 4.6) However, spirulina-treated cells did not migrate as quickly
and had only filled in 64% of their scratch gap at 24h.
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Figure 4.6. Spirulina reduced migration in OVCAR5 cells. OVCAR5
cells were visualized in a scratch assay for 0-24h ± 100 ug/ml spirulina.
Experiment was performed in triplicate. Representative scratch assay is
illustrated in the upper panel while lower panel represents percent wound
closure.
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Spirulina does not alter OC proliferation.
To determine whether spirulina is potentially cytotoxic for normal or OC cells, IOSE and
OC cell survival and growth were measured by MTS assay for 0-72 hours when treated with a
range of concentrations of spirulina (Figure 4.7). Spirulina did not significantly alter or affect
proliferation of either OSE or OC cells.
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Figure 4.7. Spirulina did not alter IOSE or OC cell survival and proliferation. IOSE-121, IOSE144, OVCAR5 and OV-90 cells were treated with varying concentrations—0ug/ml, 50ug/ml,
100ug/ml, 150ug/ml— of spirulina and proliferation was measured every 24 hours for 72 hours.
Data are presented as the mean of two biological experiments, each performed in triplicates ±
SE.
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Phycocyanin abrogates amylase RNA expression.
IOSE-121 and OVCAR5 cells were treated with spirulina or phycocyanin in order to
determine if transcriptional downregulation of amylase by spirulina is due to one of its major active
ingredients, phycocyanin. In agreement with my earlier data (Figure 4.2), spirulina failed to
suppress amylase isozyme RNA expression in IOSE-121 (Figure 4.8), but phycocyanin increased
AMY1 and AMY2B RNA expression levels in a dose related manner. In contrast, but also in
agreement with my earlier data (Figure 4.2), spirulina completely inhibited AMY1 and AMY2B
RNA levels in OVCAR cells. Likewise, phycocyanin completely abrogated AMY1 and AMY2B
RNA levels in OC cells.
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Figure 4.8. Phycocyanin abrogates amylase expression in OC cells. IOSE-121 and OVCAR5
cells were treated with 100 ug/ml spirulina, 1ug/ml phycocyanin or 100 ug/ml phycocyanin and
subjected to qPCR for amylase isozyme RNA expression. Data are expressed as the ratio of
amylase isozyme signal to GAPDH.

116

Spirulina-induced inhibition of OC invasion is driven, in part, by phycocyanin.
To determine whether spirulina-mediated inhibition of OC invasive capacity was driven by
phycocyanin, using Boyden chamber assays, I found that neither spirulina nor phycocyanin
significantly reduced invasive capacity in IOSE-121 cells (Figure 4.9). In agreement with my
earlier data (Figure 4.5), spirulina reduced the invasive capacity of OVCAR5 cells by
approximately 51%. However, phycocyanin was only able to reduce the invasive capacity of
OVCAR5 cells by approximately 32%, suggesting that spirulina-induced inhibition of OC
invasion is driven only in part by phycocyanin.
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Figure 4.9. Spirulina driven inhibition of OC invasion is partly mediated by phycocyanin.
IOSE-121 and OVCAR5 cells were treated with 100 ug/ml spirulina or 1ug/ml phycocyanin
and assayed in collagen-coated Boyden chambers. Data are presented as the mean of
triplicates (*P<0.05).
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Discussion
Dietary supplements are widely recognized for their medicinal benefits. Many are or
contain free radical scavengers that promote improved health through anti-inflammatory activity
and clinically manifest as reduced incidence of disease, reduced damage associated with disease
and/or accelerated healing from disease. For example, curcumin, an active component of the spice
turmeric is widely used traditional Chinese herbal medicine. It has anti-cancer properties related
to suppression of the NF-κB signaling pathway which inhibits cellular proliferation and metastasis
[372]. Further, treatment of endometrial carcinoma cells, HEC-1B, with curcumin results in
decreased migration and invasion by reducing the expression and activity of MMP-2/9 via
suppression of the ERK signaling pathway [372,373].
Likewise, the clinical benefits of spirulina have also been investigated with regards to its
anti-oxidant, anti-inflammatory and anti-cancer properties. Several preclinical and clinical studies
have investigated the hypolipidemic effects of spirulina, that is, its ability to reduce cholesterol by
decreasing low-density lipoproteins (LDL), very low-density lipoproteins (HLDL), and
triglycerides (TG) and increase protective high-density lipoproteins (HDL). The cumulative data
indicates that spirulina has hypolipidemic activity in healthy young [374] and elderly volunteers,
patients with type 2 diabetes [375], patients with nephrotic syndrome [376] and patients with
ischaemic heart disease [377]. However, the exact molecular mechanism by which spirulina
promotes its hypolipidemic effects has not yet been elucidated [364].
The antioxidant and anti-inflammatory effects of spirulina were examined in in-vitro, preclinical and some clinical studies. Spirulina can decrease the inflammatory reaction induced by
toxic, oxidative and physical damaging agents [378,379]. Spirulina’s antioxidant and antiinflammatory effects have been attributed to phycocyanin and β-carotene. Phycocyanin is an
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antioxidant that can scavenge free radicals and lower lipid peroxidation [371]. Phycocyanin has
also been reported to inhibit TNF alpha and nitrile production [380]. On the other hand, the antioxidant properties of β-carotene are related to its ability to decrease production of nitric oxide
(NO) and PGE(2), inducible NO synthase (iNOS), cyclooxygenase-2, TNF-alpha, and IL-1beta
[381].
Lastly, the anti-cancer properties of spirulina have also been studied. Spirulina and
compounds isolated from spirulina, including phycocyanobilin and chlorophyllin, tetrapyrrolic,
significantly decrease proliferation of human pancreatic cancer cells in xenotransplanted nude
mice [382]. Spirulina has been reported to down-regulate inflammation and carcinogenesis
induced by UVB irradiation in the skin [383]. Additionally, spirulina exhibited anti-proliferative
activity with low cytotoxicity in five cancer cell lines – HepG2 (liver cancer cell line), MCF-7
(breast cancer cell line), SGC-7901 (gastric cancer cell line), A549 (non-small cell lung cancer),
and HT-29 (colon colorectal cancer cell line) [384]. Finally, colon colorectal cells (Caco-2) treated
with spirulina display decreased proliferation, migration and increased apoptosis that may be
related to increased intracellular reactive oxygen species (ROS) and nitric oxide (NO) levels [385].
In contrast, there have only been two reports investigating the role of spirulina in OC and
both studies were limited to the effect of phycocyanin in a single OC cell line. By targeting
mitochondrial proteins, phycocyanin was reported to inhibit cellular proliferation and induce
apoptosis by increased ROS production and activation of caspase-3, -8, and -9 in SKOV3 cells.
[386]. Ying et al. (2016) suggested that the anti-proliferative action of phycocyanin in SKOV3
cells could be mediated through 18 cellular pathways [387].
In the present study, I showed that amylase is a downstream target of spirulina. Spirulina
consistently downregulated amylase isozyme expression at the message and protein levels. As a
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result, spirulina, and to a lesser degree, phycocyanin appear to abrogate OC invasion by inhibiting
amylase-mediated OC cell migration and invasion. Importantly, spirulina did not appear to
adversely affect normal OSE cells. Given that the high mortality associated with OC is due, to a
large extent, by its propensity to metastasize early, the subset of patients whose cancers
overexpress amylase may benefit from adjuvant spirulina therapy to minimize burden of disease.
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Chapter 5
Concluding Remarks

Although its etiology is poorly understood, OC accounts for 4% of all cancer cases and
4.2% of all cancer deaths worldwide. OC is the most lethal gynecological cancer because early
symptoms of the disease are generally lacking. As a result, more than 70% of OC patients are
diagnosed in later stages when the disease has already metastasized. Women diagnosed in late
disease stage have a 5-year survival rate of less than 20% compared with approximately 90%
survival for women diagnosed with early stage disease. The current gold standard for OC
detection, serum CA-125, is only elevated in 50% of stage I OC patients so that CA-125 is more
useful as a prognostic rather than a diagnostic marker [388]. Therefore, there remains an urgent
need to better understand the cellular and molecular regulators that drive OC progression in order
to reduce metastatic spread as well as identify novel diagnostic and therapeutic targets.
A number of potential OC biomarkers have been reported to date. However, their efficacy
for disease detection or functional contribution to OC progression is limited. Therefore, I initiated
my studies with a computational analysis of the 27 most commonly reported literature-derived
ovarian cancer (LDOC) protein biomarkers. I found that LDOC protein biomarkers share many
biochemical features including a preponderance for a stable protein structure (ordered, hydrophilic,
aggregation-prone, glycosylated and sumoylated), the ability to be secreted (export signal peptide
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sequence, hydrophilic) and functionality related to ECM modification, immune response and/or
energy production. Subsequently, I analyzed the human proteome to identify additional proteins
that also share these biochemical features. Of the 70,616 proteins in the human proteome, 683
proteins were found to have similar biochemical features to the 27 LDOC proteins. With further
computational analyses I identified a subset of 21 potential additional protein regulators of ovarian
cancer (APROC) sharing similar functional and biochemical protein profiles and interactivity with
LDOCs in the humane proteome.
Three of the APROCs identified were amylase (AMY) AMY1A, AMY2A, and AMY2B,
which compromise the members of the human amylase gene family. Amylase cleaves alpha 1, 4glycosidic bonds in polysaccharides to initiate carbohydrate metabolism, thereby contributing to
energy production. Amylase is reportedly overexpressed in and secreted by ovarian tumors [262].
Hyperamylasemia has been studied as both a diagnostic and prognostic indicator even though its
functional contribution to OC progression remains unknown [1]. Since amylase can degrade
bacterial biofilms in wounds [228], it is possible that, by cleaving polysaccharide moieties in the
tumor microenvironment, amylase also plays a role in ECM remodeling. Consequently, I sought
to determine whether amylase could promote OC cell migration and invasion.
I initiated my studies on the role of amylase to drive OC invasion with additional
computational studies focused on characterizing the different amylase isozymes in order to predict
which amylase isozyme(s) is most likely overexpressed in and contributory to OC invasion. I found
that there were significant differences among the isozymes. Specifically, AMY1 and AMY2B have
unique regions of disorder, unique regions of aggregation and unique phosphorylation sites
indicating that AMY1 and AMY2B would be more likely to interact with other proteins, to
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aggregate and to be easily secreted. Using serum samples from patients with OC, I was able to
validate AMY1 and AMY2B overexpression by western immunoblotting.
I then developed an in vitro model system to study the molecular contribution of amylase
to OC using IOSE and OC cell lines. I showed that OC cells generally overexpress and secrete
metabolically active amylase isozymes AMY1 and AMY2B. Abrogating amylase activity using
siRNA silencing technology decreased the capacity of OC cells to invade collagen coated Boyden
chambers and increased sGAG production. Since a survey of OC cell lines indicated that cancer
cells have a bulkier glycocalyx compared to IOSE cells and immunogold labeling studies indicated
the presence of amylase within the immediate OC microenvironment, my data suggest that, by
cleaving alpha 1, 4-glycosidic bonds in glycoconjugates (glycosaminoglycans (GAGs),
glycoproteins, glycolipids, and proteoglycans) present within ECM, amylase may remodel the
ECM to promote an invasive cancer phenotype.
Further studies are needed to validate the hypothesis that amylase may promote OC
invasion by altering the glycocalyx/ECM architecture in OC. Assuming that amylase maintains its
traditional enzymatic activity in the OC ECM, GAGs within the glycocalyx containing α-1, 4glycosidic bonds should be susceptible to hydrolysis by amylase enzymatic activity. By cleaving
α-1, 4-glycosidic bonds in negatively charged repellant GAGs [356], amylase may lead to
proteoglycan condensation. Consequently, this proteoglycan condensation could result in integrin
clustering and dimerization, leading to an altered glycocalyx characteristic of malignant cells that
is associated with an invasive phenotype (Figure 5.1). Weaver et al. described metastatic tumors
which overexpress bulky glycan structures and glycoproteins that alter integrin organization by
funneling active integrins together. Glycocalyx –mediated integrin clustering promote phenotypes
associated with cancer [389,390].

123

Figure 5.1. Schematic of the possible influence of amylase in altering the glycocalyx of OC
cell and consequently lead to a more malignant phenotype. Amylase may cleave α-1, 4glycosidic bonds in OC cell glycocalyx which leads to proteoglycan condensation and integrin
clustering. The resulting altered glycocalyx promotes a malignant phenotype.

Amylase could, then, be a target for therapeutic intervention in OC patients with
hyperamylasemia. However, commercially available amylase inhibitors typically inhibit amylase
activity at the protein level and produce a variety of adverse gastrointestinal side effects [363]. I
established Spirulina, a dietary supplement, as a novel transcriptional inhibitor of amylase.
Spirulina inhibited amylase expression in OC cell lines at both the message and protein levels.
Spirulina reduced OC cell invasion and migration in vitro, putatively by decreasing amylase
expression. Phycocyanin, one of the active ingredients of spirulina, was investigated in order to
determine if it was responsible for the downregulation of amylase expression and reduced invasion
induced by spirulina. I found that phycocyanin reduced amylase expression in and invasive
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behavior of OC cells, but the degree to which phycocyanin reduced amylase-mediated activities
was less than that of spirulina. Therefore, multiple components of spirulina are likely responsible
for regulating amylase expression.
Clearly, further studies are warranted to determine the clinical impact of amylase in OC,
and, potentially other cancer types. Since lung cancer is also often clinically associated with
hyperamylasemia, it would be interesting to determine whether amylase similarly mediates cellular
invasion in lung cancer cells. Given the lack of sensitive and specific biomarkers for OC, it might
also be clinically impactful to examine the potential for serum amylase to serve as a biomarker of
disease based on amylase isozyme subtype. Furthermore, spirulina may be an attractive and
effective therapy/therapeutic adjuvant to reduce the migratory and invasive capabilities of OC cells
leading to decreased disease burden. Going forward, it would be important to identify and isolate
the specific components of Spirulina that transcriptionally inhibit amylase as well as examine other
dietary supplements for their ability to inhibit amylase alone or in concert with Spirulina. Lastly,
I have shown the power of computational analyses to provide insight about the different molecular
mechanisms employed by disease regulators with shared protein profiles. I would hope that future
endeavors explore the biochemical features, metabolic pathways and protein-protein networks
among the remaining APROC candidates to provide additional insights about the appearance of
diverse histologic subtypes, the propensity for metastatic spread and the emergence of drug
resistance in OC. This, in turn, could reduce the mortality of a disease that kills thousands of
women annually.
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Appendix I
Potential novel regulators or biomarkers of OC – 683 proteins in total of non-redundant,
secreted, ordered and aggregation-prone human proteins.
Appendix I
Uniprot
Uniprot
Gene name
Protein name
entry
entry
name
Proteins functionally related to ECM/microenvironment modifications
A8K2U0 A2ML1
A2ML1 CPAMD9
Q9Y653
AGRG1 ADGRG1 GPR56 TM7LN4
TM7XN1 UNQ540/PRO1083
P01019
ANGT
AGT SERPINA8
Angiotensinogen (Serpin A8)
[Cleaved into: Angiotensin-1
(Angiotensin 1-10) (Angiotensin I)
(Ang I); Angiotensin-2
(Angiotensin 1-8) (Angiotensin II)
(Ang II); Angiotensin-3
(Angiotensin 2-8) (Angiotensin
III) (Ang III) (Des-Asp[1]angiotensin II); Angiotensin-4
(Angiotensin 3-8) (Angiotensin
IV) (Ang IV); Angiotensin 1-9;
Angiotensin 1-7; Angiotensin 1-5;
Angiotensin 1-4]
Q13740
CD166
ALCAM MEMD
CD166 antigen (Activated
leukocyte cell adhesion molecule)
(CD antigen CD166)
S4R3Y4
S4R3Y4 AMBP
Protein AMBP
Q15389
ANGP1
ANGPT1 KIAA0003
Angiopoietin-1 (ANG-1)
O15123
ANGP2
ANGPT2
Angiopoietin-2 (ANG-2)
O95841
ANGL1
ANGPTL1 ANG3 ANGPT3
Angiopoietin-related protein 1
ARP1 PSEC0154
(Angiopoietin-3) (ANG-3)
UNQ162/PRO188
(Angiopoietin-like protein 1)
Q9UKU9 ANGL2
ANGPTL2 ARP2
Angiopoietin-related protein 2
UNQ170/PRO196
(Angiopoietin-like protein 2)
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P58335

ANTR2

ANTXR2 CMG2

O95393

BMP10

BMP10

P22003

BMP5

BMP5

P22004

BMP6

BMP6 VGR

P18075

BMP7

BMP7 OP1

P59826

BPIB3

BPIFB3 C20orf185 LPLUNC3

Q075Z2

BSPH1

BSPH1

P35070

BTC

BTC

Q9BXJ1

C1QT1

C1QTNF1 CTRP1
UNQ310/PRO353

Q9BXJ0

C1QT5

P60827

C1QT8

C1QTNF5 CTRP5
UNQ303/PRO344
C1QTNF8
UNQ5829/PRO19648

Q8IUK8
P48960
Q9H5V8

CBLN2
CD97
CDCP1

P13688

CEAM1

CBLN2 UNQ1892/PRO4338
CD97
CDCP1 TRASK
UNQ2486/PRO5773
CEACAM1 BGP BGP1

Q2WEN9

CEA16

CEACAM16 CEAL2

Anthrax toxin receptor 2
(Capillary morphogenesis gene 2
protein) (CMG-2)
Bone morphogenetic protein 10
(BMP-10)
Bone morphogenetic protein 5
(BMP-5)
Bone morphogenetic protein 6
(BMP-6) (VG-1-related protein)
(VG-1-R) (VGR-1)
Bone morphogenetic protein 7
(BMP-7) (Osteogenic protein 1)
(OP-1) (Eptotermin alfa)
BPI fold-containing family B
member 3 (Ligand-binding protein
RYA3) (Long palate, lung and
nasal epithelium carcinomaassociated protein 3)
Binder of sperm protein homolog
1 (Bovine seminal plasma protein
homolog 1) (Bovine seminal
plasma protein-like 1)
Probetacellulin [Cleaved into:
Betacellulin (BTC)]
Complement C1q tumor necrosis
factor-related protein 1 (G proteincoupled receptor-interacting
protein) (GIP)
Complement C1q tumor necrosis
factor-related protein 5
Complement C1q tumor necrosis
factor-related protein 8 (C1q/TNFrelated protein 8) (CTRP8)
Cerebellin-2

Carcinoembryonic antigen-related
cell adhesion molecule 1 (Biliary
glycoprotein 1) (BGP-1) (CD
antigen CD66a)
Carcinoembryonic antigen-related
cell adhesion molecule 16
(Carcinoembryonic antigen-like 2)
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Q9UNI1

CELA1

CELA1 ELA1

P08217

CEL2A

CELA2A ELA2A

Q9BXR6

FHR5

CFHR5 CFHL5 FHR5

Q15782

CH3L2

CHI3L2

Q9BU40

CRDL1

CHRDL1 NRLN1

Q9UQC9
O43405

CLCA2
COCH

P12109
P12111
A8TX70
A6NMZ7
Q8IVL8

CO6A1
CO6A3
CO6A5
CO6A6
CBPO

CLCA2 CACC3
COCH COCH5B2
UNQ257/PRO294
COL6A1
COL6A3
COL6A5 COL29A1 VWA4
COL6A6
CPO

O75629

CREG1

Q9H0B8

CRLD2

O60676

CST8

CST8 CRES

Q9H4G1

CST9L

Q8N907

DAND5

CST9L CTES7B
UNQ1835/PRO3543
DAND5 CER2 CKTSF1B3
GREM3 SP1

Q07507

DERM

DPT

O60469
Q14507

DSCAM
EP3A

DSCAM
EDDM3A FAM12A HE3A

CREG1 CREG
UNQ727/PRO1409
CRISPLD2 CRISP11 LCRISP2
UNQ2914/PRO1156/PRO9783

Chymotrypsin-like elastase family
member 1 (EC 3.4.21.36)
(Elastase-1) (Pancreatic elastase 1)
Chymotrypsin-like elastase family
member 2A (EC 3.4.21.71)
(Elastase-2A)
Complement factor H-related
protein 5 (FHR-5)
Chitinase-3-like protein 2
(Chondrocyte protein 39) (YKL39)
Chordin-like protein 1 (Neuralin1) (Neurogenesin-1) (Ventroptin)
Cochlin (COCH-5B2)

Carboxypeptidase O (CPO) (EC
3.4.17.-)
Protein CREG1 (Cellular repressor
of E1A-stimulated genes 1)
Cysteine-rich secretory protein
LCCL domain-containing 2
(Cysteine-rich secretory protein
11) (CRISP-11) (LCCL domaincontaining cysteine-rich secretory
protein 2)
Cystatin-8 (Cystatin-related
epididymal spermatogenic protein)
Cystatin-9 (Cystatin-like
molecule)
DAN domain family member 5
(Cerberus-like protein 2) (Cerl-2)
(Cysteine knot superfamily 1,
BMP antagonist 3) (Gremlin-3)
Dermatopontin (Tyrosine-rich
acidic matrix protein) (TRAMP)
Epididymal secretory protein E3alpha (Human epididymis-specific
protein 3-alpha) (HE3-alpha)
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P56851

EP3B

EDDM3B FAM12B HE3B
UNQ6412/PRO21187

O43854

EDIL3

EDIL3 DEL1

Q12805

FBLN3

EFEMP1 FBLN3 FBNL

O95967

FBLN4

EFEMP2 FBLN4
UNQ200/PRO226

P20827

EFNA1

EFNA1 EPLG1 LERK1
TNFAIP4

P52798

EFNA4

EFNA4 EPLG4 LERK4

Q96BH3
Q9UJA9

ESPB1
ENPP5

ELSPBP1 E12
ENPP5 UNQ550/PRO1107

Q6UW88
M5A8F1

EPGN
SUPYN

Q5T1H1

EYS

P03951

FA11

Epididymal secretory protein E3beta (Human epididymis-specific
protein 3-beta) (HE3-beta)
EGF-like repeat and discoidin Ilike domain-containing protein 3
(Developmentally-regulated
endothelial cell locus 1 protein)
(Integrin-binding protein DEL1)
EGF-containing fibulin-like
extracellular matrix protein 1
(Extracellular protein S1-5)
(Fibrillin-like protein) (Fibulin-3)
(FIBL-3)
EGF-containing fibulin-like
extracellular matrix protein 2
(Fibulin-4) (FIBL-4) (Protein
UPH1)
Ephrin-A1 (EPH-related receptor
tyrosine kinase ligand 1) (LERK1) (Immediate early response
protein B61) (Tumor necrosis
factor alpha-induced protein 4)
(TNF alpha-induced protein 4)
[Cleaved into: Ephrin-A1, secreted
form]
Ephrin-A4 (EPH-related receptor
tyrosine kinase ligand 4) (LERK4)

Ectonucleotide
pyrophosphatase/phosphodiesteras
e family member 5 (E-NPP 5)
(NPP-5) (EC 3.1.-.-)
EPGN UNQ3072/PRO9904
Epigen (Epithelial mitogen) (EPG)
ERVH48-1 C21orf105 HERVSuppressyn (Endogenous
Fb1 NDUFV3-AS1
retrovirus group 48 member 1)
(NDUFV3 antisense RNA 1)
(endogenous retrovirus group Fb
member 1)
EYS C6orf178 C6orf179 C6orf180 EGFL10 EGFL11 SPAM
UNQ9424/PRO34591
F11
Coagulation factor XI (FXI) (EC
3.4.21.27) (Plasma thromboplastin
antecedent) (PTA) [Cleaved into:
Coagulation factor XIa heavy
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P13726

TF

F3

P08709
P00740

FA7
FA9

F7
F9

Q96MK3
Q8IXL6

FA20A
FA20C

FAM20A UNQ9388/PRO34279
FAM20C DMP4

Q9Y6R7
P08620

FCGBP
FGF4

FCGBP
FGF4 HST HSTF1 KS3

P10767

FGF6

FGF6 HST2 HSTF2

P21781

FGF7

FGF7 KGF

P02679
Q9NZU1

FIBG
FLRT1

FGG PRO2061
FLRT1 UNQ752/PRO1483

O43155

FLRT2

FLRT2 KIAA0405
UNQ232/PRO265

chain; Coagulation factor XIa light
chain]
Tissue factor (TF) (Coagulation
factor III) (Thromboplastin) (CD
antigen CD142)
Coagulation factor VII
Coagulation factor IX (EC
3.4.21.22) (Christmas factor)
(Plasma thromboplastin
component) (PTC) [Cleaved into:
Coagulation factor IXa light chain;
Coagulation factor IXa heavy
chain]
Pseudokinase FAM20A
Extracellular serine/threonine
protein kinase FAM20C (EC
2.7.11.1) (Dentin matrix protein 4)
(DMP-4) (Golgi casein kinase)
(Golgi-enriched fraction casein
kinase) (GEF-CK)
Fibroblast growth factor 4 (FGF4) (Heparin secretorytransforming protein 1) (HST)
(HST-1) (HSTF-1) (Heparinbinding growth factor 4) (HBGF4) (Transforming protein KS3)
Fibroblast growth factor 6 (FGF6) (Heparin secretorytransforming protein 2) (HST-2)
(HSTF-2) (Heparin-binding
growth factor 6) (HBGF-6)
Fibroblast growth factor 7 (FGF7) (Heparin-binding growth factor
7) (HBGF-7) (Keratinocyte
growth factor)
Fibrinogen gamma chain
Leucine-rich repeat
transmembrane protein FLRT1
(Fibronectin-like domaincontaining leucine-rich
transmembrane protein 1)
Leucine-rich repeat
transmembrane protein FLRT2
(Fibronectin-like domain180

containing leucine-rich
transmembrane protein 2)
Leucine-rich repeat
transmembrane protein FLRT3
(Fibronectin-like domaincontaining leucine-rich
transmembrane protein 3)

Q9NZU0

FLRT3

FLRT3 KIAA1469
UNQ856/PRO1865

P0C091
P01225

FREM3
FSHB

FREM3
FSHB

Q9BTY2

FUCO2

FUCA2 PSEC0151
UNQ227/PRO260

Q9UBS5
Q9NR23

GABR1
GDF3

GABBR1 GPRC3A
GDF3 UNQ222/PRO248

O60383

GDF9

Q3B7J2

GFOD2

P10912

GHR

Q86XP6

GKN2

P0CG01
Q6UWM
5
P01148

GKN3
GPRL1

Growth/differentiation factor 3
(GDF-3)
GDF9
Growth/differentiation factor 9
(GDF-9)
GFOD2 UNQ9430/PRO34691
Glucose-fructose oxidoreductase
domain-containing protein 2 (EC
1.-.-.-)
GHR
Growth hormone receptor (GH
receptor) (Somatotropin receptor)
[Cleaved into: Growth hormonebinding protein (GH-binding
protein) (GHBP) (Serum-binding
protein)]
GKN2 BLOT GDDR TFIZ1
Gastrokine-2 (Blottin) (DownUNQ465/PRO813
regulated in gastric cancer)
(Trefoil factor interactions(z) 1)
GKN3P
Gastrokine-3
GLIPR1L1 UNQ2972/PRO7434 GLIPR1-like protein 1

GON1

GNRH1 GNRH GRH LHRH

Follitropin subunit beta (Folliclestimulating hormone beta subunit)
(FSH-B) (FSH-beta) (Follitropin
beta chain)
Plasma alpha-L-fucosidase (EC
3.2.1.51) (Alpha-L-fucoside
fucohydrolase 2) (Alpha-Lfucosidase 2)

Progonadoliberin-1
(Progonadoliberin I) [Cleaved
into: Gonadoliberin-1
(Gonadoliberin I) (Gonadorelin)
(Gonadotropin-releasing hormone
I) (GnRH-I) (Luliberin I)
(Luteinizing hormone-releasing
hormone I) (LH-RH I); GnRHassociated peptide 1 (GnRHassociated peptide I)]
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P51654

GPC3

GPC3 OCI5

O75487

GPC4

GPC4 UNQ474/PRO937

P78333

GPC5

GPC5

Q9Y625

GPC6

GPC6 UNQ369/PRO705

Q96T91

GPHA2

GPHA2 GPA2 ZSIG51

Q86YW7

GPHB5

GPHB5 GPB5 ZLUT1

Q02747

GUC2A

GUCA2A GUCA2

Q96RW7
Q9Y251

HMCN1
HPSE

HMCN1 FIBL6
HPSE HEP HPA HPA1 HPR1
HPSE1 HSE1

Q8WWQ
2
P02790

HPSE2

HPSE2 HPA2

HEMO

HPX

Q92743

HTRA1

HTRA1 HTRA PRSS11

P83110

HTRA3

HTRA3 PRSP

P83105

HTRA4

HTRA4

Q12794

HYAL1

HYAL1 LUCA1

Glypican-3 (GTR2-2) (Intestinal
protein OCI-5) (MXR7) [Cleaved
into: Secreted glypican-3]
Glypican-4 (K-glypican) [Cleaved
into: Secreted glypican-4]
Glypican-5 [Cleaved into:
Secreted glypican-5]
Glypican-6 [Cleaved into:
Secreted glypican-6]
Glycoprotein hormone alpha-2
(Putative secreted protein Zsig51)
(Thyrostimulin subunit alpha)
Glycoprotein hormone beta-5
(Thyrostimulin subunit beta)
Guanylin (Guanylate cyclase
activator 2A) (Guanylate cyclaseactivating protein 1) (Guanylate
cyclase-activating protein I)
(GCAP-I) [Cleaved into: HMWguanylin; Guanylin]
Heparanase (EC 3.2.1.166) (Endoglucoronidase) (Heparanase-1)
(Hpa1) [Cleaved into: Heparanase
8 kDa subunit; Heparanase 50 kDa
subunit]
Inactive heparanase-2 (Hpa2)
Hemopexin (Beta-1Bglycoprotein)
Serine protease HTRA1 (EC
3.4.21.-) (High-temperature
requirement A serine peptidase 1)
(L56) (Serine protease 11)
Serine protease HTRA3 (EC
3.4.21.-) (High-temperature
requirement factor A3)
(Pregnancy-related serine
protease)
Serine protease HTRA4 (EC
3.4.21.-) (High-temperature
requirement factor A4)
Hyaluronidase-1 (Hyal-1) (EC
3.2.1.35)
(Hyaluronoglucosaminidase-1)
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O43820

HYAL3

HYAL3 LUCA3

P35858

ALS

IGFALS ALS

Q8N6C5

IGSF1

P35968
Q14667
O43240

VGFR2
K0100
KLK10

IGSF1 IGDC1 KIAA0364
PGSF2
KDR FLK1 VEGFR2
KIAA0100 BCOX1
KLK10 NES1 PRSSL1

Q9UKR0

KLK12

KLK12 KLKL5
UNQ669/PRO1303

P07288

KLK3

KLK3 APS

Q9Y5K2

KLK4

KLK4 EMSP1 PRSS17 PSTS

P49862

KLK7

KLK7 PRSS6 SCCE

Q9UKQ9

KLK9

KLK9

P03952

KLKB1

KLKB1 KLK3

P25391
P24043
Q16787

LAMA1
LAMA2
LAMA3

LAMA1 LAMA
LAMA2 LAMM
LAMA3 LAMNA

(Lung carcinoma protein 1)
(LuCa-1)
Hyaluronidase-3 (Hyal-3) (EC
3.2.1.35)
(Hyaluronoglucosaminidase-3)
(Lung carcinoma protein 3)
(LuCa-3)
Insulin growth factor-like family
member 1

Kallikrein-10 (EC 3.4.21.-)
(Normal epithelial cell-specific 1)
(Protease serine-like 1)
Kallikrein-12 (EC 3.4.21.-)
(Kallikrein-like protein 5) (KLKL5)
Prostate-specific antigen (PSA)
(EC 3.4.21.77) (Gammaseminoprotein) (Seminin)
(Kallikrein-3) (P-30 antigen)
(Semenogelase)
Kallikrein-4 (EC 3.4.21.-)
(Enamel matrix serine proteinase
1) (Kallikrein-like protein 1)
(KLK-L1) (Prostase) (Serine
protease 17)
Kallikrein-7 (hK7) (EC
3.4.21.117) (Serine protease 6)
(Stratum corneum chymotryptic
enzyme) (hSCCE)
Kallikrein-9 (EC 3.4.21.-)
(Kallikrein-like protein 3) (KLKL3)
Plasma kallikrein (EC 3.4.21.34)
(Fletcher factor) (Kininogenin)
(Plasma prekallikrein) (PKK)
[Cleaved into: Plasma kallikrein
heavy chain; Plasma kallikrein
light chain]
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O15230
Q13751
Q6JVE6
Q6JVE9
Q6P5S2
O95970

LAMA5
LAMB3
LCN10
LCN8
LEG1H
LGI1

LAMA5 KIAA0533 KIAA1907
LAMB3 LAMNB1
LCN10
LCN8 LCN5
LEG1 C6orf58
LGI1 EPT UNQ775/PRO1569

P01229

LSHB

LHB

P02750

A2GL

LRG1 LRG

Q8N6Y2

LRC17

P21941

MATN1

LRRC17 P37NB
UNQ3076/PRO9909
MATN1 CMP CRTM

O15232
O95460
P08581
P08493

MATN3
MATN4
MET
MGP

MATN3
MATN4
MET
MGP MGLAP GIG36

P03956

MMP1

MMP1 CLG

P09238

MMP10

MMP10 STMY2

P39900

MMP12

MMP12 HME

P51512

MMP16

MMP16 MMPX2

Epididymal-specific lipocalin-10
Epididymal-specific lipocalin-8
Protein LEG1 homolog
Leucine-rich glioma-inactivated
protein 1 (Epitempin-1)
Lutropin subunit beta (Lutropin
beta chain) (Luteinizing hormone
subunit beta) (LH-B) (LSH-B)
(LSH-beta)
Leucine-rich alpha-2-glycoprotein
(LRG)
Leucine-rich repeat-containing
protein 17 (p37NB)
Cartilage matrix protein (Matrilin1)
Matrilin-3
Matrilin-4
Matrix Gla protein (MGP) (Cell
growth-inhibiting gene 36 protein)
Interstitial collagenase (EC
3.4.24.7) (Fibroblast collagenase)
(Matrix metalloproteinase-1)
(MMP-1) [Cleaved into: 22 kDa
interstitial collagenase; 27 kDa
interstitial collagenase]
Stromelysin-2 (SL-2) (EC
3.4.24.22) (Matrix
metalloproteinase-10) (MMP-10)
(Transin-2)
Macrophage metalloelastase
(MME) (EC 3.4.24.65)
(Macrophage elastase) (ME)
(hME) (Matrix metalloproteinase12) (MMP-12)
Matrix metalloproteinase-16
(MMP-16) (EC 3.4.24.-) (MMPX2) (Membrane-type matrix
metalloproteinase 3) (MT-MMP 3)
(MTMMP3) (Membrane-type-3
matrix metalloproteinase) (MT3MMP) (MT3MMP)

184

Q99542

MMP19

MMP19 MMP18 RASI

O60882

MMP20

MMP20

Q8N119

MMP21

MMP21

Q9H239

MMP28

MMP28 MMP25
UNQ1893/PRO4339

P08254

MMP3

MMP3 STMY1

P22894

MMP8

MMP8 CLG1

P08118

MSMB

MSMB PRSP

Q1L6U9

MSMP

MSMP PSMP

Q99972

MYOC

MYOC GLC1A TIGR

Q8TB73

NDNF

Q00604

NDP

NDNF C4orf31
UNQ2748/PRO6487
NDP EVR2

Q15223

NECT1

NECTIN1 HVEC PRR1 PVRL1

Matrix metalloproteinase-19
(MMP-19) (EC 3.4.24.-) (Matrix
metalloproteinase RASI) (Matrix
metalloproteinase-18) (MMP-18)
Matrix metalloproteinase-20
(MMP-20) (EC 3.4.24.-) (Enamel
metalloproteinase) (Enamelysin)
Matrix metalloproteinase-21
(MMP-21) (EC 3.4.24.-)
Matrix metalloproteinase-28
(MMP-28) (EC 3.4.24.-)
(Epilysin)
Stromelysin-1 (SL-1) (EC
3.4.24.17) (Matrix
metalloproteinase-3) (MMP-3)
(Transin-1)
Neutrophil collagenase (EC
3.4.24.34) (Matrix
metalloproteinase-8) (MMP-8)
(PMNL collagenase) (PMNL-CL)
Beta-microseminoprotein
(Immunoglobulin-binding factor)
(IGBF) (PN44) (Prostate secreted
seminal plasma protein) (Prostate
secretory protein of 94 amino
acids) (PSP-94) (PSP94) (Seminal
plasma beta-inhibin)
Prostate-associated
microseminoprotein (PC3-secreted
microprotein)
Myocilin (Myocilin 55 kDa
subunit) (Trabecular meshworkinduced glucocorticoid response
protein) [Cleaved into: Myocilin,
N-terminal fragment (Myocilin 20
kDa N-terminal fragment);
Myocilin, C-terminal fragment
(Myocilin 35 kDa N-terminal
fragment)]
Protein NDNF (Neuron-derived
neurotrophic factor)
Norrin (Norrie disease protein)
(X-linked exudative
vitreoretinopathy 2 protein)
Nectin-1 (Herpes virus entry
mediator C) (Herpesvirus entry
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Q96NY8

NECT4

NECTIN4 LNIR PRR4 PVRL4

Q8TDF5

NETO1

NETO1 BTCL1

Q6P988

NOTUM

NOTUM OK/SW-CL.30

P0C0P6
P47972

NPS
NPTX2

NPS
NPTX2

Q92823
O95156
Q99784

NRCAM
NXPH2
NOE1

NRCAM KIAA0343
NXPH2 NPH2
OLFM1 NOE1 NOEL1

Q6UX06

OLFM4

OLFM4 GW112
UNQ362/PRO698

Q6IE37
Q6IE36
P09466

OVOS1
OVOS2
PAEP

OVOS1
OVOS2
PAEP

P0C8F1

PATE4

PATE4

Q96QU1

PCD15

PCDH15 USH1F

mediator C) (HveC) (Herpesvirus
Ig-like receptor) (HIgR) (Nectin
cell adhesion molecule 1)
(Poliovirus receptor-related
protein 1) (CD antigen CD111)
Nectin-4 (Ig superfamily receptor
LNIR) (Nectin cell adhesion
molecule 4) (Poliovirus receptorrelated protein 4) [Cleaved into:
Processed poliovirus receptorrelated protein 4]
Neuropilin and tolloid-like protein
1 (Brain-specific transmembrane
protein containing 2 CUB and 1
LDL-receptor class A domains
protein 1)
Palmitoleoyl-protein
carboxylesterase NOTUM (EC
3.1.1.98) (hNOTUM)
Neuropeptide S
Neuronal pentraxin-2 (NP2)
(Neuronal pentraxin II) (NP-II)
Neurexophilin-2
Noelin (Neuronal olfactomedinrelated ER localized protein)
(Olfactomedin-1)
Olfactomedin-4 (OLM4)
(Antiapoptotic protein GW112)
(G-CSF-stimulated clone 1
protein) (hGC-1) (hOLfD)

Glycodelin (GD) (Placental
protein 14) (PP14) (Pregnancyassociated endometrial alpha-2
globulin) (PAEG) (PEG)
(Progestagen-associated
endometrial protein)
(Progesterone-associated
endometrial protein)
Prostate and testis expressed
protein 4 (PATE-like protein B)
(PATE-B)
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Q15113

PCOC1

PCOLCE PCPE1

Q9UKZ9

PCOC2

PCOLCE2 PCPE2
UNQ250/PRO287

Q15198

PGFRL

PDGFRL PRLTS

P12273

PIP

PIP GCDFP15 GPIP4

Q504Y2

PKDCC

PKDCC SGK493 VLK

P00750

TPA

PLAT

P00749

UROK

PLAU

Procollagen C-endopeptidase
enhancer 1 (Procollagen COOHterminal proteinase enhancer 1)
(PCPE-1) (Procollagen Cproteinase enhancer 1) (Type 1
procollagen C-proteinase enhancer
protein) (Type I procollagen
COOH-terminal proteinase
enhancer)
Procollagen C-endopeptidase
enhancer 2 (Procollagen COOHterminal proteinase enhancer 2)
(PCPE-2) (Procollagen Cproteinase enhancer 2)
Platelet-derived growth factor
receptor-like protein (PDGFR-like
protein) (PDGF receptor beta-like
tumor suppressor)
Prolactin-inducible protein (Gross
cystic disease fluid protein 15)
(GCDFP-15) (Prolactin-induced
protein) (Secretory actin-binding
protein) (SABP) (gp17)
Extracellular tyrosine-protein
kinase PKDCC (EC 2.7.10.2)
(Protein kinase domain-containing
protein, cytoplasmic) (Protein
kinase-like protein SgK493)
(Sugen kinase 493) (Vertebrate
lonesome kinase)
Tissue-type plasminogen activator
(t-PA) (t-plasminogen activator)
(tPA) (EC 3.4.21.68) (Alteplase)
(Reteplase) [Cleaved into: Tissuetype plasminogen activator chain
A; Tissue-type plasminogen
activator chain B]
Urokinase-type plasminogen
activator (U-plasminogen
activator) (uPA) (EC 3.4.21.73)
[Cleaved into: Urokinase-type
plasminogen activator long chain
A; Urokinase-type plasminogen
activator short chain A;
Urokinase-type plasminogen
activator chain B]
187

Q15195

PLGA

P40967

PMEL

Q7Z5L7

PODN

Q15063
P07478

POSTN
TRY2

Q8NHM4

TRY6

Q6UWY2 PRS57
Q16557

PSG3

Q00889

PSG6

Q13046

PSG7

PLGLA PLGLA1 PLGP2
PRGA

Plasminogen-like protein A
(Plasminogen-like protein A1)
(Plasminogen-related protein A)
PMEL D12S53E PMEL17 SILV Melanocyte protein PMEL
(ME20-M) (ME20M) (Melanocyte
protein Pmel 17) (Melanocytes
lineage-specific antigen GP100)
(Melanoma-associated ME20
antigen) (P1) (P100)
(Premelanosome protein) (Silver
locus protein homolog) [Cleaved
into: M-alpha (95 kDa
melanocyte-specific secreted
glycoprotein) (P26) (Secreted
melanoma-associated ME20
antigen) (ME20-S) (ME20S); Mbeta]
PODN SLRR5A
Podocan
UNQ293/PRO332
POSTN OSF2
PRSS2 TRY2 TRYP2
Trypsin-2 (EC 3.4.21.4) (Anionic
trypsinogen) (Serine protease 2)
(Trypsin II)
PRSS3P2 T6 TRY6
Putative trypsin-6 (EC 3.4.21.4)
(Serine protease 3 pseudogene 2)
(Trypsinogen C)
PRSS57 PRSSL1
Serine protease 57 (EC 3.4.21.-)
UNQ782/PRO1599
(Serine protease 1-like protein 1)
PSG3
Pregnancy-specific beta-1glycoprotein 3 (PS-beta-G-3)
(PSBG-3) (Pregnancy-specific
glycoprotein 3)
(Carcinoembryonic antigen SG5)
PSG6 CGM3 PSG10 PSG12
Pregnancy-specific beta-1PSGGB
glycoprotein 6 (PS-beta-G-6)
(PSBG-6) (Pregnancy-specific
glycoprotein 6) (Pregnancyspecific beta-1-glycoprotein 10)
(PS-beta-G-10) (PSBG-10)
(Pregnancy-specific glycoprotein
10) (Pregnancy-specific beta-1glycoprotein 12) (PS-beta-G-12)
(PSBG-12) (Pregnancy-specific
glycoprotein 12)
PSG7
Putative pregnancy-specific beta1-glycoprotein 7 (PS-beta-G-7)
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Q9UQ74

PSG8

PSG8

Q96A98

TIP39

PTH2 TIP39 TIPF39

P21246

PTN

PTN HBNF1 NEGF1

P10082

PYY

PYY

P20742
P78509
Q6XE38

PZP
RELN
SG1D4

PZP CPAMD6
RELN
SCGB1D4 UNQ517/PRO812

Q96PL1

SG3A2

SCGB3A2 PNSP1 UGRP1
UNQ566/PRO1128

Q07699
P01009

SCN1B
A1AT

SCN1B
SERPINA1 AAT PI PRO0684
PRO2209

P29622

KAIN

SERPINA4 KST PI4

P05154

IPSP

SERPINA5 PCI PLANH3
PROCI

(PSBG-7) (Pregnancy-specific
glycoprotein 7)
Pregnancy-specific beta-1glycoprotein 8 (PS-beta-G-8)
(PSBG-8) (Pregnancy-specific
glycoprotein 8)
Tuberoinfundibular peptide of 39
residues (TIP39) (Parathyroid
hormone 2)
Pleiotrophin (PTN) (Heparinbinding brain mitogen) (HBBM)
(Heparin-binding growth factor 8)
(HBGF-8) (Heparin-binding
growth-associated molecule) (HBGAM) (Heparin-binding neurite
outgrowth-promoting factor 1)
(HBNF-1) (Osteoblast-specific
factor 1) (OSF-1)
Peptide YY (PYY) (PYY-I)
(Peptide tyrosine tyrosine)
[Cleaved into: Peptide YY(3-36)
(PYY-II)]

Secretoglobin family 1D member
4 (IFN-gamma-inducible
secretoglobin) (IIS)
Secretoglobin family 3A member
2 (Pneumo secretory protein 1)
(PnSP-1) (Uteroglobin-related
protein 1)
Sodium channel subunit beta-1
Alpha-1-antitrypsin (Alpha-1
protease inhibitor) (Alpha-1antiproteinase) (Serpin A1)
[Cleaved into: Short peptide from
AAT (SPAAT)]
Kallistatin (Kallikrein inhibitor)
(Peptidase inhibitor 4) (PI-4)
(Serpin A4)
Plasma serine protease inhibitor
(Acrosomal serine protease
inhibitor) (Plasminogen activator
inhibitor 3) (PAI-3) (PAI3)
(Protein C inhibitor) (PCI) (Serpin
A5)
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P01008

ANT3

SERPINC1 AT3 PRO0309

Antithrombin-III (ATIII) (Serpin
C1)
Plasminogen activator inhibitor 1
(PAI) (PAI-1) (Endothelial
plasminogen activator inhibitor)
(Serpin E1)
Glia-derived nexin (GDN)
(Peptidase inhibitor 7) (PI-7)
(Protease nexin 1) (PN-1)
(Protease nexin I) (Serpin E2)
Serpin E3
Pigment epithelium-derived factor
(PEDF) (Cell proliferationinducing gene 35 protein) (EPC-1)
(Serpin F1)
Alpha-2-antiplasmin (Alpha-2AP) (Alpha-2-plasmin inhibitor)
(Alpha-2-PI) (Serpin F2)
Plasma protease C1 inhibitor (C1
Inh) (C1Inh) (C1 esterase
inhibitor) (C1-inhibiting factor)
(Serpin G1)
Neuroserpin (Peptidase inhibitor
12) (PI-12) (Serpin I1)
Serpin I2 (Myoepithelium-derived
serine protease inhibitor)
(Pancpin) (Pancreas-specific
protein TSA2004) (Peptidase
inhibitor 14) (PI-14)
Sonic hedgehog protein (SHH)
(HHG-1) [Cleaved into: Sonic
hedgehog protein N-product;
Sonic hedgehog protein Cproduct]

P05121

PAI1

SERPINE1 PAI1 PLANH1

P07093

GDN

SERPINE2 PI7 PN1

A8MV23
P36955

SERP3
PEDF

SERPINE3
SERPINF1 PEDF PIG35

P08697

A2AP

SERPINF2 AAP PLI

P05155

IC1

SERPING1 C1IN C1NH

Q99574

NEUS

SERPINI1 PI12

O75830

SPI2

SERPINI2 MEPI PI14

Q15465

SHH

SHH

O75093
X6R3P0
O94813
P55000

SLIT1
X6R3P0
SLIT2
SLUR1

Q1W4C9

ISK13

SLIT1 KIAA0813 MEGF4 SLIL1
SLIT2
SLIT2 SLIL3
SLURP1 ARS
Secreted Ly-6/uPAR-related
protein 1 (SLURP-1) (ARS
component B) (ARS(component
B)-81/S) (Anti-neoplastic urinary
protein) (ANUP)
SPINK13 HBVDNAPTP1
Serine protease inhibitor KazalSPINK5L3
type 13 (Hepatitis B virus DNA
polymerase transactivated serine
protease inhibitor) (Hespintor)
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Q6IE38

ISK14

SPINK14 SPINK5L2

P20155

ISK2

SPINK2

O60575

ISK4

SPINK4

Q6UWN8 ISK6

SPINK6 UNQ844/PRO1782

P58062

ISK7

SPINK7 ECG2
UNQ745/PRO1474

O60687

SRPX2

SRPX2 SRPUL

P02808
P52823
Q4LDE5
Q2MV58

STAT
STC1
SVEP1
TECT1

O75443
Q96PL2
P04155

TECTA
TECTB
TFF1

STATH
STC1 STC
SVEP1 C9orf13 CCP22 SELOB
TCTN1 TECT1
UNQ9369/PRO34160
TECTA
TECTB
TFF1 BCEI PS2

P01135

TGFA

TGFA

P10600

TGFB3

TGFB3

Q9UPZ6
P01033

THS7A
TIMP1

THSD7A KIAA0960
TIMP1 CLGI TIMP

(Serine protease inhibitor Kazaltype 5-like 3)
Serine protease inhibitor Kazaltype 14
Serine protease inhibitor Kazaltype 2 (Acrosin-trypsin inhibitor)
(Epididymis tissue protein Li 172)
(HUSI-II)
Serine protease inhibitor Kazaltype 4 (Peptide PEC-60 homolog)
Serine protease inhibitor Kazaltype 6 (Kallikrein inhibitor)
Serine protease inhibitor Kazaltype 7 (Esophagus cancer-related
gene 2 protein) (ECRG-2)
Sushi repeat-containing protein
SRPX2 (Sushi-repeat protein
upregulated in leukemia)
Statherin
Stanniocalcin-1 (STC-1)
Tectonic-1

Beta-tectorin
Trefoil factor 1 (Breast cancer
estrogen-inducible protein) (PNR2) (Polypeptide P1.A) (hP1.A)
(Protein pS2)
Protransforming growth factor
alpha [Cleaved into: Transforming
growth factor alpha (TGF-alpha)
(EGF-like TGF) (ETGF) (TGF
type 1)]
Transforming growth factor beta-3
(TGF-beta-3) [Cleaved into:
Latency-associated peptide (LAP)]
Metalloproteinase inhibitor 1
(Erythroid-potentiating activity)
(EPA) (Fibroblast collagenase
inhibitor) (Collagenase inhibitor)
(Tissue inhibitor of
metalloproteinases 1) (TIMP-1)

191

P35625

TIMP3

TIMP3

Q99727

TIMP4

TIMP4

P24821
Q9UQP3
Q8WU66

TENA
TENN
TSEAR

TNC HXB
TNN
TSPEAR C21orf29

P04275
F5GYM2

VWF F8VWF
WNT5B

D6RF94
O60844

VWF
F5GYM
2
D6RF94
ZG16

P21754

ZP3

ZP3 ZP3A ZP3B ZPC

Q12836

ZP4

ZP4 ZPB

Q9BS86

ZPBP1

ZPBP ZPBP1

Q6X784

ZPBP2

ZPBP2 ZPBPL

P15151

PVR

PVR PVS

Q9Y5C1

ANGL3

ANGPTL3 ANGPT5
UNQ153/PRO179

WNT8A
ZG16

Metalloproteinase inhibitor 2
(CSC-21K) (Tissue inhibitor of
metalloproteinases 2) (TIMP-2)
Metalloproteinase inhibitor 3
(Protein MIG-5) (Tissue inhibitor
of metalloproteinases 3) (TIMP-3)

Thrombospondin-type laminin G
domain and EAR repeatcontaining protein (TSP-EAR)
Protein Wnt-5b
Protein Wnt-8a (Protein Wnt-8d)
Zymogen granule membrane
protein 16 (Zymogen granule
protein 16) (hZG16) (Secretory
lectin ZG16)
Zona pellucida sperm-binding
protein 3 (Sperm receptor)
(ZP3A/ZP3B) (Zona pellucida
glycoprotein 3) (Zp-3) (Zona
pellucida protein C) [Cleaved into:
Processed zona pellucida spermbinding protein 3]
Zona pellucida sperm-binding
protein 4 (Zona pellucida
glycoprotein 4) (Zp-4) (Zona
pellucida protein B) [Cleaved into:
Processed zona pellucida spermbinding protein 4]
Zona pellucida-binding protein 1
(Sp38)
Zona pellucida-binding protein 2
(ZPBP-like protein)
Poliovirus receptor (Nectin-like
protein 5) (NECL-5) (CD antigen
CD155)
Angiopoietin-related protein 3
(Angiopoietin-5) (ANG-5)
(Angiopoietin-like protein 3)
[Cleaved into: ANGPTL3(17221); ANGPTL3(17-224)]
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Q6GPI1

CTRB2

CTRB2

Chymotrypsinogen B2 (EC
3.4.21.1) [Cleaved into:
Chymotrypsin B2 chain A;
Chymotrypsin B2 chain B;
Chymotrypsin B2 chain C]
Q99983
OMD
OMD SLRR2C
Osteomodulin (Keratan sulfate
UNQ190/PRO216
proteoglycan osteomodulin)
(KSPG osteomodulin)
(Osteoadherin) (OSAD)
Proteins functionally related to the regulation/modulation of the immune response
Q6UW15 REG3G
REG3G PAP1B
Regenerating islet-derived protein
UNQ429/PRO162
3-gamma (REG-3-gamma)
(Pancreatitis-associated protein
1B) (PAP-1B) (Pancreatitisassociated protein IB) (PAP IB)
(Regenerating islet-derived protein
III-gamma) (REG III) (Reg IIIgamma) [Cleaved into:
Regenerating islet-derived protein
3-gamma 16.5 kDa form;
Regenerating islet-derived protein
3-gamma 15 kDa form]
P07360
CO8G
C8G
Complement component C8
gamma chain
O43699
SIGL6
SIGLEC6 CD33L CD33L1
Sialic acid-binding Ig-like lectin 6
OBBP1
(Siglec-6) (CD33 antigen-like 1)
(CDw327) (Obesity-binding
protein 1) (OB-BP1) (CD antigen
CD327)
Q9BY15
AGRE3
ADGRE3 EMR3
Adhesion G protein-coupled
UNQ683/PRO1562
receptor E3 (EGF-like module
receptor 3) (EGF-like modulecontaining mucin-like hormone
receptor-like 3)
P02771
FETA
AFP HPAFP
Alpha-fetoprotein (Alpha-1fetoprotein) (Alpha-fetoglobulin)
P28039
AOAH
AOAH
Acyloxyacyl hydrolase (EC
3.1.1.77) [Cleaved into:
Acyloxyacyl hydrolase small
subunit; Acyloxyacyl hydrolase
large subunit]
O75882
ATRN
ATRN KIAA0548 MGCA
P61769
B2MG
B2M CDABP0092 HDCMA22P
Q13072
BAGE1
BAGE BAGE1
B melanoma antigen 1 (B
melanoma antigen) (Antigen
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O95972

BMP15

BMP15 GDF9B

P17213

BPI

BPI

Q9NP55

BPIA1

BPIFA1 LUNX NASG PLUNC
SPLUNC1 SPURT
UNQ787/PRO1606

Q96DR5

BPIA2

BPIFA2 C20orf70 SPLUNC2
UNQ510/PRO1025

Q8TDL5

BPIB1

BPIFB1 C20orf114 LPLUNC1
UNQ706/PRO1357

Q8NFQ6

BPIFC

BPIFC BPIL2

Q13410

BT1A1

BTN1A1 BTN

Q6UWK7 CJ099

C10orf99 UNQ1833/PRO3446

P02745

C1QA

C1QA

P02746

C1QB

C1QB

P02747

C1QC

C1QC C1QG

Q9BXJ4

C1QT3

C1QTNF3 CTRP3
UNQ753/PRO1484

MZ2-BA) (Cancer/testis antigen
2.1) (CT2.1)
Bone morphogenetic protein 15
(BMP-15) (Growth/differentiation
factor 9B) (GDF-9B)
Bactericidal permeabilityincreasing protein (BPI) (CAP 57)
BPI fold-containing family A
member 1 (Lung-specific protein
X) (Nasopharyngeal carcinomarelated protein) (Palate lung and
nasal epithelium clone protein)
(Secretory protein in upper
respiratory tracts) (Short
PLUNC1) (SPLUNC1) (Tracheal
epithelium-enriched protein) (Von
Ebner protein Hl)
BPI fold-containing family A
member 2 (Parotid secretory
protein) (PSP) (Short palate, lung
and nasal epithelium carcinomaassociated protein 2)
BPI fold-containing family B
member 1 (Long palate, lung and
nasal epithelium carcinomaassociated protein 1) (Von Ebner
minor salivary gland protein)
(VEMSGP)
BPI fold-containing family C
protein (Bactericidal/permeabilityincreasing protein-like 2) (BPIlike 2)
Butyrophilin subfamily 1 member
A1 (BT)
Secreted protein C10orf99
(Antimicrobial peptide-57) (AP57) (Colon-derived SUSD2
binding factor) (CSBF)
Complement C1q subcomponent
subunit A
Complement C1q subcomponent
subunit B
Complement C1q subcomponent
subunit C
Complement C1q tumor necrosis
factor-related protein 3
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Q9BXI9

C1QT6

Q9BXJ2

C1QT7

C1QTNF6 CTRP6
UNQ581/PRO1151
C1QTNF7 CTRP7

Q9NZP8

C1RL

C1RL C1RL1 C1RLP CLSPA

P01024
P0C0L4
P0C0L5
P04003

CO3
CO4A
CO4B
C4BPA

C3 CPAMD1
C4A CO4 CPAMD2
C4B CO4 CPAMD3; C4B_2
C4BPA C4BP

P07358

CO8B

C8B

P02748

CO9

C9

P49913

CAMP

CAMP CAP18 FALL39 HSD26

P22362

CCL1

CCL1 SCYA1

P51671

CCL11

CCL11 SCYA11

Q99616

CCL13

CCL13 MCP4 NCC1 SCYA13

(Collagenous repeat-containing
sequence 26 kDa protein)
(CORS26) (Secretory protein
CORS26)
Complement C1q tumor necrosis
factor-related protein 6
Complement C1q tumor necrosis
factor-related protein 7
Complement C1r subcomponentlike protein (C1r-LP) (C1r-like
protein) (EC 3.4.21.-) (C1r-like
serine protease analog protein)
(CLSPa)

C4b-binding protein alpha chain
(C4bp) (Proline-rich protein)
(PRP)
Complement component C8 beta
chain (Complement component 8
subunit beta)
Complement component C9
[Cleaved into: Complement
component C9a; Complement
component C9b]
Cathelicidin antimicrobial peptide
(18 kDa cationic antimicrobial
protein) (CAP-18) (hCAP-18)
[Cleaved into: Antibacterial
peptide FALL-39 (FALL-39
peptide antibiotic); Antibacterial
peptide LL-37]
C-C motif chemokine 1 (Smallinducible cytokine A1) (T
lymphocyte-secreted protein I309)
Eotaxin (C-C motif chemokine 11)
(Eosinophil chemotactic protein)
(Small-inducible cytokine A11)
C-C motif chemokine 13 (CKbeta-10) (Monocyte
chemoattractant protein 4)
(Monocyte chemotactic protein 4)
(MCP-4) (NCC-1) (Smallinducible cytokine A13) [Cleaved
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Q16627

CCL14

CCL14 NCC2 SCYA14

Q16663

CCL15

CCL15 MIP5 NCC3 SCYA15

O15467

CCL16

CCL16 ILINCK NCC4
SCYA16

Q92583

CCL17

CCL17 SCYA17 TARC

P55774

CCL18

CCL18 AMAC1 DCCK1 MIP4
PARC SCYA18

into: C-C motif chemokine 13,
long chain; C-C motif chemokine
13, medium chain; C-C motif
chemokine 13, short chain]
C-C motif chemokine 14
(Chemokine CC-1/CC-3) (HCC1/HCC-3) (HCC-1(1-74)) (NCC2) (Small-inducible cytokine A14)
[Cleaved into: HCC-1(3-74);
HCC-1(4-74); HCC-1(9-74)]
C-C motif chemokine 15
(Chemokine CC-2) (HCC-2)
(Leukotactin-1) (LKN-1) (MIP-1
delta) (Macrophage inflammatory
protein 5) (MIP-5) (Mrp-2b)
(NCC-3) (Small-inducible
cytokine A15) [Cleaved into:
CCL15(22-92); CCL15(25-92);
CCL15(29-92)]
C-C motif chemokine 16
(Chemokine CC-4) (HCC-4)
(Chemokine LEC) (IL-10inducible chemokine) (LCC-1)
(Liver-expressed chemokine)
(Lymphocyte and monocyte
chemoattractant) (LMC)
(Monotactin-1) (MTN-1) (NCC-4)
(Small-inducible cytokine A16)
C-C motif chemokine 17 (CC
chemokine TARC) (Smallinducible cytokine A17) (Thymus
and activation-regulated
chemokine)
C-C motif chemokine 18
(Alternative macrophage
activation-associated CC
chemokine 1) (AMAC-1) (CC
chemokine PARC) (Dendritic cell
chemokine 1) (DC-CK1)
(Macrophage inflammatory
protein 4) (MIP-4) (Pulmonary
and activation-regulated
chemokine) (Small-inducible
cytokine A18) [Cleaved into:
CCL18(1-68); CCL18(3-69);
CCL18(4-69)]
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Q99731

CCL19

CCL19 ELC MIP3B SCYA19

P13500

CCL2

CCL2 MCP1 SCYA2

P78556

CCL20

CCL20 LARC MIP3A SCYA20

O00626

CCL22

CCL22 MDC SCYA22 A152E5.1

O00175

CCL24

CCL24 MPIF2 SCYA24

O15444

CCL25

CCL25 SCYA25 TECK

Q9Y258

CCL26

CCL26 SCYA26
UNQ216/PRO242

C-C motif chemokine 19 (Betachemokine exodus-3) (CK beta11) (Epstein-Barr virus-induced
molecule 1 ligand chemokine)
(EBI1 ligand chemokine) (ELC)
(Macrophage inflammatory
protein 3 beta) (MIP-3-beta)
(Small-inducible cytokine A19)
C-C motif chemokine 2 (HC11)
(Monocyte chemoattractant
protein 1) (Monocyte chemotactic
and activating factor) (MCAF)
(Monocyte chemotactic protein 1)
(MCP-1) (Monocyte secretory
protein JE) (Small-inducible
cytokine A2)
C-C motif chemokine 20 (Betachemokine exodus-1) (CC
chemokine LARC) (Liver and
activation-regulated chemokine)
(Macrophage inflammatory
protein 3 alpha) (MIP-3-alpha)
(Small-inducible cytokine A20)
[Cleaved into: CCL20(1-67);
CCL20(1-64); CCL20(2-70)]
C-C motif chemokine 22 (CC
chemokine STCP-1) (MDC(1-69))
(Macrophage-derived chemokine)
(Small-inducible cytokine A22)
(Stimulated T-cell chemotactic
protein 1) [Cleaved into: MDC(369); MDC(5-69); MDC(7-69)]
C-C motif chemokine 24 (CKbeta-6) (Eosinophil chemotactic
protein 2) (Eotaxin-2) (Myeloid
progenitor inhibitory factor 2)
(MPIF-2) (Small-inducible
cytokine A24)
C-C motif chemokine 25
(Chemokine TECK) (Smallinducible cytokine A25) (Thymusexpressed chemokine)
C-C motif chemokine 26 (CC
chemokine IMAC) (Eotaxin-3)
(Macrophage inflammatory
protein 4-alpha) (MIP-4-alpha)
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Q9Y4X3

CCL27

CCL27 ILC SCYA27

P10147

CCL3

CCL3 G0S19-1 MIP1A SCYA3

P16619

CL3L1

CCL3L1 D17S1718 G0S19-2
SCYA3L1; CCL3L3

P13236

CCL4

CCL4 LAG1 MIP1B SCYA4

Q8NHW4

CC4L

CCL4L1 CCL4L LAG1
SCYA4L1; CCL4L2 CCL4L
SCYA4L2

(Small-inducible cytokine A26)
(Thymic stroma chemokine-1)
(TSC-1)
C-C motif chemokine 27 (CC
chemokine ILC) (Cutaneous Tcell-attracting chemokine)
(CTACK) (ESkine) (IL-11 Ralpha-locus chemokine)
(Skinkine) (Small-inducible
cytokine A27)
C-C motif chemokine 3 (G0/G1
switch regulatory protein 19-1)
(Macrophage inflammatory
protein 1-alpha) (MIP-1-alpha)
(PAT 464.1) (SIS-beta) (Smallinducible cytokine A3) (Tonsillar
lymphocyte LD78 alpha protein)
[Cleaved into: MIP-1-alpha(4-69)
(LD78-alpha(4-69))]
C-C motif chemokine 3-like 1
(G0/G1 switch regulatory protein
19-2) (LD78-beta(1-70)) (PAT
464.2) (Small-inducible cytokine
A3-like 1) (Tonsillar lymphocyte
LD78 beta protein) [Cleaved into:
LD78-beta(3-70); LD78-beta(570)]
C-C motif chemokine 4 (G-26 Tlymphocyte-secreted protein)
(HC21) (Lymphocyte activation
gene 1 protein) (LAG-1) (MIP-1beta(1-69)) (Macrophage
inflammatory protein 1-beta)
(MIP-1-beta) (PAT 744) (Protein
H400) (SIS-gamma) (Smallinducible cytokine A4) (T-cell
activation protein 2) (ACT-2)
[Cleaved into: MIP-1-beta(3-69)]
C-C motif chemokine 4-like
(Lymphocyte activation gene 1
protein) (LAG-1) (Macrophage
inflammatory protein 1-beta)
(MIP-1-beta) (Monocyte
adherence-induced protein 5alpha) (Small-inducible cytokine
A4-like)
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P13501

CCL5

CCL5 D17S136E SCYA5

P80098

CCL7

CCL7 MCP3 SCYA6 SCYA7

P80075

CCL8

CCL8 MCP2 SCYA10 SCYA8

Q8TD46

MO2R1

CD200R1 CD200R CRTR2
MOX2R OX2R
UNQ2522/PRO6015

P13987

CD59

CD59 MIC11 MIN1 MIN2
MIN3 MSK21

P01732

CD8A

CD8A MAL

P10966

CD8B

CD8B CD8B1

P00746

CFAD

CFD DF PFD

P05156

CFAI

CFI IF

C-C motif chemokine 5 (EoCP)
(Eosinophil chemotactic cytokine)
(SIS-delta) (Small-inducible
cytokine A5) (T cell-specific
protein P228) (TCP228) (T-cellspecific protein RANTES)
[Cleaved into: RANTES(3-68);
RANTES(4-68)]
C-C motif chemokine 7
(Monocyte chemoattractant
protein 3) (Monocyte chemotactic
protein 3) (MCP-3) (NC28)
(Small-inducible cytokine A7)
C-C motif chemokine 8 (HC14)
(Monocyte chemoattractant
protein 2) (Monocyte chemotactic
protein 2) (MCP-2) (Smallinducible cytokine A8) [Cleaved
into: MCP-2(6-76)]
Cell surface glycoprotein CD200
receptor 1 (CD200 cell surface
glycoprotein receptor) (Cell
surface glycoprotein OX2 receptor
1)
CD59 glycoprotein (1F5 antigen)
(20 kDa homologous restriction
factor) (HRF-20) (HRF20) (MACinhibitory protein) (MAC-IP)
(MEM43 antigen) (Membrane
attack complex inhibition factor)
(MACIF) (Membrane inhibitor of
reactive lysis) (MIRL) (Protectin)
(CD antigen CD59)
T-cell surface glycoprotein CD8
alpha chain (T-lymphocyte
differentiation antigen T8/Leu-2)
(CD antigen CD8a)
T-cell surface glycoprotein CD8
beta chain (CD antigen CD8b)
Complement factor D (EC
3.4.21.46) (Adipsin) (C3
convertase activator) (Properdin
factor D)
Complement factor I (EC
3.4.21.45) (C3B/C4B inactivator)
[Cleaved into: Complement factor
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P36222

CH3L1

CHI3L1

Q2VPA4

CR1L

CR1L

Q9HC73

CRLF2

CRLF2 CRL2 ILXR TSLPR

P02741

CRP

CRP PTX1

P15509

CSF2R

CSF2RA CSF2R CSF2RY

P01037

CYTN

CST1

P01036

CYTS

CST4

O76096

CYTF

CST7

Q5W186

CST9

CST9 CLM CTES7A

P02778

CXL10

CXCL10 INP10 SCYB10

O14625

CXL11

CXCL11 ITAC SCYB11
SCYB9B

P48061

SDF1

CXCL12 SDF1 SDF1A SDF1B

I heavy chain; Complement factor
I light chain]
Chitinase-3-like protein 1 (39 kDa
synovial protein) (Cartilage
glycoprotein 39) (CGP-39) (GP39) (hCGP-39) (YKL-40)
Complement component receptor
1-like protein (Complement C4bbinding protein CR-1-like protein)
Cytokine receptor-like factor 2
(Cytokine receptor-like 2) (IL-XR)
(Thymic stromal lymphopoietin
protein receptor) (TSLP receptor)
C-reactive protein [Cleaved into:
C-reactive protein(1-205)]
Granulocyte-macrophage colonystimulating factor receptor subunit
alpha (GM-CSF-R-alpha)
(GMCSFR-alpha) (GMR-alpha)
(CDw116) (CD antigen CD116)
Cystatin-SN (Cystain-SA-I)
(Cystatin-1) (Salivary cystatinSA-1)
Cystatin-S (Cystatin-4) (CystatinSA-III) (Salivary acidic protein 1)
Cystatin-F (Cystatin-7) (Cystatinlike metastasis-associated protein)
(CMAP) (Leukocystatin)
Cystatin-9 (Cystatin-like
molecule)
C-X-C motif chemokine 10 (10
kDa interferon gamma-induced
protein) (Gamma-IP10) (IP-10)
(Small-inducible cytokine B10)
[Cleaved into: CXCL10(1-73)]
C-X-C motif chemokine 11 (BetaR1) (H174) (Interferon gammainducible protein 9) (IP-9)
(Interferon-inducible T-cell alpha
chemoattractant) (I-TAC) (Smallinducible cytokine B11)
Stromal cell-derived factor 1
(SDF-1) (hSDF-1) (C-X-C motif
chemokine 12) (Intercrine reduced
in hepatomas) (IRH) (hIRH) (PreB cell growth-stimulating factor)
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O43927

CXL13

CXCL13 BCA1 BLC SCYB13

P42830

CXCL5

CXCL5 ENA78 SCYB5

P80162

CXCL6

CXCL6 GCP2 SCYB6

P10145
Q9NRR1

IL8
CYTL1

P59665

DEF1

CXCL8 IL8
CYTL1 C4orf4
UNQ1942/PRO4425
DEFA1 DEF1 DEFA2 MRS;
DEFA1B

P59666

DEF3

DEFA3 DEF3

P12838

DEF4

DEFA4 DEF4

Q01523

DEF5

DEFA5 DEF5

Q01524

DEF6

DEFA6 DEF6

(PBSF) [Cleaved into: SDF-1beta(3-72); SDF-1-alpha(3-67)]
C-X-C motif chemokine 13
(Angie) (B cell-attracting
chemokine 1) (BCA-1) (B
lymphocyte chemoattractant)
(CXC chemokine BLC) (Smallinducible cytokine B13)
C-X-C motif chemokine 5 (ENA78(1-78)) (Epithelial-derived
neutrophil-activating protein 78)
(Neutrophil-activating peptide
ENA-78) (Small-inducible
cytokine B5) [Cleaved into: ENA78(8-78); ENA-78(9-78)]
C-X-C motif chemokine 6
(Chemokine alpha 3) (CKA-3)
(Granulocyte chemotactic protein
2) (GCP-2) (Small-inducible
cytokine B6) [Cleaved into:
Small-inducible cytokine B6, Nprocessed variant 1; Smallinducible cytokine B6, Nprocessed variant 2; Smallinducible cytokine B6, Nprocessed variant 3]
Neuferricin (Cytochrome b5
domain-containing protein 2)
Neutrophil defensin 1 (Defensin,
alpha 1) (HNP-1) (HP-1) (HP1)
[Cleaved into: HP 1-56;
Neutrophil defensin 2 (HNP-2)
(HP-2) (HP2)]
Neutrophil defensin 3 (Defensin,
alpha 3) (HNP-3) (HP-3) (HP3)
[Cleaved into: HP 3-56;
Neutrophil defensin 2 (HNP-2)
(HP-2) (HP2)]
Neutrophil defensin 4 (Defensin,
alpha 4) (HNP-4) (HP-4)
Defensin-5 (Defensin, alpha 5)
(HD5(20-94)) [Cleaved into:
HD5(23-94); HD5(29-94);
HD5(56-94); HD5(63-94)]
Defensin-6 (Defensin, alpha 6)
201

P60022

DEFB1

DEFB1 BD1 HBD1

P81534

D103A

DEFB103A BD3 DEFB103
DEFB3; DEFB103B

Q8NG35

D105A

DEFB105A BD5 DEFB105
DEFB5; DEFB105B

Q8IZN7

D107A

DEFB107A DEFB107 DEFB7;
DEFB107B

Q30KR1

DB109

DEFB109P1 DEFB109
DEFB109A; DEFB109P1B

Q30KQ9

DB110

DEFB110 DEFB10 DEFB11
DEFB111

Q30KQ7

DB113

DEFB113 DEFB13

Q30KQ6

DB114

DEFB114 DEFB14

Q30KQ5

DB115

DEFB115 DEFB15

Q8N690

DB119

DEFB119 DEFB120 DEFB19
DEFB20 UNQ2449/PRO5729

Q5J5C9

DB121

DEFB121 DEFB21

Q8N688

DB123

DEFB123 DEFB23
UNQ1963/PRO4485

Q8NES8

DB124

DEFB124 DEFB24

Q9BYW3

DB126

DEFB126 C20orf8 DEFB26

Beta-defensin 1 (BD-1) (hBD-1)
(Defensin, beta 1)
Beta-defensin 103 (Beta-defensin
3) (BD-3) (DEFB-3) (HBD3)
(hBD-3) (Defensin, beta 103)
(Defensin-like protein)
Beta-defensin 105 (Beta-defensin
5) (BD-5) (DEFB-5) (Defensin,
beta 105)
Beta-defensin 107 (Beta-defensin
7) (BD-7) (DEFB-7) (Defensin,
beta 107)
Beta-defensin 109 (Defensin, beta
109) (Defensin, beta 109,
pseudogene 1/1B)
Beta-defensin 110 (Beta-defensin
10) (DEFB-10) (Beta-defensin 11)
(DEFB-11) (Beta-defensin 111)
(Defensin, beta 110) (Defensin,
beta 111)
Beta-defensin 113 (Beta-defensin
13) (DEFB-13) (Defensin, beta
113)
Beta-defensin 114 (Beta-defensin
14) (DEFB-14) (Defensin, beta
114)
Beta-defensin 115 (Beta-defensin
15) (DEFB-15) (Defensin, beta
115)
Beta-defensin 119 (Beta-defensin
120) (Beta-defensin 19) (DEFB19) (Beta-defensin 20) (DEFB-20)
(Defensin, beta 119) (Defensin,
beta 120) (ESC42-RELA)
Beta-defensin 121 (Beta-defensin
21) (DEFB-21) (Defensin, beta
121)
Beta-defensin 123 (Beta-defensin
23) (DEFB-23) (Defensin, beta
123)
Beta-defensin 124 (Beta-defensin
24) (DEFB-24) (Defensin, beta
124)
Beta-defensin 126 (Beta-defensin
26) (DEFB-26) (Defensin, beta
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Q9H1M4

DB127

DEFB127 C20orf73 DEFB27
UNQ1956/PRO6071

Q7Z7B8

DB128

DEFB128 DEFB28

Q9H1M3

DB129

DEFB129 C20orf87 DEFB29
UNQ5794/PRO19599

Q30KQ2

DB130

DEFB130 DEFB30; DEFB130L

P59861

DB131

DEFB131 DEFB31

Q7Z7B7

DB132

DEFB132 DEFB32
UNQ827/PRO1754

Q30KQ1

DB133

DEFB133

Q4QY38

DB134

DEFB134

Q30KP9

DB135

DEFB135

Q30KP8

DB136

DEFB136

O15263

DFB4A

DEFB4A DEFB102 DEFB2
DEFB4; DEFB4B

Q6UX07

DHR13

DHRS13 SDR7C5
UNQ419/PRO853

Q92874

DNSL2

DNASE1L2 DHP1 DNAS1L2

Q9UHL4

DPP2

DPP7 DPP2 QPP

126) (Epididymal secretory
protein 13.2) (ESP13.2) (HBD26)
Beta-defensin 127 (Beta-defensin
27) (DEFB-27) (Defensin, beta
127)
Beta-defensin 128 (Beta-defensin
28) (DEFB-28) (Defensin, beta
128)
Beta-defensin 129 (Beta-defensin
29) (DEFB-29) (Defensin, beta
129)
Beta-defensin 130 (Beta-defensin
30) (DEFB-30) (Defensin, beta
130)
Beta-defensin 131 (Beta-defensin
31) (DEFB-31) (Defensin, beta
131)
Beta-defensin 132 (Beta-defensin
32) (BD-32) (DEFB-32) (Defensin
HEL-75) (Defensin, beta 132)
Beta-defensin 133 (Defensin, beta
133)
Beta-defensin 134 (Defensin, beta
134)
Beta-defensin 135 (Defensin, beta
135)
Beta-defensin 136 (Defensin, beta
136)
Beta-defensin 4A (Beta-defensin
2) (BD-2) (hBD-2) (Defensin, beta
2) (Skin-antimicrobial peptide 1)
(SAP1)
Dehydrogenase/reductase SDR
family member 13 (EC 1.1.-.-)
(Short chain
dehydrogenase/reductase family
7C member 5)
Deoxyribonuclease-1-like 2 (EC
3.1.21.-) (DNase I homolog
protein DHP1)
(Deoxyribonuclease I-like 2)
(DNase I-like 2)
Dipeptidyl peptidase 2 (EC
3.4.14.2) (Dipeptidyl
aminopeptidase II) (Dipeptidyl
peptidase 7) (Dipeptidyl peptidase
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Q14213

IL27B

P19235
Q7Z5A8

EPOR
F19A3

P98173

FAM3A

P24071

FCAR

P08637

FCG3A

O75015

FCG3B

Q6BAA4

FCRLB

Q8NFU4

FDSCP

O15520

FGF10

Q14314

FGL2

Q9UK05

GDF2

P55259

GP2

II) (DPP II) (Quiescent cell proline
dipeptidase)
EBI3 IL27B
Interleukin-27 subunit beta (IL-27
subunit beta) (IL-27B) (EpsteinBarr virus-induced gene 3 protein)
(EBV-induced gene 3 protein)
EPOR
Erythropoietin receptor (EPO-R)
FAM19A3 TAFA3
Protein FAM19A3 (Chemokinelike protein TAFA-3)
FAM3A 2-19 2.19
Protein FAM3A (Cytokine-like
protein 2-19)
FCAR CD89
Immunoglobulin alpha Fc receptor
(IgA Fc receptor) (CD antigen
CD89)
FCGR3A CD16A FCG3
Low affinity immunoglobulin
FCGR3 IGFR3
gamma Fc region receptor III-A
(CD16a antigen) (Fc-gamma RIIIalpha) (Fc-gamma RIII) (Fcgamma RIIIa) (FcRIII) (FcRIIIa)
(FcR-10) (IgG Fc receptor III-2)
(CD antigen CD16a)
FCGR3B CD16B FCG3 FCGR3 Low affinity immunoglobulin
IGFR3
gamma Fc region receptor III-B
(Fc-gamma RIII-beta) (Fc-gamma
RIII) (Fc-gamma RIIIb) (FcRIII)
(FcRIIIb) (FcR-10) (IgG Fc
receptor III-1) (CD antigen
CD16b)
FCRLB FCRL2 FCRLM2
Fc receptor-like B (Fc receptor
FCRY FREB2
homolog expressed in B-cells
protein 2) (FREB-2) (Fc receptorlike and mucin-like protein 2) (Fc
receptor-like protein 2) (Fc
receptor-related protein Y) (FcRY)
FDCSP C4orf7
Follicular dendritic cell secreted
UNQ733/PRO1419
peptide (FDC secreted protein)
(FDC-SP)
FGF10
Fibroblast growth factor 10 (FGF10) (Keratinocyte growth factor 2)
FGL2
Fibroleukin (Fibrinogen-like
protein 2) (pT49)
GDF2 BMP9
Growth/differentiation factor 2
(GDF-2) (Bone morphogenetic
protein 9) (BMP-9)
GP2
Pancreatic secretory granule
membrane major glycoprotein
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P12544

GRAA

GZMA CTLA3 HFSP

P49863

GRAK

GZMK TRYP2

P51124

GRAM

GZMM MET1

A8MTL9

HMSD

HMSD

P15516

HIS3

HTN3 HIS2

GP2 (Pancreatic zymogen granule
membrane protein GP-2) (ZAP75)
Granzyme A (EC 3.4.21.78) (CTL
tryptase) (Cytotoxic T-lymphocyte
proteinase 1) (Fragmentin-1)
(Granzyme-1) (Hanukkah factor)
(H factor) (HF)
Granzyme K (EC 3.4.21.-)
(Fragmentin-3) (Granzyme-3)
(NK-tryptase-2) (NK-Tryp-2)
Granzyme M (EC 3.4.21.-) (Met-1
serine protease) (Hu-Met-1) (Metase) (Natural killer cell granular
protease)
Serpin-like protein HMSD (Minor
histocompatibility protein HMSD)
(Minor histocompatibility serpin
domain-containing protein)
Histatin-3 (Basic histidine-rich
protein) (Hst) (Histidine-rich
protein 3) (PB) [Cleaved into:
Histatin-3; His3-(20-44)-peptide
(His3 20/44) (His3-(1-25)-peptide)
(His3 1/25) (Histatin-3 1/25)
(Histatin-6); His3-(20-43)-peptide
(His3 20/43) (His3-(1-24)-peptide)
(His3 1/24) (Histatin-3 1/24)
(Histatin-5); His3-(20-32)-peptide
(His3 20/32) (His3-(1-13)-peptide)
(His3 1/13) (Histatin-3 1/13);
His3-(20-31)-peptide (His3 20/31)
(His3-(1-12)-peptide) (His3 1/12)
(Histatin-3 1/12); His3-(20-30)peptide (His3 20/30) (His3-(1-11)peptide) (His3 1/11) (Histatin-3
1/11); His3-(24-32)-peptide (His3
24/32) (His3-(5-13)-peptide) (His3
5/13) (Histatin-3 5/13); His3-(2431)-peptide (His3 24/31) (His3-(512)-peptide) (His3 5/12) (Histatin11) (Histatin-3 5/12); His3-(2430)-peptide (His3 24/30) (His3-(511)-peptide) (His3 5/11) (Histatin12) (Histatin-3 5/11); His3-(2532)-peptide (His3 25/32) (His3-(613)-peptide) (His3 6/13) (Histatin205

3 6/13); His3-(25-30)-peptide
(His3 25/30) (His3-(6-11)-peptide)
(His3 6/11) (Histatin-3 6/11);
His3-(26-32)-peptide (His3 26/32)
(His3-(7-13)-peptide) (His3 7/13)
(Histatin-3 7/13); His3-(26-31)peptide (His3 26/31) (His3-(7-12)peptide) (His3 7/12) (Histatin-3
7/12); His3-(26-30)-peptide (His3
26/30) (His3-(7-11)-peptide) (His3
7/11) (Histatin-3 7/11); His3-(3151)-peptide (His3 31/51) (His3(12-32)-peptide) (His3 12/32)
(Histatin-3 12/32) (Histatin-4);
His3-(31-44)-peptide (His3 31/44)
(His3-(12-25)-peptide) (His3
12/25) (Histatin-3 12/25)
(Histatin-9); His3-(31-43)-peptide
(His3 31/43) (His3-(12-24)peptide) (His3 12/24) (Histatin-3
12/24) (Histatin-7); His3-(32-44)peptide (His3 32/44) (His3-(1325)-peptide) (His3 13/25)
(Histatin-10) (Histatin-3 13/25);
His3-(32-43)-peptide (His3 32-43)
(His3-(13-24)-peptide) (His3
13/24) (Histatin-3 13/24)
(Histatin-8); His3-(33-44)-peptide
(His3 33/44) (His3-(14-25)peptide) (His3 14/25) (Histatin-3
14/25); His3-(33-43)-peptide
(His3 33/43) (His3-(14-24)peptide) (His3 14/24) (Histatin-3
14/24); His3-(34-44)-peptide
(His3 34/44) (His3-(15-25)peptide) (His3 15/25) (Histatin-3
15/25); His3-(34-43)-peptide
(His3 34/43) (His3-(15-24)peptide) (His3 15/24) (Histatin-3
15/24); His3-(45-51)-peptide
(His3 45/51) (His3-(26-32)peptide) (His3 26/32) (Histatin-3
26/32); His3-(47-51)-peptide
(His3 47/51) (His3-(28-32)peptide) (His3 28/32) (Histatin-3
28/32); His3-(48-51)-peptide
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Q14773

ICAM4

ICAM4 LW

Q9Y6W8

ICOS

ICOS AILIM

P13284

GILT

IFI30 GILT IP30

P01562

IFNA1

IFNA1; IFNA13

P01566

IFN10

IFNA10

P01570

IFN14

IFNA14

P05015

IFN16

IFNA16

P01571

IFN17

IFNA17

P01563

IFNA2

P01568

IFN21

IFNA2 IFNA2A IFNA2B
IFNA2C
IFNA21

P05014

IFNA4

IFNA4

P05013

IFNA6

IFNA6

P01567

IFNA7

IFNA7

(His3 48/51) (His3-(29-32)peptide) (His3 29/32) (Histatin-3
29/32)]
Intercellular adhesion molecule 4
(ICAM-4) (Landsteiner-Wiener
blood group glycoprotein) (LW
blood group protein) (CD antigen
CD242)
Inducible T-cell costimulator
(Activation-inducible lymphocyte
immunomediatory molecule) (CD
antigen CD278)
Gamma-interferon-inducible
lysosomal thiol reductase (EC
1.8.-.-) (Gamma-interferoninducible protein IP-30)
(Legumaturain)
Interferon alpha-1/13 (IFN-alpha1/13) (Interferon alpha-D) (LeIF
D)
Interferon alpha-10 (IFN-alpha10) (Interferon alpha-6L)
(Interferon alpha-C) (LeIF C)
Interferon alpha-14 (IFN-alpha14) (Interferon alpha-H) (LeIF H)
(Interferon lambda-2-H)
Interferon alpha-16 (IFN-alpha16) (Interferon alpha-WA)
Interferon alpha-17 (IFN-alpha17) (Interferon alpha-88)
(Interferon alpha-I') (LeIF I)
(Interferon alpha-T)
Interferon alpha-2 (IFN-alpha-2)
(Interferon alpha-A) (LeIF A)
Interferon alpha-21 (IFN-alpha21) (Interferon alpha-F) (LeIF F)
Interferon alpha-4 (IFN-alpha-4)
(Interferon alpha-4B) (Interferon
alpha-76) (Interferon alpha-M1)
Interferon alpha-6 (IFN-alpha-6)
(Interferon alpha-54) (Interferon
alpha-K) (LeIF K)
Interferon alpha-7 (IFN-alpha-7)
(Interferon alpha-J) (LeIF J)
(Interferon alpha-J1) (IFN-alphaJ1)
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P32881

IFNA8

IFNA8

P48551

INAR2

IFNAR2 IFNABR IFNARB

P01574

IFNB

IFNB1 IFB IFNB

Q86WN2

IFNE

IFNE IFNE1 UNQ360/PRO655

P01579

IFNG

IFNG

P05000

IFNW1

IFNW1

A6NJS3

IV1U1

IGHV1OR21-1

A6NJ16

IV4F8

IGHV4OR15-8 VSIG6

A6NJ69
A6NGN9
Q96ID5

IGIP
IGLO5
IGS21

IGIP C5orf53
IGLON5
IGSF21

P29459

IL12A

IL12A NKSF1

P29460

IL12B

IL12B NKSF2

Interferon alpha-8 (IFN-alpha-8)
(Interferon alpha-B) (LeIF B)
(Interferon alpha-B2)
Interferon alpha/beta receptor 2
(IFN-R-2) (IFN-alpha binding
protein) (IFN-alpha/beta receptor
2) (Interferon alpha binding
protein) (Type I interferon
receptor 2)
Interferon beta (IFN-beta)
(Fibroblast interferon)
Interferon epsilon (IFN-epsilon)
(Interferon epsilon-1)
Interferon gamma (IFN-gamma)
(Immune interferon)
Interferon omega-1 (Interferon
alpha-II-1)
Putative V-set and
immunoglobulin domaincontaining-like protein
IGHV1OR21-1 (Immunoglobulin
heavy variable 1 orphon 21-1)
Putative V-set and
immunoglobulin domaincontaining-like protein
IGHV4OR15-8 (Immunoglobulin
heavy variable 4 orphon 15-8)
(Putative V-set and
immunoglobulin domaincontaining protein 6)
IgA-inducing protein homolog
IgLON family member 5
Immunoglobulin superfamily
member 21 (IgSF21)
Interleukin-12 subunit alpha (IL12A) (Cytotoxic lymphocyte
maturation factor 35 kDa subunit)
(CLMF p35) (IL-12 subunit p35)
(NK cell stimulatory factor chain
1) (NKSF1)
Interleukin-12 subunit beta (IL12B) (Cytotoxic lymphocyte
maturation factor 40 kDa subunit)
(CLMF p40) (IL-12 subunit p40)
(NK cell stimulatory factor chain
2) (NKSF2)
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P35225
Q16552

IL13
IL17

IL13 NC30
IL17A CTLA8 IL17

Q9NRM6

I17RB

IL17RB CRL4 EVI27 IL17BR
UNQ2501/PRO19612

O95998

I18BP

IL18BP

Q9UHD0

IL19

IL19 ZMDA1

P14778

IL1R1

IL1R1 IL1R IL1RA IL1RT1

P27930

IL1R2

IL1R2 IL1RB

Q9NPH3

IL1AP

IL1RAP C3orf13 IL1R3

Q01638

ILRL1

IL1RL1 DER4 ST2 T1

Interleukin-13 (IL-13)
Interleukin-17A (IL-17) (IL-17A)
(Cytotoxic T-lymphocyteassociated antigen 8) (CTLA-8)
Interleukin-17 receptor B (IL-17
receptor B) (IL-17RB) (Cytokine
receptor-like 4) (IL-17 receptor
homolog 1) (IL-17Rh1) (IL17Rh1)
(Interleukin-17B receptor) (IL17B receptor)
Interleukin-18-binding protein
(IL-18BP) (Tadekinig-alfa)
Interleukin-19 (IL-19) (Melanoma
differentiation-associated proteinlike protein) (NG.1)
Interleukin-1 receptor type 1 (IL1R-1) (IL-1RT-1) (IL-1RT1)
(CD121 antigen-like family
member A) (Interleukin-1 receptor
alpha) (IL-1R-alpha) (Interleukin1 receptor type I) (p80) (CD
antigen CD121a) [Cleaved into:
Interleukin-1 receptor type 1,
membrane form (mIL-1R1) (mIL1RI); Interleukin-1 receptor type
1, soluble form (sIL-1R1) (sIL1RI)]
Interleukin-1 receptor type 2 (IL1R-2) (IL-1RT-2) (IL-1RT2)
(CD121 antigen-like family
member B) (CDw121b) (IL-1 type
II receptor) (Interleukin-1 receptor
beta) (IL-1R-beta) (Interleukin-1
receptor type II) (CD antigen
CD121b) [Cleaved into:
Interleukin-1 receptor type 2,
membrane form (mIL-1R2) (mIL1RII); Interleukin-1 receptor type
2, soluble form (sIL-1R2) (sIL1RII)]
Interleukin-1 receptor accessory
protein (IL-1 receptor accessory
protein) (IL-1RAcP) (Interleukin1 receptor 3) (IL-1R-3) (IL-1R3)
Interleukin-1 receptor-like 1
(Protein ST2)
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P18510

IL1RA

IL1RN IL1F3 IL1RA

P60568

IL2

IL2

Q9NYY1

IL20

Q9GZX6

IL22

IL20 ZCYTO10
UNQ852/PRO1801
IL22 ILTIF ZCYTO18
UNQ3099/PRO10096

Q9NPF7

IL23A

IL23A SGRF
UNQ2498/PRO5798

Q13007

IL24

IL24 MDA7 ST16

Q8NEV9

IL27A

IL27 IL27A IL30

Q6EBC2
Q6ZMJ4
P05113

IL31
IL34
IL5

IL31
IL34 C16orf77
IL5

P13232
P16871

IL7
IL7RA

IL7
IL7R

P15248

IL9

IL9

Q01113

IL9R

IL9R

P08476

INHBA

INHBA

Q8TB96

TIP

ITFG1 LNKN-1 TIP CDA08

Interleukin-1 receptor antagonist
protein (IL-1RN) (IL-1ra) (IRAP)
(ICIL-1RA) (IL1 inhibitor)
(Anakinra)
Interleukin-2 (IL-2) (T-cell growth
factor) (TCGF) (Aldesleukin)
Interleukin-20 (IL-20) (Cytokine
Zcyto10)
Interleukin-22 (IL-22) (Cytokine
Zcyto18) (IL-10-related T-cellderived-inducible factor) (IL-TIF)
Interleukin-23 subunit alpha (IL23 subunit alpha) (IL-23-A)
(Interleukin-23 subunit p19) (IL23p19)
Interleukin-24 (IL-24) (Melanoma
differentiation-associated gene 7
protein) (MDA-7) (Suppression of
tumorigenicity 16 protein)
Interleukin-27 subunit alpha (IL27 subunit alpha) (IL-27-A)
(IL27-A) (Interleukin-30) (p28)
Interleukin-31 (IL-31)
Interleukin-34 (IL-34)
Interleukin-5 (IL-5) (B-cell
differentiation factor I)
(Eosinophil differentiation factor)
(T-cell replacing factor) (TRF)
Interleukin-7 (IL-7)
Interleukin-7 receptor subunit
alpha (IL-7 receptor subunit alpha)
(IL-7R subunit alpha) (IL-7Ralpha) (IL-7RA) (CDw127) (CD
antigen CD127)
Interleukin-9 (IL-9) (Cytokine
P40) (T-cell growth factor P40)
Interleukin-9 receptor (IL-9
receptor) (IL-9R) (CD antigen
CD129)
Inhibin beta A chain (Activin betaA chain) (Erythroid differentiation
protein) (EDF)
T-cell immunomodulatory protein
(Protein TIP) (Integrin-alpha FGGAP repeat-containing protein 1)
(Linkin)
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Q9BX67

JAM3

JAM3 UNQ859/PRO1868

P01591

IGJ

JCHAIN IGCJ IGJ

P21583

SCF

KITLG MGF SCF

Q9UEF7
P18428

KLOT
LBP

KL
LBP

Q08380

LG3BP

LGALS3BP M2BP

P15018

LIF

LIF HILDA

Q8N149

LIRA2

LILRA2 ILT1 LIR7

Q8N6C8

LIRA3

LILRA3 ILT6 LIR4

P01374

TNFB

LTA TNFB TNFSF1

Q8NDX9

LY65B

LY6G5B C6orf19 G5B

Junctional adhesion molecule C
(JAM-C) (JAM-2) (Junctional
adhesion molecule 3) (JAM-3)
Immunoglobulin J chain (Joining
chain of multimeric IgA and IgM)
Kit ligand (Mast cell growth
factor) (MGF) (Stem cell factor)
(SCF) (c-Kit ligand) [Cleaved
into: Soluble KIT ligand
(sKITLG)]
Lipopolysaccharide-binding
protein (LBP)
Galectin-3-binding protein
(Basement membrane autoantigen
p105) (Lectin galactoside-binding
soluble 3-binding protein) (Mac-2binding protein) (MAC2BP)
(Mac-2 BP) (Tumor-associated
antigen 90K)
Leukemia inhibitory factor (LIF)
(Differentiation-stimulating factor)
(D factor) (Melanoma-derived
LPL inhibitor) (MLPLI)
(Emfilermin)
Leukocyte immunoglobulin-like
receptor subfamily A member 2
(CD85 antigen-like family
member H) (Immunoglobulin-like
transcript 1) (ILT-1) (Leukocyte
immunoglobulin-like receptor 7)
(LIR-7) (CD antigen CD85h)
Leukocyte immunoglobulin-like
receptor subfamily A member 3
(CD85 antigen-like family
member E) (Immunoglobulin-like
transcript 6) (ILT-6) (Leukocyte
immunoglobulin-like receptor 4)
(LIR-4) (Monocyte inhibitory
receptor HM43/HM31) (CD
antigen CD85e)
Lymphotoxin-alpha (LT-alpha)
(TNF-beta) (Tumor necrosis factor
ligand superfamily member 1)
Lymphocyte antigen 6 complex
locus protein G5b
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Q5SRR4

LY65C

LY6G5C C6orf20 G5C NG33

O95711

LY86

LY86 MD1

Q9Y6Y9

LY96

LY96 ESOP1 MD2

Q9BZG9

LYNX1

LYNX1 SLURP2

Q6UX82

LYPD8

LYPD8 UNQ511/PRO1026

Q6UWQ5 LYZL1

LYZL1 LYC2
UNQ648/PRO1278
LYZL2

Q7Z4W2

LYZL2

O75951

LYZL6

Q95460

HMR1

LYZL6 LYC1
UNQ754/PRO1485
MR1

Q969H8

MYDGF

MYDGF C19orf10 IL25

P02763

A1AG1

ORM1 AGP1

P19652

A1AG2

ORM2 AGP2

Q9BQ51

PD1L2

PDCD1LG2 B7DC CD273
PDCD1L2 PDL2

P02776

PLF4

PF4 CXCL4 SCYB4

P10720

PF4V

PF4V1 CXCL4V1 SCYB4V1

Lymphocyte antigen 6 complex
locus protein G5c
Lymphocyte antigen 86 (Ly-86)
(Protein MD-1)
Lymphocyte antigen 96 (Ly-96)
(ESOP-1) (Protein MD-2)
Ly-6/neurotoxin-like protein 1
(Secreted Ly-6/uPAR domaincontaining protein 2) (Secreted
Ly-6/uPAR-related protein 2)
(SLURP-2)
Ly6/PLAUR domain-containing
protein 8
Lysozyme-like protein 1 (EC
3.2.1.17)
Lysozyme-like protein 2
(Lysozyme-2) (EC 3.2.1.17)
Lysozyme-like protein 6 (EC
3.2.1.17)
Major histocompatibility complex
class I-related gene protein (MHC
class I-related gene protein) (Class
I histocompatibility antigen-like
protein)
Myeloid-derived growth factor
(MYDGF) (Interleukin-25) (IL25) (Stromal cell-derived growth
factor SF20)
Alpha-1-acid glycoprotein 1 (AGP
1) (Orosomucoid-1) (OMD 1)
Alpha-1-acid glycoprotein 2 (AGP
2) (Orosomucoid-2) (OMD 2)
Programmed cell death 1 ligand 2
(PD-1 ligand 2) (PD-L2) (PDCD1
ligand 2) (Programmed death
ligand 2) (Butyrophilin B7-DC)
(B7-DC) (CD antigen CD273)
Platelet factor 4 (PF-4) (C-X-C
motif chemokine 4) (Iroplact)
(Oncostatin-A) [Cleaved into:
Platelet factor 4, short form]
Platelet factor 4 variant (C-X-C
motif chemokine 4 variant)
(CXCL4L1) (PF4alt) (PF4var1)
[Cleaved into: Platelet factor 4
variant(4-74); Platelet factor 4
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Q96LB9

PGRP3

PGLYRP3 PGRPIA

Q96LB8

PGRP4

PGLYRP4 PGRPIB SBBI67

P19957

ELAF

PI3 WAP3 WFDC14

Q02325

PLGB

P14222

PERF

PLGLB1 PLGL PRGB;
PLGLB2 PLGP1
PRF1 PFP

P13727

PRG2

PRG2 MBP

P01236
Q9HC23

PRL
PROK2

PRL
PROK2 BV8

P07477

TRY1

PRSS1 TRP1 TRY1 TRYP1

P11465

PSG2

PSG2 PSBG2

variant(5-74); Platelet factor 4
variant(6-74)]
Peptidoglycan recognition protein
3 (Peptidoglycan recognition
protein I-alpha) (PGLYRPIalpha)
(PGRP-I-alpha) (Peptidoglycan
recognition protein intermediate
alpha)
Peptidoglycan recognition protein
4 (Peptidoglycan recognition
protein I-beta) (PGLYRPIbeta)
(PGRP-I-beta) (Peptidoglycan
recognition protein intermediate
beta)
Elafin (Elastase-specific inhibitor)
(ESI) (Peptidase inhibitor 3) (PI-3)
(Protease inhibitor WAP3) (Skinderived antileukoproteinase)
(SKALP) (WAP four-disulfide
core domain protein 14)
Plasminogen-like protein B
(Plasminogen-related protein B)
Perforin-1 (P1) (Cytolysin)
(Lymphocyte pore-forming
protein) (PFP)
Bone marrow proteoglycan
(BMPG) (Proteoglycan 2)
[Cleaved into: Eosinophil granule
major basic protein (EMBP)
(MBP) (Pregnancy-associated
major basic protein)]
Prolactin (PRL)
Prokineticin-2 (PK2) (Protein Bv8
homolog)
Trypsin-1 (EC 3.4.21.4) (Betatrypsin) (Cationic trypsinogen)
(Serine protease 1) (Trypsin I)
[Cleaved into: Alpha-trypsin chain
1; Alpha-trypsin chain 2]
Pregnancy-specific beta-1glycoprotein 2 (PS-beta-G-2)
(PSBG-2) (Pregnancy-specific
glycoprotein 2) (Pregnancyspecific beta-1 glycoprotein E)
(PS-beta-E)
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Q00888

PSG4

PSG4 CGM4 PSG9

Q15238

PSG5

PSG5

Q96A99
Q8TD07

PTX4
N2DL4

PTX4 C16orf38
RAET1E LETAL N2DL4
ULBP4 UNQ1867/PRO4303

Q99969

RARR2

RARRES2 TIG2

Q06141

REG3A

REG3A HIP PAP PAP1

P12724

ECP

RNASE3 ECP RNS3

Q96QR1

SG3A1

SCGB3A1 HIN1 PNSP2
UGRP2 UNQ629/PRO1245

Pregnancy-specific beta-1glycoprotein 4 (PS-beta-G-4)
(PSBG-4) (Pregnancy-specific
glycoprotein 4) (Pregnancyspecific beta-1-glycoprotein 9)
(PS-beta-G-9) (PSBG-9)
(Pregnancy-specific glycoprotein
9)
Pregnancy-specific beta-1glycoprotein 5 (PS-beta-G-5)
(PSBG-5) (Pregnancy-specific
glycoprotein 5) (Fetal liver nonspecific cross-reactive antigen 3)
(FL-NCA-3)
Pentraxin-4
NKG2D ligand 4 (N2DL-4)
(NKG2DL4) (Lymphocyte
effector toxicity activation ligand)
(RAE-1-like transcript 4) (RL-4)
(Retinoic acid early transcript 1E)
Retinoic acid receptor responder
protein 2 (Chemerin) (RARresponsive protein TIG2)
(Tazarotene-induced gene 2
protein)
Regenerating islet-derived protein
3-alpha (REG-3-alpha)
(Hepatointestinal pancreatic
protein) (HIP/PAP) (Human
proislet peptide) (Pancreatitisassociated protein 1)
(Regenerating islet-derived protein
III-alpha) (Reg III-alpha) [Cleaved
into: Regenerating islet-derived
protein 3-alpha 16.5 kDa form;
Regenerating islet-derived protein
3-alpha 15 kDa form]
Eosinophil cationic protein (ECP)
(EC 3.1.27.-) (Ribonuclease 3)
(RNase 3)
Secretoglobin family 3A member
1 (Cytokine HIN-1) (High in
normal 1) (Pneumo secretory
protein 2) (PnSP-2) (Uteroglobinrelated protein 2)
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Q8WVN6

SCTM1

SECTM1 K12

O95025
P01011

SEM3D
AACT

SEMA3D UNQ760/PRO1491
SERPINA3 AACT GIG24
GIG25

Q13291

SLAF1

SLAMF1 SLAM

Q5VX71
P61812

SUSD4
TGFB2

SUSD4 UNQ196/PRO222
TGFB2

Q15661

TRYB1

TPSAB1 TPS1 TPS2 TPSB1

P20231

TRYB2

TPSB2 TPS2

Q9NP99

TREM1

TREM1

Q6UXN2

TRML4

TREML4 TLT4
UNQ9425/PRO34675

Q969D9
Q96RP3

TSLP
UCN2

TSLP
UCN2 SRP URP

Q9BZM5

N2DL2

ULBP2 N2DL2 RAET1H
UNQ463/PRO791

P01282

VIP

VIP

Secreted and transmembrane
protein 1 (Protein K-12)
Alpha-1-antichymotrypsin (ACT)
(Cell growth-inhibiting gene 24/25
protein) (Serpin A3) [Cleaved
into: Alpha-1-antichymotrypsin
His-Pro-less]
Signaling lymphocytic activation
molecule (CDw150) (IPO-3)
(SLAM family member 1) (CD
antigen CD150)
Sushi domain-containing protein 4
Transforming growth factor beta-2
(TGF-beta-2) (BSC-1 cell growth
inhibitor) (Cetermin)
(Glioblastoma-derived T-cell
suppressor factor) (G-TSF)
(Polyergin) [Cleaved into:
Latency-associated peptide (LAP)]
Tryptase alpha/beta-1 (Tryptase-1)
(EC 3.4.21.59) (Tryptase I)
(Tryptase alpha-1)
Tryptase beta-2 (Tryptase-2) (EC
3.4.21.59) (Tryptase II)
Triggering receptor expressed on
myeloid cells 1 (TREM-1)
(Triggering receptor expressed on
monocytes 1) (CD antigen
CD354)
Trem-like transcript 4 protein
(TLT-4) (Triggering receptor
expressed on myeloid cells-like
protein 4)
Thymic stromal lymphopoietin
Urocortin-2 (Stresscopin-related
peptide) (Urocortin II) (Ucn II)
(Urocortin-related peptide)
NKG2D ligand 2 (N2DL-2)
(NKG2DL2) (ALCAN-alpha)
(Retinoic acid early transcript 1H)
(UL16-binding protein 2)
VIP peptides [Cleaved into:
Intestinal peptide PHV-42
(Peptide histidine valine 42);
Intestinal peptide PHM-27
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(Peptide histidine methioninamide
27); Vasoactive intestinal peptide
(VIP) (Vasoactive intestinal
polypeptide)]
Q8IW00
VSTM4
VSTM4 C10orf72
V-set and transmembrane domaincontaining protein 4 [Cleaved into:
Peptide Lv]
P47992
XCL1
XCL1 LTN SCYC1
Lymphotactin (ATAC) (C motif
chemokine 1) (Cytokine SCM-1)
(Lymphotaxin) (SCM-1-alpha)
(Small-inducible cytokine C1)
(XC chemokine ligand 1)
Q9UBD3 XCL2
XCL2 SCYC2
Cytokine SCM-1 beta (C motif
chemokine 2) (XC chemokine
ligand 2)
P04217
A1BG
A1BG
Alpha-1B-glycoprotein (Alpha-1B glycoprotein)
Q86SQ3
AGRE4
ADGRE4P EMR4 EMR4P
Putative adhesion G proteinGPR127 PGR16
coupled receptor E4P (EGF-like
module receptor 4) (EGF-like
module-containing mucin-like
hormone receptor-like 4) (Gprotein coupled receptor 127) (Gprotein coupled receptor PGR16)
Q92485
ASM3B SMPDL3B ASML3B
Acid sphingomyelinase-like
phosphodiesterase 3b (ASM-like
phosphodiesterase 3b) (EC 3.1.4.-)
Proteins functionally related to energy production and metabolism
Q96PD5
PGRP2
PGLYRP2 PGLYRPL PGRPL
N-acetylmuramoyl-L-alanine
UNQ3103/PRO10102
amidase (EC 3.5.1.28)
(Peptidoglycan recognition protein
2) (Peptidoglycan recognition
protein long) (PGRP-L)
P01242
SOM2
GH2
Growth hormone variant (GH-V)
(Growth hormone 2) (Placentaspecific growth hormone)
P22303
ACES
ACHE
Acetylcholinesterase (AChE) (EC
3.1.1.7)
Q15848
ADIPO
ADIPOQ ACDC ACRP30
Adiponectin (30 kDa adipocyte
APM1 GBP28
complement-related protein)
(Adipocyte complement-related 30
kDa protein) (ACRP30)
(Adipocyte, C1q and collagen
domain-containing protein)
(Adipose most abundant gene
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Q9BRR6

ADPGK

ADPGK PSEC0260

P43652

AFAM

AFM ALB2 ALBA

P04745

AMY1

AMY1A AMY1; AMY1B
AMY1; AMY1C AMY1

P19961

AMY2B

AMY2B

P02743

SAMP

APCS PTX2

P02652

APOA2

APOA2

P04114
Q13790

APOB
APOF

APOB
APOF

Q9BPW4

APOL4

APOL4

O95445

APOM

APOM G3A NG20 HSPC336

Q9BUR5

MIC26

APOO FAM121B MIC23
MIC26 My025
UNQ1866/PRO4302

P54793
Q5FYB1
Q5FYB0
Q6UWY0

ARSF
ARSI
ARSJ
ARSK

P06276

CHLE

ARSF
ARSI
ARSJ UNQ372/PRO708
ARSK TSULF
UNQ630/PRO1246
BCHE CHE1

transcript 1 protein) (apM-1)
(Gelatin-binding protein)
ADP-dependent glucokinase
(ADP-GK) (ADPGK) (EC
2.7.1.147) (RbBP-35)
Afamin (Alpha-albumin) (AlphaAlb)
Alpha-amylase 1 (EC 3.2.1.1)
(1,4-alpha-D-glucan
glucanohydrolase 1) (Salivary
alpha-amylase)
Alpha-amylase 2B (EC 3.2.1.1)
(1,4-alpha-D-glucan
glucanohydrolase 2B) (Carcinoid
alpha-amylase)
Serum amyloid P-component
(SAP) (9.5S alpha-1-glycoprotein)
[Cleaved into: Serum amyloid Pcomponent(1-203)]
Apolipoprotein A-II (Apo-AII)
(ApoA-II) (Apolipoprotein A2)
[Cleaved into: Proapolipoprotein
A-II (ProapoA-II); Truncated
apolipoprotein A-II
(Apolipoprotein A-II(1-76))]
Apolipoprotein F (Apo-F) (Lipid
transfer inhibitor protein) (LTIP)
Apolipoprotein L4
(Apolipoprotein L-IV) (ApoL-IV)
Apolipoprotein M (Apo-M)
(ApoM) (Protein G3a)
MICOS complex subunit MIC26
(Apolipoprotein O) (MICOS
complex subunit MIC23) (Protein
FAM121B)
Arylsulfatase F (ASF) (EC 3.1.6.-)
Arylsulfatase I (ASI) (EC 3.1.6.-)
Arylsulfatase J (ASJ) (EC 3.1.6.-)
Arylsulfatase K (ASK) (EC 3.1.6.) (Telethon sulfatase)
Cholinesterase (EC 3.1.1.8)
(Acylcholine acylhydrolase)
(Butyrylcholine esterase) (Choline
esterase II) (Pseudocholinesterase)
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P43251

BTD

BTD

P23280

CAH6

CA6

P08218

CEL2B

CELA2B ELA2B

Q9UKY3

CES1P

CES1P1 CES4

Q5XG92

EST4A

P11597

CETP

CES4A CES8
UNQ440/PRO873
CETP

Q92496

FHR4

CFHR4 CFHL4 FHR4

Q9BZP6

CHIA

CHIA

Q6UXF7

CL18B

CLEC18B MRLP1
UNQ306/PRO347

Q8NCF0

CL18C

CLEC18C MRLP3

P04118
Q6UWE3

COL
COLL2

Q96KN2

CNDP1

CLPS
CLPSL2 C6orf126
UNQ3045/PRO9861
CNDP1 CN1 CPGL2
UNQ1915/PRO4380

P15085

CBPA1

CPA1 CPA

P48052

CBPA2

CPA2

Q8N4T0

CBPA6

CPA6 CPAH

P15086

CBPB1

CPB1 CPB PCPB

Biotinidase (Biotinase) (EC
3.5.1.12)
Carbonic anhydrase 6 (EC 4.2.1.1)
(Carbonate dehydratase VI)
(Carbonic anhydrase VI) (CA-VI)
(Salivary carbonic anhydrase)
(Secreted carbonic anhydrase)
Chymotrypsin-like elastase family
member 2B (EC 3.4.21.71)
(Elastase-2B)
Putative inactive carboxylesterase
4 (Inactive carboxylesterase 1
pseudogene 1) (Placental
carboxylesterase 3) (PCE-3)
Carboxylesterase 4A (EC 3.1.1.-)
Cholesteryl ester transfer protein
(Lipid transfer protein I)
Complement factor H-related
protein 4 (FHR-4)
Acidic mammalian chitinase
(AMCase) (EC 3.2.1.14) (Lungspecific protein TSA1902)
C-type lectin domain family 18
member B (Mannose receptor-like
protein 1)
C-type lectin domain family 18
member C (Mannose receptor-like
protein 3)
Colipase
Colipase-like protein 2
Beta-Ala-His dipeptidase (EC
3.4.13.20) (CNDP dipeptidase 1)
(Carnosine dipeptidase 1)
(Glutamate carboxypeptidase-like
protein 2) (Serum carnosinase)
Carboxypeptidase A1 (EC
3.4.17.1)
Carboxypeptidase A2 (EC
3.4.17.15)
Carboxypeptidase A6 (EC 3.4.17.)
Carboxypeptidase B (EC 3.4.17.2)
(Pancreas-specific protein)
(PASP)
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Q96IY4

CBPB2

CPB2

P16870

CBPE

CPE

P17538

CTRB1

CTRB1 CTRB

Q6PKH6

DR4L2

DHRS4L2 SDR25C3

A6NNS2

DRS7C

DHRS7C SDR32C2

Q9UGM3
O75356

DMBT1
ENTP5

DMBT1 GP340
ENTPD5 CD39L4 PCPH

Q8NAU1

FNDC5

FNDC5 FRCP2

Q92820

GGH

GGH

P27352

IF

GIF IFMH

Q6UWU2 GLB1L

GLB1L UNQ229/PRO262

Carboxypeptidase B2 (EC
3.4.17.20) (Carboxypeptidase U)
(CPU) (Plasma carboxypeptidase
B) (pCPB) (Thrombin-activable
fibrinolysis inhibitor) (TAFI)
Carboxypeptidase E (CPE) (EC
3.4.17.10) (Carboxypeptidase H)
(CPH) (Enkephalin convertase)
(Prohormone-processing
carboxypeptidase)
Chymotrypsinogen B (EC
3.4.21.1) [Cleaved into:
Chymotrypsin B chain A;
Chymotrypsin B chain B;
Chymotrypsin B chain C]
Dehydrogenase/reductase SDR
family member 4-like 2 (EC 1.1.-.) (Short chain
dehydrogenase/reductase family
25C member 3)
Dehydrogenase/reductase SDR
family member 7C (EC 1.1.-.-)
(Short-chain
dehydrogenase/reductase family
32C member 2)
Ectonucleoside triphosphate
diphosphohydrolase 5 (NTPDase
5) (EC 3.6.1.6) (CD39 antigen-like
4) (ER-UDPase) (Guanosinediphosphatase ENTPD5) (GDPase
ENTPD5) (EC 3.6.1.42)
(Nucleoside diphosphatase)
(Uridine-diphosphatase ENTPD5)
(UDPase ENTPD5)
Fibronectin type III domaincontaining protein 5 (Fibronectin
type III repeat-containing protein
2) [Cleaved into: Irisin]
Gamma-glutamyl hydrolase (EC
3.4.19.9) (Conjugase) (GH)
(Gamma-Glu-X carboxypeptidase)
Gastric intrinsic factor (Intrinsic
factor) (IF) (INF)
Beta-galactosidase-1-like protein
(EC 3.2.1.-)
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Q96SL4

GPX7

GPX7 GPX6 UNQ469/PRO828

Q16661

GUC2B

GUCA2B

P81172

HEPC

HAMP HEPC LEAP1
UNQ487/PRO1003

P10997

IAPP

IAPP

P01569

IFNA5

IFNA5

Q6UW32

IGFL1

IGFL1 UNQ644/PRO1274

Q6UWQ7 IGFL2

IGFL2 UNQ645/PRO1275

Q6UXB1
P01308

IGFL3
INS

IGFL3 UNQ483/PRO982
INS

P04180

LCAT

LCAT

Q6JVE5
Q5VSP4

LCN12
LC1L1

LCN12
LCN1P1 LCN1L1

Q8WX39

LCN9

LCN9

P48357
P11150

LEPR
LIPC

LEPR DB OBR
LIPC HTGL

P07098

LIPG

LIPF

Q9Y5X9

LIPE

LIPG UNQ387/PRO719

Glutathione peroxidase 7 (GPx-7)
(GSHPx-7) (EC 1.11.1.9) (CL683)
Guanylate cyclase activator 2B
[Cleaved into: Guanylate cyclase
C-activating peptide 2 (Guanylate
cyclase C-activating peptide II)
(GCAP-II); Uroguanylin (UGN)]
Hepcidin (Liver-expressed
antimicrobial peptide 1) (LEAP-1)
(Putative liver tumor regressor)
(PLTR) [Cleaved into: Hepcidin25 (Hepc25); Hepcidin-20
(Hepc20)]
Islet amyloid polypeptide
(Amylin) (Diabetes-associated
peptide) (DAP) (Insulinoma
amyloid peptide)
Interferon alpha-5 (IFN-alpha-5)
(Interferon alpha-61) (Interferon
alpha-G) (LeIF G)
Insulin growth factor-like family
member 2
Insulin growth factor-like family
member 3
Insulin [Cleaved into: Insulin B
chain; Insulin A chain]
Phosphatidylcholine-sterol
acyltransferase (EC 2.3.1.43)
(Lecithin-cholesterol
acyltransferase) (Phospholipidcholesterol acyltransferase)
Epididymal-specific lipocalin-12
Putative lipocalin 1-like protein 1
(Lipocalin 1-like pseudogene 1)
Epididymal-specific lipocalin-9
(MUP-like lipocalin)
Hepatic triacylglycerol lipase (HL)
(Hepatic lipase) (EC 3.1.1.3)
(Lipase member C)
Gastric triacylglycerol lipase (GL)
(Gastric lipase) (EC 3.1.1.3)
Endothelial lipase (EC 3.1.1.3)
(Endothelial cell-derived lipase)
(EDL) (EL)
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Q8WWY
8

LIPH

LIPH LPDLR MPAPLA1
PLA1B

Q6XZB0

LIPI

LIPI LPDL PRED5

Q5VXJ0

LIPK

LIPK LIPL2

Q5VYY2

LIPM

LIPM LIPL3

Q5VXI9

LIPN

LIPN LIPL4

P06858

LIPL

LPL LIPD

Q9Y2E5
Q08431
A6NG13

MA2B2
MFGM
MGT4D

MAN2B2 KIAA0935
MFGE8
MGAT4D

O96009

NAPSA

NAPSA NAP1 NAPA

P61916

NPC2

NPC2 HE1

P0DJD8

PEPA3

PGA3

P0DJD7

PEPA4

PGA4

P0DJD9

PEPA5

PGA5

P20142

PEPC

PGC

Lipase member H (LIPH) (EC
3.1.1.-) (LPD lipase-related
protein) (Membrane-associated
phosphatidic acid-selective
phospholipase A1-alpha) (mPAPLA1 alpha) (Phospholipase A1
member B)
Lipase member I (LIPI) (EC
3.1.1.-) (Cancer/testis antigen 17)
(CT17) (LPD lipase) (Membraneassociated phosphatidic acidselective phospholipase A1-beta)
(mPA-PLA1 beta)
Lipase member K (EC 3.1.1.-)
(Lipase-like abhydrolase domaincontaining protein 2)
Lipase member M (EC 3.1.1.-)
(Lipase-like abhydrolase domaincontaining protein 3)
Lipase member N (EC 3.1.1.-)
(Lipase-like abhydrolase domaincontaining protein 4)
Lipoprotein lipase (LPL) (EC
3.1.1.34)

Alpha-1,3-mannosyl-glycoprotein
4-beta-Nacetylglucosaminyltransferase-like
protein MGAT4D (EC 2.4.1.-)
Napsin-A (EC 3.4.23.-) (Aspartyl
protease 4) (ASP4) (Asp 4)
(Napsin-1) (TA01/TA02)
Epididymal secretory protein E1
(Human epididymis-specific
protein 1) (He1) (Niemann-Pick
disease type C2 protein)
Pepsin A-3 (EC 3.4.23.1)
(Pepsinogen-3)
Pepsin A-4 (EC 3.4.23.1)
(Pepsinogen-4)
Pepsin A-5 (EC 3.4.23.1)
(Pepsinogen-5)
Gastricsin (EC 3.4.23.3)
(Pepsinogen C)
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O43692

PI15

PI15 CRISP8 P25TI

Q53H76

PLA1A

PLA1A NMD PSPLA1

H3BRW4

PLA2G10 hCG_1746186

Q8NCC3

H3BRW
4
PAG15

P04054

PA21B

PLA2G1B PLA2 PLA2A
PPLA2

Q5R387

PA2GC

PLA2G2C

Q13093

PAFA

PLA2G7 PAFAH

P55058

PLTP

PLTP

P16233

LIPP

PNLIP

P54315

LIPR1

PNLIPRP1 PLRP1

PLA2G15 LYPLA3
UNQ341/PRO540

Peptidase inhibitor 15 (PI-15) (25
kDa trypsin inhibitor) (p25TI)
(Cysteine-rich secretory protein 8)
(CRISP-8) (SugarCrisp)
Phospholipase A1 member A (EC
3.1.1.-) (Phosphatidylserinespecific phospholipase A1) (PSPLA1)
Phospholipase A(2) (EC 3.1.1.4)
Group XV phospholipase A2 (EC
2.3.1.-) (1-O-acylceramide
synthase) (ACS) (LCAT-like
lysophospholipase) (LLPL)
(Lysophospholipase 3)
(Lysosomal phospholipase A2)
(LPLA2)
Phospholipase A2 (EC 3.1.1.4)
(Group IB phospholipase A2)
(Phosphatidylcholine 2acylhydrolase 1B)
Putative inactive group IIC
secretory phospholipase A2
(Phosphatidylcholine 2acylhydrolase-like protein GIIC)
Platelet-activating factor
acetylhydrolase (PAF
acetylhydrolase) (EC 3.1.1.47) (1alkyl-2acetylglycerophosphocholine
esterase) (2-acetyl-1alkylglycerophosphocholine
esterase) (Group-VIIA
phospholipase A2) (gVIIA-PLA2)
(LDL-associated phospholipase
A2) (LDL-PLA(2)) (PAF 2acylhydrolase)
Phospholipid transfer protein
(Lipid transfer protein II)
Pancreatic triacylglycerol lipase
(PL) (PTL) (Pancreatic lipase)
(EC 3.1.1.3)
Inactive pancreatic lipase-related
protein 1 (PL-RP1)
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P54317

LIPR2

PNLIPRP2 PLRP2

Q17RR3

LIPR3

PNLIPRP3

P27169

PON1

PON1 PON

Q15166

PON3

PON3

Q13162

PRDX4

PRDX4

P04070
Q9BQR3

PROC
PRS27

P07602

SAP

PROC
PRSS27 MPN
UNQ1884/PRO4327
PSAP GLBA SAP1

Q6NUJ1

SAPL1

PSAPL1

Q9NRI6

PYY2

PYY2

P02753

RET4

RBP4 PRO2222

Pancreatic lipase-related protein 2
(PL-RP2) (EC 3.1.1.26) (EC
3.1.1.3) (Galactolipase)
Pancreatic lipase-related protein 3
(PL-RP3) (EC 3.1.1.3)
Serum paraoxonase/arylesterase 1
(PON 1) (EC 3.1.1.2) (EC
3.1.1.81) (EC 3.1.8.1) (Aromatic
esterase 1) (A-esterase 1) (K-45)
(Serum aryldialkylphosphatase 1)
Serum paraoxonase/lactonase 3
(EC 3.1.1.2) (EC 3.1.1.81) (EC
3.1.8.1)
Peroxiredoxin-4 (EC 1.11.1.15)
(Antioxidant enzyme AOE372)
(AOE37-2) (Peroxiredoxin IV)
(Prx-IV) (Thioredoxin peroxidase
AO372) (Thioredoxin-dependent
peroxide reductase A0372)
Vitamin K-dependent protein C
Serine protease 27 (EC 3.4.21.-)
(Marapsin) (Pancreasin)
Prosaposin (Proactivator
polypeptide) [Cleaved into:
Saposin-A (Protein A); Saposin-BVal; Saposin-B (Cerebroside
sulfate activator) (CSAct)
(Dispersin) (Sphingolipid activator
protein 1) (SAP-1)
(Sulfatide/GM1 activator);
Saposin-C (A1 activator) (Cobeta-glucosidase)
(Glucosylceramidase activator)
(Sphingolipid activator protein 2)
(SAP-2); Saposin-D (Component
C) (Protein C)]
Proactivator polypeptide-like 1
[Cleaved into: Saposin A-like;
Saposin B-Val-like; Saposin Blike; Saposin C-like; Saposin Dlike]
Putative peptide YY-2 (Putative
peptide YY2)
Retinol-binding protein 4 (Plasma
retinol-binding protein) (PRBP)
(RBP) [Cleaved into: Plasma
223

P05451

REG1A

REG1A PSPS PSPS1 REG

P35542

SAA4

SAA4 CSAA

Q8IW75

SPA12

SERPINA12

Q9HAT2

SIAE

SIAE YSG2

P17405

ASM

SMPD1 ASM

Q92484

ASM3A

SMPDL3A ASML3A

P00995

ISK1

SPINK1 PSTI

P20061

TCO1

TCN1 TC1

P20062

TCO2

TCN2 TC2

P01222

TSHB

TSHB

retinol-binding protein(1-182);
Plasma retinol-binding protein(1181); Plasma retinol-binding
protein(1-179); Plasma retinolbinding protein(1-176)]
Lithostathine-1-alpha (Islet cells
regeneration factor) (ICRF) (Islet
of Langerhans regenerating
protein) (REG) (Pancreatic stone
protein) (PSP) (Pancreatic thread
protein) (PTP) (Regenerating isletderived protein 1-alpha) (REG-1alpha) (Regenerating protein I
alpha)
Serum amyloid A-4 protein
(Constitutively expressed serum
amyloid A protein) (C-SAA)
Serpin A12 (OL-64) (Visceral
adipose tissue-derived serine
protease inhibitor) (Vaspin)
(Visceral adipose-specific serpin)
Sialate O-acetylesterase (EC
3.1.1.53) (H-Lse) (Sialic acidspecific 9-O-acetylesterase)
Sphingomyelin phosphodiesterase
(EC 3.1.4.12) (Acid
sphingomyelinase) (aSMase)
Acid sphingomyelinase-like
phosphodiesterase 3a (ASM-like
phosphodiesterase 3a) (EC 3.1.4.-)
Serine protease inhibitor Kazaltype 1 (Pancreatic secretory
trypsin inhibitor) (Tumorassociated trypsin inhibitor)
(TATI)
Transcobalamin-1 (TC-1)
(Haptocorrin) (HC) (Protein R)
(Transcobalamin I) (TC I) (TCI)
Transcobalamin-2 (TC-2)
(Transcobalamin II) (TC II) (TCII)
Thyrotropin subunit beta
(Thyroid-stimulating hormone
subunit beta) (TSH-B) (TSH-beta)
(Thyrotropin beta chain)
(Thyrotropin alfa)
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P02766

TTHY

TTR PALB

P55089
O95399

UCN1
UTS2

UCN
UTS2 UNQ525/PRO1068

Q765I0

UTS2B

UTS2B URP UTS2D

Q13231

CHIT1

CHIT1

A5D8T8

CL18A

CLEC18A MRLP2

P04746

AMYP

AMY2A

P80188

NGAL

LCN2 HNL NGAL

Q9NZK5

CECR1

CECR1 ADA2 ADGF IDGFL

Transthyretin (ATTR)
(Prealbumin) (TBPA)
Urocortin
Urotensin-2 (Urotensin II) (U-II)
(UII)
Urotensin-2B (Urotensin II-related
peptide) (Urotensin IIB) (U-IIB)
(UIIB) (Urotensin-2 domaincontaining protein)
Chitotriosidase-1 (EC 3.2.1.14)
(Chitinase-1)
C-type lectin domain family 18
member A (Mannose receptor-like
protein 2)
Pancreatic alpha-amylase (PA)
(EC 3.2.1.1) (1,4-alpha-D-glucan
glucanohydrolase)
Neutrophil gelatinase-associated
lipocalin (NGAL) (25 kDa alpha2-microglobulin-related subunit of
MMP-9) (Lipocalin-2) (Oncogene
24p3) (Siderocalin LCN2) (p25)
Adenosine deaminase CECR1 (EC
3.5.4.4) (Cat eye syndrome critical
region protein 1)

Proteins of unknown function
Q6P093
ADCL2
AADACL2
Q5VST6

AB17B

O43827

ANGL7

P0DMC3

ELA

Q86Y30

BAGE2

Q86Y29

BAGE3

Arylacetamide deacetylase-like 2
(EC 3.1.1.-)
ABHD17B C9orf77 FAM108B1 Protein ABHD17B (EC 3.-.-.-)
CGI-67
(Alpha/beta hydrolase domaincontaining protein 17B)
(Abhydrolase domain-containing
protein 17B)
ANGPTL7 CDT6
Angiopoietin-related protein 7
UNQ313/PRO356
(Angiopoietin-like factor)
(Angiopoietin-like protein 7)
(Cornea-derived transcript 6
protein)
APELA ELA TDL
Apelin receptor early endogenous
ligand (Protein Elabela) (Protein
Toddler)
BAGE2
B melanoma antigen 2
(Cancer/testis antigen 2.2) (CT2.2)
BAGE3
B melanoma antigen 3
(Cancer/testis antigen 2.3) (CT2.3)
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Q86Y28

BAGE4

BAGE4 MLL3P

Q7Z5Y6

BMP8A

BMP8A

P34820

BMP8B

BMP8B BMP8

Q86YQ2

LATH

BPIFA4P BASE LATH

Q8N4F0

BPIB2

BPIFB2 BPIL1 C20orf184
LPLUNC2 UNQ2489/PRO5776

P59827

BPIB4

BPIFB4 C20orf186 LPLUNC4

Q8NFQ5

BPIB6

BPIFB6 BPIL3

Q8N8R5
P23435

CB069
CBLN1

C2orf69
CBLN1

Q6UW01
Q9NTU7

CBLN3
CBLN4

Q9H6E4

CC134

CBLN3 UNQ755/PRO1486
CBLN4 CBLNL1
UNQ718/PRO1382
CCDC134

Q04900

MUC24

CD164

Q5VXM1
Q6NT32

CDCP2
EST5A

CDCP2
CES5A CES7

B melanoma antigen 4
(Cancer/testis antigen 2.4) (CT2.4)
Bone morphogenetic protein 8A
(BMP-8A)
Bone morphogenetic protein 8B
(BMP-8) (BMP-8B) (Osteogenic
protein 2) (OP-2)
Putative BPIFA4P protein (BPI
fold containing family A, member
4, pseudogene) (Breast cancer and
salivary gland-expressed protein)
(Putative latherin)
BPI fold-containing family B
member 2
(Bactericidal/permeabilityincreasing protein-like 1) (BPIlike 1) (Long palate, lung and
nasal epithelium carcinomaassociated protein 2) (RYSR)
BPI fold-containing family B
member 4 (Ligand-binding protein
RY2G5) (Long palate, lung and
nasal epithelium carcinomaassociated protein 4)
BPI fold-containing family B
member 6
(Bactericidal/permeabilityincreasing protein-like 3)
UPF0565 protein C2orf69
Cerebellin-1 (Precerebellin)
[Cleaved into: Cerebellin (CER);
[des-Ser1]-cerebellin]
Cerebellin-3
Cerebellin-4 (Cerebellin-like
glycoprotein 1)
Coiled-coil domain-containing
protein 134
Sialomucin core protein 24
(MUC-24) (Endolyn) (Multiglycosylated core protein 24)
(MGC-24) (MGC-24v) (CD
antigen CD164)
CUB domain-containing protein 2
Carboxylesterase 5A (EC 3.1.1.1)
(Carboxylesterase-like urinary
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P01215

GLHA

CGA

H9KV56

H9KV56

CGB2

P0DN87
Q9BWS9

CGB7
CHID1

CGB7
CHID1 GL008 PSEC0104
SB139

Q9Y6N3

CLCA3

CLCA3P CLCA3

A2RUU4
Q9UI42

COLL1
CBPA4

Q8WXQ8

CBPA5

CLPSL1 C6orf127
CPA4 CPA3
UNQ694/PRO1339
CPA5

P15169

CBPN

CPN1 ACBP

P22792

CPN2

CPN2 ACBP

excreted protein homolog)
(Cauxin)
Glycoprotein hormones alpha
chain (Anterior pituitary
glycoprotein hormones common
subunit alpha)
(Choriogonadotropin alpha chain)
(Chorionic gonadotrophin subunit
alpha) (CG-alpha) (Folliclestimulating hormone alpha chain)
(FSH-alpha) (Follitropin alpha
chain) (Luteinizing hormone alpha
chain) (LSH-alpha) (Lutropin
alpha chain) (Thyroid-stimulating
hormone alpha chain) (TSH-alpha)
(Thyrotropin alpha chain)
Choriogonadotropin subunit beta
variant 2
Choriogonadotropin subunit beta 7
Chitinase domain-containing
protein 1 (Stabilin-1-interacting
chitinase-like protein) (SI-CLP)
Calcium-activated chloride
channel regulator family member
3 (Calcium-activated chloride
channel family member 3)
(hCLCA3)
Colipase-like protein 1
Carboxypeptidase A4 (EC 3.4.17.) (Carboxypeptidase A3)
Carboxypeptidase A5 (EC 3.4.17.)
Carboxypeptidase N catalytic
chain (CPN) (EC 3.4.17.3)
(Anaphylatoxin inactivator)
(Arginine carboxypeptidase)
(Carboxypeptidase N polypeptide
1) (Carboxypeptidase N small
subunit) (Kininase-1) (Lysine
carboxypeptidase) (Plasma
carboxypeptidase B) (Serum
carboxypeptidase N) (SCPN)
Carboxypeptidase N subunit 2
(Carboxypeptidase N 83 kDa
chain) (Carboxypeptidase N large
subunit) (Carboxypeptidase N
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P24387

CRHBP

CRHBP CRFBP

P07498

CASK

CSN3 CASK CSN10 CSNK

P09228

CYTT

CST2

Q5W188

CST9P

CST9LP1

Q6UWP2

DHR11

DHRS11 SDR24C1
UNQ836/PRO1774

P24855

DNAS1

DNASE1 DNL1 DRNI

Q7Z5P4

DHB13

HSD17B13 SCDR9 SDR16C3
HMFN0376 UNQ497/PRO1014

Q8N0V4

LGI2

LGI2 KIAA1916 LGIL2

Q6UXI9

NPNT

NPNT EGFL6L POEM
UNQ295/PRO334

Q9GZU5
O95897
Q96PB7

NYX
NOE2
NOE3

A8MZH6

OOSP1

NYX CLRP
OLFM2 NOE2
OLFM3 NOE3
UNQ1924/PRO4399
OOSP1

Q3ZCN5
Q7RTZ1

OTOGL
OVCH2

OTOGL C12orf64
OVCH2 OVTN

polypeptide 2) (Carboxypeptidase
N regulatory subunit)
Corticotropin-releasing factorbinding protein (CRF-BP) (CRFbinding protein) (Corticotropinreleasing hormone-binding
protein) (CRH-BP)
Granulocyte colony-stimulating
factor (G-CSF) (Pluripoietin)
(Filgrastim) (Lenograstim)
Cystatin-SA (Cystatin-2)
(Cystatin-S5)
Putative cystatin-9-like protein
CST9LP1 (Cystatin-9-like
pseudogene 1)
Dehydrogenase/reductase SDR
family member 11 (EC 1.1.-.-)
(Short-chain
dehydrogenase/reductase family
24C member 1)
Deoxyribonuclease-1 (EC
3.1.21.1) (Deoxyribonuclease I)
(DNase I) (Dornase alfa)
17-beta-hydroxysteroid
dehydrogenase 13 (17-beta-HSD
13) (EC 1.1.-.-) (Short chain
dehydrogenase/reductase family
16C member 3) (Short-chain
dehydrogenase/reductase 9)
Leucine-rich repeat LGI family
member 2 (LGI1-like protein 2)
(Leucine-rich glioma-inactivated
protein 2)
Nephronectin (Preosteoblast EGFlike repeat protein with MAM
domain) (Protein EGFL6-like)
Nyctalopin
Noelin-2 (Olfactomedin-2)
Noelin-3 (Olfactomedin-3)
(Optimedin)
Putative oocyte-secreted protein 1
homolog
Ovochymase-2 (EC 3.4.21.-)
(Oviductin)
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Q8WXA2

PATE1

Q6UY27

PATE2

B3GLJ2

PATE3

E5RFR1
Q9HBJ0
Q6GTS8

E5RFR1
PLAC1
P20D1

Q9BSG0
Q9P1C3

PADC1
YN010

A6NIE9

PRS29

A4D1T9

PRS37

A1L453

PRS38

Q7Z5A4

PRS42

E7EML9

PRS44

A8MTI9

PRS47

Q7RTY5

PRS48

Q6PEW0

PRS54

Q8IYP2

PRS58

Q5JQD4

PYY3

P00797

RENI

PATE1 PATE

Prostate and testis expressed
protein 1
PATE2 C11orf38
Prostate and testis expressed
UNQ3112/PRO10144
protein 2 (PATE-like protein M)
(PATE-M)
PATE3
Prostate and testis expressed
protein 3 (Acrosomal vesicle
protein HEL-127) (PATE-like
protein DJ) (PATE-DJ)
PENK
Proenkephalin-A (Fragment)
PLAC1
Placenta-specific protein 1
PM20D1
Probable carboxypeptidase
PM20D1 (EC 3.4.17.-) (Peptidase
M20 domain-containing protein 1)
PRADC1 C2orf7 PAP21 UNQ833/PRO1760
PRO2829
Putative uncharacterized protein
PRO2829
PRSS29P ISP2
Putative serine protease 29 (EC
3.4.21.-) (Implantation serine
proteinase 2-like protein) (ISP2like protein)
PRSS37 TRYX2
Probable inactive serine protease
37 (Probable inactive trypsin-X2)
PRSS38 MPN2
Serine protease 38 (EC 3.4.21.-)
(Marapsin-2)
PRSS42 TESSP2
Serine protease 42 (EC 3.4.21.-)
(Testis serine protease 2)
PRSS44 TESSP4
Serine protease 44 (EC 3.4.21.-)
(Testis serine protease 4) (TESSP4)
PRSS47
Putative serine protease 47 (EC
3.4.21.-)
PRSS48 ESSPL
Serine protease 48 (EC 3.4.21.-)
(Epidermis-specific serine
protease-like protein)
PRSS54 KLKBL4
Inactive serine protease 54
(Cancer/testis antigen 67) (CT67)
(Plasma kallikrein-like protein 4)
PRSS58 TRY1 TRYX3
Serine protease 58 (EC 3.4.21.4)
UNQ2540/PRO6090
(Trypsin-X3)
PYY3
Putative peptide YY-3 (Putative
peptide YY3) (PYY-III)
REN
Renin (EC 3.4.23.15)
(Angiotensinogenase)

229

P34096

RNAS4

RNASE4 RNS4

P11684

UTER

SCGB1A1 CC10 CCSP UGB

Q8TD33

SG1C1

SCGB1C1

P0DMR2

SG1C2

SCGB1C2

Q9HB40

RISC

SCPEP1 RISC SCP1 MSTP034
UNQ265/PRO302

Q9UK55

ZPI

SERPINA10 ZPI
UNQ707/PRO1358

P08185

CBG

SERPINA6 CBG

P05543

THBG

SERPINA7 TBG

P05120

PAI2

SERPINB2 PAI2 PLANH2

P0C7L1

ISK8

SPINK8

Q5DT21

ISK9

SPINK9 LEKTI2

P49223

SPIT3

SPINT3

Q6UDR6
P01266
Q9P2K2
P07911

SPIT4
THYG
TXD16
UROM

SPINT4 C20orf137
TG
TXNDC16 KIAA1344
UMOD

Q6UY13

YB003

UNQ5830/PRO19650/PRO1981
6

Ribonuclease 4 (RNase 4) (EC
3.1.27.-)
Uteroglobin (Clara cell
phospholipid-binding protein)
(CCPBP) (Clara cells 10 kDa
secretory protein) (CC10)
(Secretoglobin family 1A member
1) (Urinary protein 1) (UP-1)
(UP1) (Urine protein 1)
Secretoglobin family 1C member
1 (Secretoglobin RYD5)
Secretoglobin family 1C member
2
Retinoid-inducible serine
carboxypeptidase (EC 3.4.16.-)
(Serine carboxypeptidase 1)
Protein Z-dependent protease
inhibitor (PZ-dependent protease
inhibitor) (PZI) (Serpin A10)
Corticosteroid-binding globulin
(CBG) (Serpin A6) (Transcortin)
Thyroxine-binding globulin
(Serpin A7) (T4-binding globulin)
Plasminogen activator inhibitor 2
(PAI-2) (Monocyte Arg-serpin)
(Placental plasminogen activator
inhibitor) (Serpin B2) (Urokinase
inhibitor)
Serine protease inhibitor Kazaltype 8
Serine protease inhibitor Kazaltype 9 (Lymphoepithelial Kazaltype-related inhibitor 2)
Kunitz-type protease inhibitor 3
(HKIB9)
Kunitz-type protease inhibitor 4

Uromodulin (Tamm-Horsfall
urinary glycoprotein) (THP)
[Cleaved into: Uromodulin,
secreted form]
Putative uncharacterized protein
UNQ5830/PRO19650/PRO19816
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Q9H1F0

WF10A

WFDC10A C20orf146 WAP10

Q8IUB3
Q8NEX5
P60852

WF10B
WFDC9
ZP1

WFDC10B WAP12
WFDC9 WAP9
ZP1

WAP four-disulfide core domain
protein 10A (Putative protease
inhibitor WAP10A)
Protein WFDC10B
Protein WFDC9
Zona pellucida sperm-binding
protein 1 (Zona pellucida
glycoprotein 1) (Zp-1) [Cleaved
into: Processed zona pellucida
sperm-binding protein 1]
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